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 Most of the chemotherapeutics used in the clinic indiscriminately act on healthy 
proliferating cells along with malignant cells resulting in nonspecific toxicities, a narrow 
therapeutic index and reduced patient quality of life. Most of such agents are also limited 
by very low aqueous solubility. One strategy to overcome these challenges is to use 
biocompatible, water-soluble polymeric carriers to deliver chemotherapeutics with higher 
selectivity to sites of action (tumors), resulting in a better safety profile, increased 
maximum tolerated dose, and potentially better efficacy. Poly(amido amine) or PAMAM 
dendrimers are a class of branched polymers being extensively investigated for their 
potential as carriers for the delivery of anticancer agents. Their commercial availability, 
well-defined physicochemical and architectural features, ease of surface functionalization 
and encapsulation make PAMAM dendrimers useful for the delivery of 
chemotherapeutics. This dissertation focusses on two aspects of PAMAM dendrimers as 
drug carriers. The influence of PAMAM’s molecular architecture on biodistribution and 
pharmacokinetics is compared with traditionally used and clinically investigated linear 
polymers at various molecular weights. Architecture of the polymer affected its 
hydrodynamic size at different molecular weights. A difference in accumulation of 
polymers of varying architecture in nonspecific elimination organs (kidney, liver) as well 
as site-specific organs (tumor) was observed. Variation in polymer architecture also 
resulted in a decrease in blood clearance with increase in hydrodynamic size and affinity 
 to passively target the tumor by the enhanced permeability and retention effect when 
circulating in the blood. This dissertation also explored the use of PAMAM dendrimers 
for oral delivery of chemotherapeutics. By virtue of their unique three-dimensional 
architecture, PAMAM dendrimers are known to encapsulate, complex and solubilize 
hydrophobic drugs, modify epithelial tight junctions and act as drug carriers for oral 
delivery. It was observed that co-administration with dendrimers increased oral 
bioavailability of camptothecin, a schedule-dependent drug limited in oral use by low and 
variable absorption. Results suggest that this increase in absorption was not due to 
epithelial tight junction modulation and that drug inclusion in PAMAM interior 
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1.1.   Introduction 
Most anticancer drugs used in the clinic have disadvantages of a narrow 
therapeutic index, indiscriminately acting on healthy proliferating cells along with 
malignant cells and resulting in nonspecific toxicities. Conjugating and complexing small 
molecular weight anticancer drugs to biocompatible, water-soluble polymeric carriers 
increases therapeutic index, facilitates passive targeting to solid tumors, decreases 
toxicities and has the potential to increase efficacy [1, 2]. 
One such class of polymers being explored as drug carriers is poly(amido amine) 
or PAMAM dendrimers. PAMAM dendrimers are hyperbranched polymers with a very 
well-defined architecture due to their controlled synthesis [3]. With increase in the extent 
of branching, the generation of the dendrimer increases and the number of surface 
terminal groups double [4]. As a result of the divergent branching, PAMAM dendrimers 
have a relatively hollow core and a dense surface exterior that can be tailor-made to have 
different terminal groups [4]. The large number of functional groups on the exterior as 
well as the relatively hollow interior provides the opportunity of loading various cargo 
like drugs, imaging agents and targeting moieties by surface conjugation, complexation 
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or encapsulation within the dendrimer core (Figure 1-1) [5-15]. Their commercial 
availability, monodisperse physicochemical characteristics, ease of functionalization and 
potential for encapsulation make PAMAM dendrimers excellent carriers for polymer 
therapeutics. They are extensively being investigated as carriers for delivery of anticancer 
drugs to solid tumors [16].  
Traditionally, polymer therapeutics have been linear or random coil 
conformations in solutions. Many polymer therapeutics in clinical investigation have had 
poly(N-(2-hydroxypropyl)methacrylamide) (HPMA) as carriers that are known to assume 
a random coil conformation in solution [17, 18]. The passive targeting of polymer-
conjugated drugs based on the enhanced permeability and retention (EPR) effect has also 
been primarily investigated with such linear polymers [19-21]. PAMAM dendrimers, on 
the other hand, are hyperbranched in architecture. They are known to undergo a 
conformational change with increase in generation, with the lower generation dendrimers 
(G0.0-G3.0) being more flexible in conformation [4]. The intermediate generation 
dendrimers (G4.0-G6.0) have a relatively hollow core and dense surface possessing nano-
container-like properties allowing host-guest interactions, and the higher generation ones 
(G7.0-G9.0) becoming increasingly rigid and globular in conformation [4]. This 
difference in molecular conformation and polymer architecture of PAMAM dendrimers 
from clinically used random-coiled polymers like HPMA is likely to affect its 
biodistribution and pharmacokinetics in vivo.  
The unique three-dimensional architecture of PAMAM dendrimers has also been 
exploited for delivery of drugs across epithelial barriers by virtue of 1) encapsulation 




Figure 1-1. Schematic of a dendrimer-based delivery system functionalized with 




solubilization of hydrophobic drugs [13, 14], 2) tight junction modulation of epithelial 
barriers by densely charged positive or negative surface groups [22, 23], and 3) 
endocytotic uptake of PAMAM dendrimers [24-26]. PAMAM dendrimers have been 
extensively studied in vitro across Caco-2 monolayers for their transepithelial transport 
and as oral delivery systems for hydrophobic drugs [27, 28]. In vitro studies lacked the 
variables of mucous layer, gastrointestinal transit time and harsh enzymatic and pH 
conditions of the gastrointestinal tract (GIT). There have been very limited studies in vivo 
to assess PAMAM dendrimers as oral drug carriers [29, 30]. 
1.2.   Aims and scope of this dissertation 
This dissertation focusses on two aspects of PAMAM dendrimers as drug carriers 
for delivery of anticancer drugs. In the first part of the dissertation (Chapters 3 and 4), the 
effect of architectural difference between hyperbranched PAMAM dendrimers and 
clinically used linear polymers on in vivo biodistribution and pharmacokinetics is 
described. In the second part of this dissertation (Chapter 5), the unique three-
dimensional architecture of the PAMAM dendrimer consisting of a densely-charged 
surface exterior and relatively hollow and hydrophobic core is exploited for oral delivery 
of a chemotherapeutic. Three specific aims were pursued: 
Specific aim 1: To compare the biodistribution of hyperbrancehd PAMAM-OH 
dendrimers and linear HPMA copolymers of comparable MW over a physiologically 
relevant MW range. 
In Chapter 3, the biodistribution of a series of hydroxyl-terminated PAMAM 
dendrimers were compared with HPMA copolymers of comparable molecular weights in 
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physiologically relevant molecular weight range of kidney filtration, extended plasma 
circulation and tumor accumulation. The biodistribution studies of both the polymer 
series were done under consistent experimental conditions of physicochemical 
characterization, animal model, and in vivo detection system in order to facilitate a head 
to head comparison and to evaluate the effect of hydrodynamic size and polymer 
architecture on accumulation in target organ, tumor, and nonspecific organs like kidney 
and liver. The studies were carried out in animals bearing orthotopic ovarian carcinoma 
tumors, which is a non-metastatic, solid tumor model known to better simulate ovarian 
malignancy. Biodistribution studies were performed by dosing tumor-bearing mice with 
125
Iodine-labeled polymers. Radiolabeled polymers were detected in organ systems by 
measuring gamma emission of the 
125
Iodine radiolabel which facilitated a direct and 
accurate measurement. Polymer architecture affected hydrodynamic size at different 
molecular weights [31]. In addition to molecular weight, hydrodynamic size and polymer 
architecture affected the accumulation of these constructs in nonspecific elimination 
organs, kidney and liver, and site-specific organs, tumor and blood [31].  
Specific aim 2: To compare the blood and tumor pharmacokinetics of 
hyperbranched PAMAM-OH dendrimers and linear HPMA copolymers of comparable 
MW over a physiologically relevant MW range. 
In Chapter 4, the biodistribution data collected in Chapter 3 were analyzed by 
compartmental pharmacokinetic analysis. Specifically, blood and tumor pharmacokinetic 
parameters were computed that gave additional insight onto the effect of polymer 
architecture on in vivo fate of the carriers. Blood concentration data were modeled by 
two-compartment analysis comprising of a central blood compartment and a peripheral 
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fast-distribution compartment. Polymer architecture influenced elimination and renal 
clearance [32]. These results suggest a difference in extravasation of polymers of varying 
architecture through the glomerular basement membrane. A blood-tumor link model was 
fitted to experimental blood and tumor data by varying the tumor extravasation (K4, K6) 
and elimination (K5) rate constants using multivariable constrained optimization. Polymer 
architecture affected tumor extravasation rates and tumor to blood exposure ratios [32]. 
Along with MW and Rh, the difference in polymer architecture of PAMAM-OH 
dendrimers and HPMA copolymers was critical in affecting the blood and tumor 
pharmacokinetics of these polymeric carriers. 
Specific aim 3: To evaluate PAMAM dendrimers as absorption enhancers for the 
oral delivery of chemotherapeutic. 
By virtue of their unique three-dimensional architecture, PAMAM dendrimers of 
certain generations are known to solubilize and/or encapsulate hydrophobic drugs, 
modify epithelial tight junctions and act as drug carriers for oral delivery of conjugated or 
complexed drugs. Their potential in oral delivery has been extensively evaluated in vitro 
and in situ, however there have been very limited studies in vivo. In Chapter 5, cationic, 
amine-terminated PAMAM dendrimer generation 4.0 and anionic, carboxylate-
terminated PAMAM generation 3.5, known to solubilize drugs and modulate tight 
junctions, were evaluated as absorption enhancers for the oral delivery of anticancer drug 
camptothecin [33]. Camptothecin is a BCS class IV drug with poor solubility and 
permeability. It is a schedule-dependent drug that benefits from low and frequent oral 
dosing. Its oral use for hepatic metastasis of colorectal cancer is limited by low and 
variable oral bioavailability. Camptothecin was formulated and co-delivered orally with 
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G4.0-NH2 and G3.5-COOH in CD-1 mice at different ratios of drug to dendrimer. 
PAMAM surface charge influenced camptothecin association with the dendrimer [33]. 
The hypothesis was that PAMAM dendrimers at nontoxic concentrations can increase 
oral absorption of drug either by 1) drug solubilization in gastric conditions or 2) by tight 
junction modulation. Both PAMAM G4.0 and G3.5 controlled drug solubilization in 
gastric conditions and increased oral absorption of camptothecin [33]. PAMAM G4.0 and 
G3.5 did not increase oral absorption of mannitol, a paracellular marker, suggesting that 
increase in oral absorption of camptothecin was not due to tight junction modulation [33]. 
This study demonstrated that both cationic and anionic PAMAM dendrimers were 
equally effective in enhancing the oral absorption of camptothecin [33]. Results suggest 
that drug inclusion in PAMAM interior controlled drug solubilization in gastric 
conditions and increased oral bioavailability [33]. 
The following chapters of this dissertation include a review of the relevant 
literature (Chapter 2), parts of which were published elsewhere [27], the scientific work 
used to address specific aims 1-3 (Chapters 3-5) [31-33] and the project’s conclusions 
and future directions (partly adapted from [27]) (Chapter 6). 
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2.1. Polymer therapeutics 
The term ‘polymer therapeutics’ encompasses polymer-drug conjugates, polymer-
protein conjugates and supramolecular polymer-drug systems such as drug-containing 
polymeric micelles, polymer-drug complexes, polyplexes as non-viral vectors for nucleic 
acid delivery [1, 2]. Conjugation or complexation of small molecular weight drugs to 
polymeric carriers can result in increased drug solubility, prolonged circulation half-life , 
increased concentration at the site of action (such as tumors) and decreased non-specific 
toxicity. [1, 3-6]. The rationale of polymer therapeutics is similar to other 
macromolecular therapeutics such as proteins, antibodies as well as their prodrugs [7, 8]. 
However, it is possible to synthetically tailor the polymeric carrier with  greater 
versatility in the right size range, required molecular conformation and with specific 
functionalities [1, 9-14].  
 
1
Note-Parts of literature background reprinted with permission from S. Sadekar, H. 
Ghandehari, Transepithelial Transport and Toxicity of PAMAM Dendrimers: 




2.1.1. Polymer-drug conjugates 
A model polymer-drug conjugate was first described by Ringsdorf, consisting of a 
linear polymeric backbone and pendant side chains containing drugs, targeting moieties 
and imaging agents [15]. Polymer-drug conjugates are known to passively target the 
tumor by the enhanced permeability and retention (EPR) effect (discussed in Section 
2.1.2) and can also be actively targeted to the tumor [16-19]. These conjugates are known 
to be taken up in tumor cells via receptor-mediated endocytosis [20, 21]. Drug release is 
by hydrolytic or enzymatic cleavage of the spacer group in the extracellular tumor 
environment or intracellular lysosomal compartment [3, 22-26]. An ideal polymeric 
carrier should be water-soluble, biocompatible, have attachment sites for linkers carrying 
cargo and should have reproducible synthetic methodology with the ability to tailor 
molecular weight, size and cargo load [1].  
All polymer-drug conjugates evaluated in the clinic except one (HPMA-
doxorubicin-galactosamine) rely on passive targeting to the tumor via the EPR effect 
(discussed in Section 2.1.2) [27, 28]. The synthetic polymeric carriers used to synthesize 
polymer-drug conjugates in the clinic are N-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymers, poly(ethylene glycol) (PEG) and poly(glutamic acid) (PGA) [2, 27, 28]. 
Majority of the polymeric carriers employed under clinical investigation have a linear 
backbone (e.g., HPMA, PEG) (Table 2-1). Polymeric carriers of increasing complexity 
(described in Section 2.2.) have evolved and are being assessed as drug carriers. The 
dendritic systems offer advantages of being more defined in their chemical composition 
and architecture resulting in monodisperse systems that can be tailor-made to have 




Table 2-1. Polymer-anticancer drug conjugates investigated clinically. (Compiled 
from Ref [2, 27, 28]) 
Polymer-drug conjugate Polymeric carrier 
architecture/conformation  




Linear-random coil- side 
chains 
HPMA copolymer-paclitaxel [31] Linear-random coil- side 
chains 
AP5280, HPMA copolymer-carboplatinate 
analogue [32] 
Linear-random coil- side 
chains 
AP5346, HPMA copolymer-
diaminocyclohexane palatinate analogue [33, 
34] 
Linear-random coil- side 
chains 
HPMA copolymer-camptothecin [35] Linear-random coil- side 
chains 
PEG-camptothecin [36] Linear-random coil- side 
chains 
PEG-Irinotecan [37] 4-arm branched 
PEG-SN38 [38] 4-arm branched 
PEG-docetaxel [39] 4-arm branched 
PGA-taxol [40] Linear-extended- side chains 
PGA-camptothecin [6, 41] Linear-extended- side chains 
 




2.1.2. The enhanced permeability and retention (EPR) effect- 
Passive tumor targeting of polymer therapeutics 
The enhanced permeability and retention (EPR) effect was first reported by 
Maeda and coworkers postulating that particles of a certain size accumulate and retain in 
solid tumors [42]. Elevated levels of vascular permeability factors cause high vascular 
density in a short period of time [43]. The abnormally fast growth of vasculature results 
in a defective architecture of  endothelial cells with wide fenestrations that lack a smooth 
muscle layer and an interstitium that has a compromised lymphatic drainage [43].  
A time dependent accumulation of macromolecules has been noted for proteins, 
polymers, liposomes and other nanocarriers as a result of increased blood circulation time 
and the enhanced permeability and retention in the tumor [16, 19, 44, 45]. Amongst 
polymeric carriers, the EPR effect has been extensively studied in random coil polymers 
like poly(ethylene glycol) and N-(2-hydroxy)propyl methacrylamide copolymers to study 
the effect of polymer molecular weight (MW) on the extent of tumor accumulation 
(Figure 2-1) [46-48]. It has, however, not been well established in polymers of varying 
architecture. 
For the random coil HPMA copolymers evaluated in vivo in subcutaneous 
sarcoma models, the EPR effect was observed for polymers in the MW range of 40 to 
800 kDa [48]. At about 6 hours after intravenous administration, the EPR effect was 
observed to kick in and a tumor to blood accumulation ratio of 10 to 30 was achieved. 
Retention of about 10-20 % injected dose/g was observed for up to months [48].  
While molecular weight (MW) is an important indicator of hydrodynamic size of 
a polymer, the correlation of MW to hydrodynamic radius (Rh) can be different for 
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Figure 2-1. Schematic representing the effect of particle size on the enhanced 
permebability and retention (EPR) effect. (After 6 hours in blood circulation) 
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polymers of different architectures. Hydrodynamic size and conformational flexibility are 
more physiologically relevant parameters over MW, that are likely to control passive 
targeting via the EPR effect [49, 50]. 
Jain and coworkers have characterized the EPR effect on a micro-scale where 
they took a closer look at transport barriers within the tumor for the delivery of 
macromolecules [51, 52]. Transport barrier to drug transport within the tumor include 1) 
transvascular transport across capillaries into tumor interstitial space, 2) movement in the 
tumor interstitial space to reach  tumor cells and 3) cellular uptake [53]. The unique 
pathophysiology of the tumor, while making it more permeable to macromolecules, can 
also augment their transport barriers by: 1) growth-induced solid stress, 2) tortuous 
vasculature, 3) elevated interstitial fluid pressure and 4) dense interstitial structure [53-
56]. 
There has been extensive research on increasing the transport of macromolecules 
to the tumor and augmenting the EPR effect [57]. One of the strategies includes tuning 
the properties of the therapeutic moiety [58-60]. While size and surface charge of a 
macromolecule have been exploited to increase plasma circulation and target the tumor, 
conformation and flexibility of the molecule have been the least studied properties [47, 
48, 61-67].  
The diffusion coefficients of structures comparable in size but having different 
flexibilities (proteins, dextrans, polymer beads and DNA) were measured in agarose gels, 
that simulated the porous structure of the extracellular matrix in biological systems [63]. 
Flexible macromolecules like DNA chains had a higher diffusion coefficient in the gel 
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than rigid spherical particles of comparable hydrodynamic size in solution [63]. Chain 
like macromolecules also showed reptation-like behavior in the gel [63].  
The tumor uptake of polymeric contrast agents of different conformations was 
compared [64-66]. Polylysine chains were substituted with 1,2-diamine-N,N-
N′,N′,N″,N″-pentaacetic acid (DTPA). The extent of substitution controlled conformation 
of the polymer in solution. A higher degree of substitution (5-10%) caused the polymers 
to assume an extended conformation in solution distinct from the coiled conformation of 
the lower substituted polymers [64, 65]. Polymers with an extended rod-like 
conformation showed higher tumor uptake than ones with coiled conformations inspite of 
a similar opportunity to partition into the tumor (with comparable plasma circulation) 
[64, 65]. It was hypothesized that the rod-like polymer had more efficient cell-surface 
assisted reptation in the porous tissue matrix, explaining its higher tumor uptake [66]. 
These studies suggested that flexible chain-like macromolecules would be more effective 
in permeating the tumor and delivering drug.   
2.2. Architecture and its effect on in vivo fate of polymeric carriers 
Polymer architecture is determined by molecular conformation, chain flexibility, 
deforming capacity and extent of branching in solution [68]. Polymeric carriers in drug 
delivery may be linear or graft, dendritic, cyclic and hybrid architectures (structure-
physicochemical property relationships of linear and dendritic polymers summarized in 
Table 2-2).  
Physicochemical properties of a polymeric carrier such as composition, molecular 














Higher generations (> G3) are 
globular, shape-persistant molecular 
spheres [69] 






with increase in MW 
[49]. 
Spherical shape results in maximum 
surface area to volume ratio.  
Increased solubility and reactivity 
over linear polymers is observed [71]. 
Rheology Chain entanglement 
causes increase in 
viscosity with 
increased chain length 
[72].  
Intermolecular chain entanglement 
suppressed at higher generations [69] 
Intrinsic viscosity initially increases 
with MW, goes through a maximum 
and then decreases with further 
increase in MW [73] 
Examples HPMA, PEG, PGA PAMAM, polyester, PLL, PEI, PPI 
dendrimers 
 
Note- Conjugation of drugs or other moieties is known to alter physicochemical 
properties and drastically modify conformation.  
 
Note- Hybrid of linear and dendritic architectures such as dendronized polymers or 
bow-tie architecture show a range of physicochemical properties between those of 
linear and dendritic systems. 
Table 2-2. Structure-physicochemical property relationships of linear and dendritic 
carriers explored in drug delivery applications. (Compiled from Ref [49]) 
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architecture is one of the least studied physicochemical properties that can affect 
biodistribution and pharmacokinetics. 
Architecture of a polymer can influence its renal clearance, blood circulation 
time, tumor penetration and uptake. One of the first reports in literature to assess the 
effect of polymer architecture on biodistribution and pharmacokinetics was the evaluation 
of polyester dendrimers-poly(ethylene oxide) (PEO) hybrids with tunable molecular 
weight and architecture [74]. The  architecture was controlled by dendrimer generation 
and number of PEO arms (2-8) [74]. The molecular weights ranged from 20 to 160 kDa. 
Polymers above 40 kDa had a longer plasma elimination half-life and showed reduced 
renal clearance. For polymers of comparable MW, renal clearance decreased with extent 
of branching, attributed to decreased flexibility [74]. 
Polyester backbones with PEG grafts in linear and cyclized forms were evaluated 
for their circulation half-life [75]. For polymers just above renal filtration threshold, at 50 
kDa, the cyclized polymer that lacked a chain end showed a longer plasma elimination 
half-life [75]. The authors attributed this to the ability of the linear polymer to reptate 
through pores of vasculature in elimination systems of the body (specifically the kidney 
filtration system). However, the cyclized polymers lacked a chain end and had to deform 
in order to extravasate [75]. 
A series of PEGylated poly acrylic comb-shaped polymers were also synthesized 
at different molecular weights as linear and cyclized versions [76]. The same 
phenomenon was observed again with the cyclized polymer showing a greater plasma 
half-life than the linear counterpart above renal filtration threshold [76]. This study was 
carried out in tumor-bearing mice (subcutaneous colorectal carcinoma tumors). As a 
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consequence of increased plasma circulation, the tumor accumulation of the cyclic 
polymers was also greater than the linear polymer of comparable molecular weight [76]. 
In all of these studies molecular weight was used as an indicator for polymer size. 
Hydrodynamic radius is a more physiologically relevant indicator of polymer size in vivo. 
These studies also used plasma elimination half-life as the primary pharmacokinetic 
parameter to define effect of polymer architecture on plasma circulation. The terminal 
half-life expresses the overall rate of polymer elimination process during the terminal 
phase. This rate of elimination depends upon extent of polymer clearance and polymer 
distribution. A long terminal half-life can be attributed to either a large volume of 
distribution or a small plasma clearance or both [77]. Therefore, terminal half-life is not 
the most robust parameter to assess the ability of the body to eliminate the polymer [77]. 
On the other hand, plasma clearance expresses the ability of the body to eliminate the 
polymer and is a more robust pharmacokinetic parameter to evaluate the effect of 
polymer architecture on elimination through vasculature systems of the body. It has been 
postulated that at comparable hydrodynamic sizes, polymer architecture affects the rate at 
which  it transports across pores in vasculature of elimination systems of the body, which 
are of the same order of magnitude as the polymer size (2-10 nm) (Figure 2-2) [50]. 
The hypothesis was that the shape and deforming capability of a polymer impacts 
its passage through a pore, which in turn influences the glomerular filtration rate and 
hence plasma exposure [50]. In Figure 2-2 (a) a random coil polymer orients one chain 
end into the pore and reptates through, (b) a globular polymer has to deform in order to 
pass through, (c) a cyclic polymer also has to deform in order to pass through, (d) a linear 
polymer or a rod shaped nanoparticle has to orient along its vertical axis in order to 
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Figure 2-2. Polymers of varying architecture and equivalent hydrodynamic 
size passing through pores. Size of pores is comparable to size of polymers 
(2.0-6.0 nm). Size of arrow is indicative of ease of transport.  
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permeate [50]. It was also suggested that this difference in extravasation of polymers of 
varying architecture would not be observed if the pore size was an order of magnitude 
greater than that of the polymer size, which is the case for transendothelial openings of 
fenestrated capillaries in the tumor and liver fenestrations (40-80 nm) [50]. 
The review also data mined for plasma elimination half-lives of macromolecules 
of different molecular conformations as a function of molecular weight [50]. It was noted 
that the plasma elimination half-lives increased more drastically with increase in MW for 
the branched or globular polymers than polymers with a random coil conformation in 
solution [50]. Half-life increase was the slowest for linear polymers with an extended 
conformation [50]. It should be noted that these trends were generated out of experiments 
performed under inconsistent conditions of polymer characterization, animal models and 
detection systems.  
Some studies have focused on the effect of polymer architecture on the 
extravasation of macromolecules across capillary endothelium [78-80]. Capillary 
endothelium may be continuous such as those found in skeletal and smooth muscle as 
well as subcutaneous and mucous membrane with fenestrations that do not allow passage 
of macromolecules > 2.0 nm in size [81]. It may be discontinuous such as those found in 
organs of the reticuloendothelial system such as liver, spleen, and bone marrow with 
fenestrations of up to 150 nm [81]. It may also be fenestrated such as in the kidney but 
with a continuous basement membrane [81].  
Elsayed et al compared the extravasation of fluorescently-labeled linear PEG and 
branched PAMAM-NH2 across a hamster cremaster muscle preparation (continuous 
endothelium) using intravital microscopy [79]. The PAMAM dendrimer extravasated 
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faster than the linear polymer of comparable MW [79]. This difference in extravasation 
rates were attributed to the difference in molecular conformation as well as surface 
charge of the two polymer types.  
Research to evaluate the effect of molecular shape on the glomerular filtration 
rates of macromolecules suggests that at comparable sizes, the deforming capability of 
macromolecules determines the rate of glomerular filtration [78, 80]. The fractional 
clearances or sieving coefficients of linear polysaccharide dextran, spherical, highly 
compressible polysacharide ficoll and globular proteins were measured across the 
glomerular capillary wall [80]. The glomerular capillary wall consists of a fenestrated 
endothelial cell layer, a continuous basement membrane and an epithelial cell layer [80]. 
Linear extended conformation of dextran and the highly compressible conformation of 
ficoll aided their fast filtration across the glomerular capillaries [80]. The globular 
proteins filtered at a slower rate that was associated with their slower deforming rate 
through pores of vasculature [80]. A similar observation was made in a study where 
polysaccharides filtered at a faster rate through glomerular capillary walls than globular 
proteins [78]. Amongst the polysaccharides, the more extended linear structure of 
poly(ethylene oxide) showed a faster filtration rate than dextran [78]. 
2.3. Poly(amido amine) dendrimers 
Poly(amido amine) or PAMAM dendrimers are a class of hyper-branched 
polymers originally developed by Tomalia in 1979 [11]. The ethylene diamine core and 
amido amine branching structure of the PAMAM lead alternatively to amine-terminated 
full generation or carboxyl-terminated half-generation dendrimers after each addition step 
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in the synthesis (Figure 2-3) [11]. For every increase in generation, the number of 
functional groups double, while the dendrimer diameter increases by about 1 nm [82]. 
Due to their controlled synthesis, these polymers have the unique advantage of having 
very low polydispersities. A full generation PAMAM dendrimer has primary amine 
groups on the surface (pKa =6.85) and tertiary amine groups within the core (pKa = 3.86) 
[82].  
Due to their high degree of branching, PAMAM dendrimers have unique physical 
and structural properties distinct from linear polymers. PAMAM dendrimers undergo a 
conformational change with increasing generation [82]. They are more flexible at lower 
generations (0.0-3.0) [82]. With increase in surface branching, their surface density 
increases, leading to a dense exterior and a relatively hollow interior (G4.0-G6.0) [82]. 
This nano-container like conformation allows for entrapment of guest molecules, 
exploited for drug delivery applications (discussed in Section 2.5.1). As the surface 
branching increases, it leads to more crowding resulting in a more compact, globular 
shape for higher generation dendrimers (G7.0- G9.0) [82]. This change in conformation 
results in an intrinsic viscosity trend different from that of linear polymers. The intrinsic 
viscosity of PAMAM dendrimers goes through a maximum for certain dendrimer 
generations (around G6.0) and then decreases as the generation increases [83]. Higher 
generation dendrimers behave as rigid molecular spheres [83]. Conformational studies 
have suggested some backfolding of surface groups into the interior void [84]. The extent 
of backfolding depends on the solvent. In a good solvent, minimum backfolding of 
peripheral groups is observed [84]. The solubility of PAMAM dendrimers is higher than 





































































































































 highest surface area to volume ratio [71]. PAMAM dendrimers also have better end-
group reactivity due to their increased solubility and better accessibility [71]. The high 
density of surface functional groups on PAMAM dendrimers presents the opportunity of 
functionalizing these polymers with various drugs, nucleic acids and imaging system 
components [85-92]. It also presents a suitable scaffold to facilitate efficient multivalent 
interactions, critical for biological processes such as cellular recognition [93]. Their 
surface charge density has also been exploited for interactions with epithelial cell 
monolayers and tight junction modulation  with implications for oral drug delivery 
(discussed in Section 2.5.2).  
2.4. PAMAM dendrimer-drug complexes  
The relatively hollow and hydrophobic interiors and dense surface exteriors of 
dendritic structures allow for host-guest encapsulation of drugs resulting in polymer-drug 
complexes with a pH sensitive drug release profile [95, 96]. Dendrimers like 
poly(glycerol), poly(ethyleneimine) (PEI), poly(propyleneimine) (PPI) and poly(amido 
amine) (PAMAM) have been explored to encapsulate anticancer drugs [95, 96]. Due to 
their commercial availability and ease of tailoring terminal groups, PAMAM dendrimers 
have been the most widely studied dendritic architectures in polymer-drug complexes. 
Dendrimer-drug interactions can occur electrostatically on the surface and within 
the core, hydrophobically or hydrogen bonding within the core (Figure 2-4) [95, 96]. 
Primary factors that influence this interaction are: 1) dendrimer characteristics such as 








and 3) physicochemical properties of drugs like size, hydrophobicity, nature of functional 
groups, and pKa.  
Reports indicate that PAMAM encapsulation and solubilization potential 
increases with increase in generation as seen for hydrophobes like nifedipine, 
indomethacin and NSAIDS like ibuprofen [97, 98]. Majority of the reports evaluate 
generation 4.0, due to its ideal molecular conformation of a hollow core and dense 
surface exterior, which allows for encapsulation as well as multiple surface interaction 
sites. Dendrimers smaller than G3.0 have an open conformation, that will allow guest 
molecules to easily escape while higher generation dendrimers, G7.0 onwards, become 
increasingly rigid and have biocompatibility issues with high surface charge density [82].  
Along with PAMAM size, surface terminal groups largely influence the 
complexation of drugs. For drugs containing acidic groups like indomethacin, and 
ibuprofen, the solubilization potential of amine-terminated dendrimers at pH above the 
pKa of the drug is much higher than that of neutral or anionic dendrimers [98, 99]. This is 
due to the electrostatic interaction of the oppositely charged drug and dendrimer. The 
opposite is true for drugs containing basic functional groups like nifedipine at pH below 
pKa, where they electrostatically interact with ionic dendrimers on the surface [97, 99].  
The pH of the formulating solution influences protonation of tertiary nitrogens in 
the interior of the PAMAM dendrimer. At pH below pKa of tertiary nitrogens (pKa 3.0-
6.0), when nitrogens are protonated, the PAMAM core becomes less hydrophobic, 
decreasing its drug encapsulation and consequently solubilization. Protonation of amine 
terminal groups and deprotonation of carboxylic acid surface groups at certain pH values 
increases surface electrostatic interaction, which aids in drug solubilization and 
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complexation. One such example is ibuprofen complexed with PAMAM G4.0-NH2 [100]. 
It showed a pH-dependent enhancement in solubility with the solubilization potential of 
the dendrimer being highest at pH 10.5, when both primary surface amines of dendrimer 
and carboxylic acid group of ibuprofen were ionized [100].  
The contributions of dendrimer surface ionic complexation with drugs versus 
encapsulation within their interior have been assessed. Evaluation was done using nuclear 
magnetic resonance and two-dimensional Overhausner effect spectroscopy (2D-NOESY) 
[101]. It was observed that electrostatic interaction on the surface of PAMAM with 
oppositely charged drug contributed more to solubility than internal encapsulation at the 
pH value where surface groups and cargo were ionized with opposite charge [102]. It was 
also observed that positively charged drugs locate only on the surface of negatively 
charged dendrimers, while negatively-charged drugs were seen to localize both on the 
surface and interior cavities [99].  
Complexation of drugs with dendrimers has the potential to control drug release 
and improve bioavailability (discussed in Section 2.5.4 and 2.5.5).   
2.5. PAMAM dendrimers in oral delivery  
PAMAM dendrimers of certain generations and surface charge can permeate the 
epithelial barrier of the gut, suggesting their potential as oral drug carriers [103-124]. It is 
important to evaluate the toxicity of PAMAM dendrimers on epithelial barriers to ensure 




2.5.1. Toxicity on Caco-2 cells 
Caco-2 cells are human colorectal carcinoma cells that develop a cell polarity 
when grown in monolayers and allow the study of transepithelial transport [125].  It is 
known that PAMAM dendrimers demonstrate a generation-, surface charge-, 
concentration- and incubation time - dependent cytotoxicity profile [126]. Initial studies 
suggested that the rank order of cytotoxicity of PAMAM dendrimers is hydroxyl-
terminated < carboxyl-terminated < amine-terminated systems [69]. As per the lactate 
dehydrogenase (LDH) assay which assessed membrane damage on Caco-2 cells, 
carboxyl-terminated dendrimers of generations 3.5 and 4.5 (G3.5-COOH and G4.5-
COOH) are toxic only at a higher donor concentration of 10.0 mM compared to amine-
terminated dendrimers of generations 3.0 and 4.0 which are toxic at 1.0 mM (G3.0-NH2 
and G4.0-NH2) [105, 107]. The LDH assay revealed plasma membrane damage of Caco-
2 cells by PAMAM dendrimers as a function of generation number, surface charge, 
incubation time and concentration.  
Transmission electron microscopy (TEM) analysis further showed a 
concentration-, generation- and surface charge-dependent effect of PAMAM dendrimers 
on Caco-2 microvilli morphology [115]. Cells treated with a concentration of 0.1 mM or 
higher G4.0-NH2 showed membrane disruption and loss of Caco-2 microvilli while those 
treated with G3.5-COOH at the same concentration were unaffected [115]. The extent of 
disruption and loss of microvilli increased with G4.0-NH2 concentration. At lower 
concentration of 0.01 mM, dendrimers did not influence microvilli morphology as per 
TEM images. Higher generation cationic dendrimers showed increased intestinal 
membrane damage compared to lower generation ones [115]. 
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In summary, in vitro toxicity studies on PAMAM dendrimers revealed that 
cationic systems are nontoxic on Caco-2 cells at lower concentrations of 0.01 mM as per 
LDH assay and microscopic evaluation. Anionic PAMAM dendrimers are tolerated to a 
higher extent than cationic dendrimers making it possible to give higher doses of the 
carboxylic acid-terminated systems. In the range of dendrimers evaluated from 
generations 0.0 to 4.0 with varying surface functional groups, it was observed that there 
is a workable nontoxic window for PAMAM dendrimers to be used as carriers for oral 
drug delivery. These studies set the stage for the in vitro evaluation of transepithelial 
transport and cellular uptake of PAMAM dendrimers across epithelial barriers. 
2.5.2. Biocompatibility and biodistribution 
One of the first reports of dendrimer biocompatibility in vivo was a preliminary 
toxicity and immunological evaluation of amine-terminated PAMAM dendrimers G3.0, 
G5.0 and G7.0 in male swiss-webster mice by intravenous administration [127]. Acute (7 
days), sub-chronic (30 days) and chronic toxicity (6 months) was evaluated at 
intravenous dendrimer doses of 5 x 10
-6
 mmol/kg, 5 x 10
-5
 mmol/kg, and 5 x 10
-4
 
mmol/kg. For chronic toxicity, a dose of 5 x 10
-4
 mmol/kg was administered 
intravenously for PAMAM G3.0-NH2 and G5.0-NH2, and 5 x 10
-5
 mmol/kg for PAMAM 
G7.0-NH2 [127]. PAMAM G7.0-NH2 was administered at a lower dose for the chronic 
toxicity study because acute toxicity was observed for PAMAM G7.0-NH2 at the higher 
dose of 5 x 10
-4
 mmol/kg [127]. Animals were monitored for routine behavioral 
abnormalities and changes in body weight. Upon sacrifice, certain tissues (liver and 
spleen) were observed for macroscopic and microscopic abnormalities by hematoxylin 
32 
 
and eosin staining. Signs of toxicity were observed only for PAMAM G7.0-NH2 at the 
highest dose tested, with 1 out of 5 animal deaths 24 hours after injection [127]. For 
immunogenicity testing, New Zealand rabbits were subcutaneously injected with 
PAMAM G3.0-NH2, G5-NH2, or G7-NH2 at two doses of 5 X 10
-5
 mmol with 3 week 
intervals. The immunogenicity of the PAMAM dendrimers was studied using two 
different methods: immunoprecipitation and an Ouchterlony double diffusion assay. 
Ouchterlony double diffusion assay is an agar immunodiffusion assay for detecting 
extractable nuclear antigens. With blood samples collected at 10 days after injection, no 
immunological reactions were seen at doses tested. This study was one of the first reports 
of the in vivo evaluation of PAMAM dendrimers. It was a preliminary evaluation of 
toxicity of cationic PAMAM dendrimers at a fixed dose and showed that PAMAM 
toxicity increased with increase in generation and surface charge density of amine groups 
[127]. PAMAMs of G5.0 or below were well tolerated up to doses 5x10
-4
 mmol/Kg but 
higher generation PAMAMs showed biological complications at the same dose. This 
toxicity study of intravenously administered PAMAM throws light on possible biological 
complications that may occur upon systemic absorption of orally dosed constructs.  
In another study the biocompatibility of cationic PAMAM dendrimers G1.0-G4.0 
and anionic PAMAM dendrimers G1.5-G5.5 was systematically investigated to evaluate 
the effect of dendrimer generation and surface functionality on biological properties in 
vitro [128]. PAMAM dendrimers were incubated with fresh rat blood cells in phosphate 
buffer saline (PBS) with shaking at 37
0
C for 1 hour. The hemoglobin released was 
spectrophotometrically determined to measure extent of hemolysis. Amine terminated 
PAMAM dendrimers displayed concentration and generation-dependent hemolysis. 
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Rounding and clumping of red blood cells was observed in the first hour even at non-
hemolytic concentrations (10 µg/ml) [128]. All cationic PAMAM dendrimers except 
G1.0 were hemolytic above 1.0 mg/mL. Anionic dendrimers caused no morphological 
changes to RBCs upto 2.0 mg/mL as per scanning electron microscopy [128]. These 
results correlated well with in vitro cytotoxicity studies in Caco-2 cells, in that anionic 
PAMAM dendrimers were more biocompatible than their cationic counterparts and that 
the cationic dendrimers showed reduced biocompatibility at higher generations. 
Recent in vivo studies have focused on establishing the maximum tolerated doses 
for PAMAM dendrimers of different generations and surface charge, administered orally 
and intravenously to CD-1 mice [129]. PAMAMs of two different generations 4.0 and 7.0 
and three different surface functionalities: amine, carboxylic acid and hydroxyl 
terminated were tested.  Acute toxicity (10 days) was inferred by monitoring routine 
behavioral changes, body weight changes, and upon animal sacrifice, changes in organ 
weight, macroscopic tissue abnormalities, blood chemistry and blood picture. It was 
observed that when intravenously administered, amine terminated dendrimers (both 
G4.0-NH2 and G7.0-NH2) were safe only at doses less than 10 mg/kg [129]. This finding 
is in agreement with a previous study by Roberts et al. summarized above, where 
biological complications were observed for G7.0-NH2 dendrimers, dosed at 5.0 x 10
-4
 
mmol/Kg which translates to about 58.3 mg/kg of the dendrimer [129]. In the same study, 
lower generation dendrimers G3.0-NH2 and G5.0-NH2, dosed at 5x10
4
 mmol/Kg (about 
3.4 and 14.4 mg/Kg respectively) were nontoxic [129]. In contrast carboxyl- (G3.5-
COOH and G6.5-COOH) and hydroxyl- (G4.0-OH and G7.0-OH) terminated dendrimers 
were tolerated intravenously at 50-fold or higher doses. Blood analysis of mice treated 
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with amine terminated dendrimers at 2 weeks showed decreased levels of fibrinogen, 
platelets and high levels of fibrin degradation products (FDP) which is known to result in 
intravascular coagulation and hemorrhage [129].  
Orally administered dendrimers demonstrated the same trend where the higher 
generation positively charged systems caused more toxicity than negatively charged ones 
[130]. Orally administered G7.0-NH2 and G7.0-OH showed signs of hemobilia and 
splenomegaly at doses above MTD. The oral MTD for these dendrimers ranged from 
30mg/kg to 200mg/kg. Anionic G6.5 or smaller generation carboxyl-, amine- or 
hydroxyl-terminated dendrimers (G3.5-COOH, G4-NH2, G4-OH) on the other hand were 
tolerated at doses of up to 500mg/kg [130].  
Overall these studies revealed that PAMAM dendrimers showed similar toxicity 
trends when administered orally and intravenously, with the higher generation cationic 
dendrimers being more toxic than their lower generation counterparts and the anionic 
dendrimers being less toxic than the cationic ones. PAMAM dendrimers were tolerated at 
10-fold higher doses when administered orally as compared to intravenously. This could 
be due to a rate limiting absorption process that reduces exposure of the dendrimers to 
blood. However, detailed oral histological evaluation of the gastrointestinal epithelium 
needs to be carried out to understand possible tissue toxicity due to PAMAM exposure in 
vivo. 
An attempt to understand histological damage to intestinal epithelial barrier by 
PAMAM was carried out in situ. Lin et al., evaluated the intestinal membrane damage in 
SD rats of amine-terminated PAMAMs generations 0.0-3.0 (0.05 to 0.5% w/v), when 
evaluating in situ absorption of hydrophilic molecules in the presence of PAMAM 
35 
 
dendrimers [131]. PAMAM dendrimers were incubated for 4 hours in the canulated 
intestinal loop and the amounts of LDH and protein released from the small intestinal 
membranes were measured, which was an indication of plasma membrane damage. At 
the highest concentration tested (0.5% w/v), PAMAM G2.0-NH2 showed signs of plasma 
membrane damage [131]. However, the extent of toxicity was less than that of 3% (v/v) 
Triton X-100, a commonly used intestinal absorption enhancer, used as a positive control. 
While co-delivery of PAMAM G2.0-NH2 enhanced the intestinal absorption of 5(6)-
Carboxyfluorescein (CF), a water-soluble dye, pretreatment with G2.0-NH2 (0.5%,w/v), 
did not alter absorption of the dye. This suggested that the absorption-enhancing effect of 
G2.0-NH2 is reversible and might not cause irreversible membrane damage in the rat 
small intestine. Data correlate with cytotoxicity and in vivo data of PAMAM-NH2 
dendrimers, with the toxicity increasing as a function of generation and concentration. At 
the highest dose employed of 0.5% w/v of PAMAM G2.0, signs of histological toxicity 
observed were found to be reversible.  
Studies on the in vivo biodistribution of 
125
I-labelled, intravenously administered 
poly(amido amine) dendrimers in rats have shown that anionic dendrimers circulate 
longer in the blood than cationic dendrimers [128]. In 1 hour, only 0.1-1.0 % of dose of 
PAMAM-NH2 dendrimers was recovered in the blood while 15-40 % of the dose of 
PAMAM-COOH of various generations was recovered. Both types of dendrimers 
showed high liver accumulation, with the cationic dendrimers showing slightly higher 
liver concentration (60-90 %) than the anionic dendrimers (25-70 %) [128].  
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2.5.3. Transepithelial transport and intracellular fate 
An important barrier to oral absorption of PAMAM dendrimers is limited 
transepithelial transport. Several methods are available to study transport of compounds 
across the epithelial barrier of the gut [125]. These include, but are not limited to, isolated 
intestinal tissue techniques, cell culture monolayer systems such as Caco-2 cells, and in 
situ perfusion models. The effect of PAMAM generation, surface group, concentration 
and incubation time with cells on transport across epithelial barriers has been extensively 
studied on epithelial cell monolayers and isolated intestinal tissue in vitro [103-109, 111-
117, 119]. In an initial study, the isolated intestinal tissue model using the everted sac 
technique was employed to assess the transepithelial transport of PAMAM dendrimers 
[16]. This technique, along with the Ussing chamber technique involving isolated 
intestinal tissue, provides mechanistic insights and additionally allows the comparison of 
differences in the segmental transport throughout different regions of the GIT [125]. The 
everted sac setup involves everting an intestinal segment, 2-4 cm long over a glass rod, 3 
mm in diameter. The setup is then put into culture medium containing desired 
concentration of substance, whose permeability is being evaluated. The flux of the 
compound is evaluated from the outside mucosal side to the inside serosal sac [132]. The 
model is a simple, quick, reproducible and inexpensive technique. However, the volume 
inside the sac is small, because of which physiologically relevant sink conditions cannot 
be maintained. In an Ussing chamber, a small segment of the intestine is clamped 
between two chambers: the serosal and the mucosal side [132]. It is also possible to 
connect electrodes in the two compartments to measure changes in transepthelial 
electrical resistance (TEER) and therefore tight junction modulation. A small amount of 
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sample is needed to evaluate absorption. However, the preparation of the intestinal 
epithelial layer can be complicated. Incomplete removal of the serosal muscle layer can 
result in false measurements of transport and puncture of the segment can drastically 
decrease TEER [132]. These ex vivo techniques may be useful to determine the segmental 
transport of compounds at different regions of the intestine. It is also useful to evaluate 
the site of action of effect of penetration enhancers [125]. Maintaining tissue viability is 
the most critical step of evaluating transport using isolated tissue.  
125
I-labelled PAMAM dendrimers were first evaluated for their uptake and 
transport in vitro using the everted intestinal sac system in rat [103]. While amine-
terminated cationic PAMAM dendrimers showed greater tissue uptake than transport 
across the isolated everted rat intestinal sac, carboxylic acid-terminated dendrimers 
showed greater serosal transfer rates than their tissue uptake. Higher generation anionic 
G5.5 had a 2-fold greater tissue uptake than that of lower generation anionic G2.5 and 
G3.5 dendrimers. The serosal transport rate of higher generation anionic dendrimers was 
less than that of lower generation dendrimers. PAMAM G5.5 was recovered on the 
serosal side (60-70%), while 80-85 % of G2.5 and G3.5 was recovered [103]. This study 
demonstrated that PAMAM generation and surface charge influence their transepithelial 
transport as well as tissue uptake and that there is an optimum range of generation and 
surface charge to use PAMAM dendrimers as drug carriers for oral delivery. 
A variety of factors before and after the epithelial barrier influence the transport 
of compounds across the isolated intestinal tissues including everted sacs. To avoid the 
influence of pre- and post-epithelial factors, and gain a detailed understanding of the 
influence of physicochemical properties of dendrimers on the extent and mechanism of 
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transepithelial transport, a series of studies were conducted to examine the effect of the 
physicochemical and structural properties of PAMAMs of various generations and 
surface charges on their transport across epithelial cell culture monolayers [103-109, 111-
117, 119]. Amongst cultured cells, Madin-Darby canine kidney (MDCK) cells, Caco-2 
monolayers, and IPEC-J2 monolayers have been used to assess the transepithelial 
transport of PAMAM dendrimers. When cultured as monolayers, these cells undergo 
differentiation, maintain a cell polarity and develop a transepithelial resistance [125]. The 
cell line polarity facilitates the study of directional transport from apical to basolateral 
side. Measuring transepithelial resistance allows the monitoring of tight junction integrity 
in cultured monolayer cells. Both cellular uptake and transepithelial transport can be 
studied. Cell monolayers can be used to evaluate transport mechanism by inhibiting 
certain cellular uptake pathways and by monitoring tight junction modulation. Cultured 
intestinal cell monolayers are useful in rank ordering permeabilities of compounds of the 
same class. A study attempting to correlate in vitro results in Caco-2 cell monolayers to 
in vivo data has demonstrated that compounds with apparent permeability coefficients 
(Papp) above 1 x 10
-6
 cm/sec are likely to be well absorbed [133]. However, cultured 
monolayers such as the Caco-2 cell monolayers widely used to assess PAMAM intestinal 
transport lack mucous secretion and therefore do not present a mucosal barrier to 
transport [125]. Caco-2 cells, which are derived from the colon also lack the cellular 
heterogeneity found in the intestinal mucosa like presence of payer’s patches and more 
closely represent the colonic than the small intestinal epithelium. Similar to isolated 
intestinal models, the cultured intestinal cells do not account for other gastrointestinal 
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physiological variables like transit time, motility, hepatic first pass clearance, hydrolytic 
and enzymatic degradation, which contribute to reduced oral bioavailability [125].  
The influence of size, charge, incubation time, and concentration of amine-
terminated PAMAM dendrimers G0.0 to G4.0 across Caco-2 cell monolayers was first 
studied by El-Sayed et al. [105]. In this study, it was observed that the basolateral to 
apical (BA) permeability of each dendrimer was generally higher than the corresponding 
apical to basolateral (AB) permeability which was attributed to the difference in tight 
junction characteristics at the apical and basolateral sides. TEER measurements and the 
permeability of a known paracellular permeability marker, 
14
C-mannitol showed that 
PAMAM dendrimers modulated tight junctions. Tight junction modulation was a 
function of PAMAM generation, nature of surface functional groups, surface charge 
density and concentration [105]. Detailed studies on the influence of surface charge of 
PAMAM dendrimers on transepithelial transport of 
14
C-mannitol across Caco-2 cells and 
their cytotoxicity showed that neutral PAMAM dendrimers with hydroxyl surface 
terminal groups (PAMAM–OH) did not significantly influence TEER or 14C-mannitol 
permeability across Caco-2 monolayers [107]. Anionic, carboxylic acid-terminated 
PAMAMs (PAMAM–COOH) had a generation-dependent effect on TEER and 14C-
mannitol permeability. Owing to a low surface charge density, smaller generation G-0.5, 
G0.5 and G1.5 did not cause decrease in TEER values or increase in 
14
C-mannitol 
permeability. Due to an increase in surface charge density, G2.5 and G3.5 caused a 
significant decline in TEER compared to control values and a 6-fold increase in 
14
C-
mannitol permeability and were not cytotoxic to cells at concentrations tested as per the 
lactate dehydrogenase (LDH) assay indicating no damage to plasma membrane [107]. 
40 
 
Amine-terminated dendrimers also decreased TEER and increased mannitol paracellular 
transport by modulating tight junctions of Caco-2 cell monolayers. 
In a subsequent study it was demonstrated that in addition to enhancing 
paracellular transport, PAMAM dendrimers are also translocated across the epithelial 
barrier of Caco-2 cells by endocytosis mechanisms [106]. The permeability of G2.0–NH2 
was significantly lower at 4
0
C than at 37
0
C, suggesting active cellular uptake and 
endocytic mechansims of transport. It was observed that the BA permeability of G2.0–
NH2 as well as 
14
C-paclitaxel, a known P-gp substrate were higher than that of AB 
permeability, suggesting a functioning P-gp efflux pump in the Caco-2 cell monolayers 
being used [106]. It was also noted that there was no significant difference in AB and BA 
permeability of 
14
C-paclitaxel in the presence of G2.0-NH2. The AB and BA permeability 
of G2.0–NH2 did not change in the presence of paclitaxel, which suggests G2.0-NH2 is 
not competing with paclitaxel for the P-gp efflux [106]. 
Since these initial studies demonstrated that PAMAM dendrimers are transported 
by both para- and transcellular routes, more detailed studies on the mechanism of 
transport of PAMAM dendrimers have been carried out which are summarized below: 
14
C-Mannitol permeability was found to significantly increase in the presence of 
both cationic (G2.0-NH2 and G4.0-NH2) and anionic (G1.5-COOH and G3.5-COOH) 
PAMAM dendrimers indicating the opening of tight junctions [112]. It did not increase 
for the hydroxyl-terminated PAMAM G2.0-OH. TEER values also decreased for cells 
incubated with charged PAMAM dendrimers. Amine-terminated PAMAM of generation 
2.0 showed the greatest decline in TEER suggesting that it caused the highest tight 
junction modulation amongst dendrimers tested. An interesting finding was that TEER 
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modulation of surface modified-G4.0-NH2 was reversible and TEER values came back to 
90% of original within 24 hours. A 1/8
th
 surface coverage with FITC masked the surface 
positive charge to some extent and possibly also altered the PAMAM conformation thus 
altering its tight junction modulation capability. Occludin is one of the major proteins of 
the tight junction protein complex, responsible for fusion of adjacent plasma membranes. 
Increased accumulation of occludin at the cellular junctions indicates tight junction 
opening. Immunofluorescence microscopy revealed increased occluding accumulation in 
Caco-cells treated with charged PAMAM dendrimers [112]. The same trend was seen for 
Actin, a cytoskeletal protein responsible for cellular integrity. Actin disruption was seen 
for cells treated with PAMAM dendrimers [112]. Immunofluorescence studies 
qualitatively demonstrated that PAMAM dendrimers modulate tight junctions. These 
studies further confirmed that PAMAM dendrimers modulated tight junction proteins 
occludin and actin and that increased permeability of dendrimers is partly due to opening 
of tight junctions, which can be reversible depending on the concentration, generation 
and surface charge of the dendrimers.  
The endocytic pathway is known to be an important route for intracellular uptake 
of macromolecules [115]. Confocoal microscopy of FITC-labeled PAMAM dendrimers 
revealed that both cationic and anionic PAMAM dendrimers were internalized within 20 
min, and localized within coated invaginated pits of the plasma membrane, early 
endosomes and lysosomes [115]. Clathrin-mediated endocytosis was found to be the 
primary mechanism of cellular uptake for the PAMAMs. Over time, the dendrimers were 
seen to concentrate within lysosomes. 
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The detailed mechanistic investigation of Caco-2 uptake of G4.0-NH2 by 
endocytosis was carried out [119]. The endocytosis inhibitors used were 1) brefeldin A 
and 2) colchicine to inhibit trafficking via formation of microtubules, 3) filipin to inhibit 
claveolin-mediated endocytosis and 4) sucrose to inhibit clathrin mediated endocytosis. 
Brefeldin A and colchicine reduced G4.0-NH2 uptake 2-fold and 3-fold, respectively 
[119]. Both filipin and sucrose reduced uptake 3-fold [119]. Along with cellular uptake, 
apparent permeabilities of G4.0-NH2 were also reduced in presence of these inhibitors, 
suggesting that cellular uptake contributed to increased transepithelial transport (Figure 
2-5). These findings support previous results that in addition to paracellular transport, 
cationic dendrimers are also endocytosed. 
While the above studies were conducted on amine terminated systems, given that 
surface charge may influence the pathway of cellular uptake, the mechanisms of 
PAMAM G3.5-COOH dendrimer cellular uptake, intracellular trafficking, transepithelial 
transport and tight junction modulation in Caco-2 cell monolayers was evaluated [123]. 
G3.5 PAMAM dendrimer showed reduction in cellular uptake in the presence of 
inhibitors for clathrin, caveolin and a combination of the two that is dynamin-mediated 
endocytosis, suggesting the involvement of both clathrin- and caveolin-mediated 
endocytosis pathways in cellular uptake [123]. The greatest reduction in uptake of 
PAMAM G3.5 was shown in the presence of dynasore, an inhibitor for dynamin-
mediated endocytosis. Upon cellular uptake, PAMAM dendrimers (tracked by labeling 
them with Oregon green dye) were seen to localize within early endosomes and lysosome 
[123]. As expected, cells treated with PAMAM G3.5 showed increased occludin, 




Figure 2-5. Reduced apparent permeability (Papp x 10
6
 cm/s) of Riboflavin (500 
nM) and G4.0-NH2 (1 μM) across Caco-2 cell monolayers in the presence of 
endocytosis inhibitors. Bars from left to right indicate: 1-5 μM brefeldin A; 10 
μM colchicine; 1 μg/ml filipin; 200 mM sucrose. Results are reported as mean ± 
SD (n = 3). **, p < 0.01: ***, p < 0.001. With permission from Ref [119]. 
Copyright 2008 American Chemical Society. 
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inhibited, tight junction modulation also decreased, seen by occludin staining (Figure 2-
6). This suggests that dendrimers self-catalyze their paracellular transport by being taken 
up intracellularly and acting on   intracellular proteins [123]. Monitoring changes in 
TEER with and without inhibition of cellular uptake, when cells are incubated with 
PAMAM dendrimers will confirm the need for dendrimer  internalization to modulate 
tight junctions. More studies are needed to evaluate whether such phenomenon is indeed 
responsible for tight junction opening of other dendrimers with a different surface charge 
or generation, and to further delineate the contributions of extracellular vs intracellular 
factors in opening of the tight junctions in the presence of dendrimers.  
More recent reports have focused on modeling the porosity of epithelial layers as 
a function of dendrimer generation, surface charge, concentration and incubation time 
[122]. Simulations show that the increase in concentration, incubation time and 
generation number (surface charge density) of cationic G0.0-NH2 to G2.0-NH2 and 
anionic G2.5-COOH to G3.5-COOH cause an increase in porosity of epithelial cell 
monolayers. These findings suggest that the transepithelial transport of PAMAM is due 
to disorganization of cell membranes along with experimentally established tight junction 
modulation and endocytic uptake [122].  
Together, these studies show that PAMAM dendrimers are transported across 
Caco-2 cell monolayers by a combination of the paracellular pathway and an energy-
dependent process, such as endocytosis (Figure 2-7). These studies have set the stage for 
evaluation of PAMAM dendrimers as drug carriers across epithelial barriers.  
Researchers have demonstrated that by engineering the surface groups of 



























































































































































































































































































































































































Figure 2-7. Transepithelial transport mechanisms of PAMAM dendrimers. With 




[108, 109, 113, 121]. It was shown that surface modification by uncharged groups (PEG, 
lauroyl, acetyl) reduced toxicity by charge masking of the primary amine groups [108, 
109, 113, 121]. Hydrophobic surface modifiers such as the acetyl groups and lauric acid 
increased permeability while hydrophilic polymers such as PEG reduced permeability 
[108, 109, 113, 121]. Thus, surface  modification provides a tool to reduce toxicity and 
influence permeability of PAMAM dendrimers across epithelial barriers.  
2.5.4. Transepithelial transport of PAMAM –  
drug complexes and conjugates 
Drugs can be attached to PAMAM dendrimers by covalent conjugation, 
complexed by surface ionic interactions or encapsulated by van der waals and 
hydrophobic interactions. Although, there has been extensive research on dendrimer-
based drug carriers for a variety of routes of delivery, very few studies have demonstrated 
transepithelial transport of such conjugates or complexes. 
Earlier studies by D’Emanuele and coworkers used PAMAM G3.0-NH2 or 
lauroyl-modified PAMAM G3.0-NH2 conjugated to propranolol in varying 
stoichiometric ratios of the drug [111]. Propranolol was conjugated to PAMAM G3.0 via 
a chloroacetyl spacer. PAMAM G3.0 was chosen because it has been shown to 
effectively permeate Caco-2 cell monolayers and was not a P-gp substrate [106]. P-
glycoprotein efflux pump reduces the absorption of orally administered drugs such as 
propranolol and decreases bioavailability. Lauroyl modification of PAMAM G3.0-NH2 is 
known to increase its permeability across Caco-2 monolayers [108]. The amine-
terminated PAMAM dendrimer was cytotoxic to Caco-2 cells and cytotoxicity decreased 
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with an increase in the amount of propranolol and lauric acid conjugated, attributed to the 
shielding of positive surface charge of primary amine groups on PAMAM G3.0-NH2. Co-
administration of P-gp inhibitors such as cyclosporine A can increase bioavailability by 
blocking the P-gp efflux. As expected, the Papp of free propranolol was increased in the 
presence of the P-gp inhibitor cyclosporin A but not in the presence of PAMAM G3.0-
NH2 conjugated propranolol, suggesting that the conjugate was not a substrate of the P-gp 
efflux pump. The enhancement of propranolol transepithelial transport was independent 
of attachment ratio of drug to dendrimer over the range studied (2–6 moles of propranolol 
per mole of G3.0-NH2). The maximum enhancement (3.5 fold) was achieved when 6 
lauroyl chains were attached to PAMAM G3.0-NH2 containing 2 propranolol moieties 
[111]. The conjugate permeability decreased at 4
0
C as compared to 37
0
C, suggestive of 
active endocytic uptake of the conjugate in Caco-2 cells followed by transcellular 
transport [111]. TEER values suggested that paracellular route did not contribute to 
transport of the lauroyl-modified conjugate. Overall this study showed that conjugation of 
propranolol with dendrimers increased transepithelial transport of the drug by increasing 
drug solubility and circumvention of the P-gp efflux pump [111]. However, detailed 
evaluation of the stability of the conjugated system in presence of Caco-2 cell culture 
medium and GI conditions warranted further investigation in order to understand stability 
of the conjugate. 
A conjugate of Naproxen, a poorly water-soluble drug, and PAMAM G0.0 was 
also evaluated as an oral prodrug. The drug was linked to the dendrimers directly by an 
amide bond or by ester bond or using spacers-l-lactic acid and diethylene glycol [134]. 
The type of linkage between the dendrimer and drug affected the release characteristics 
49 
 
of the drug from the delivery system. While the direct amide linkage was stable under the 
conditions of plasma and liver homogenate tested, the ester linkage could be tailored to 
be stable in plasma and release the drug at the desired site of action in the liver [114, 
134]. The conjugates were hydrolytically stable under different pH conditions ranging 
from gastric to intestinal and colonic pH. However, conjugates were susceptible to 
enzymatic hydrolysis. Efficient drug release was achieved for both ester conjugates in 
plasma with the lactic ester conjugate (G0-lact-Nap) hydrolyzing more slowly than the 
diethylene glycol ester conjugate (G0-deg-Nap) [134]. The same trend was observed in 
presence of plasma [134]. The length of the spacer affected enzymatic release of the drug. 
The longer spacer (diethylene glycol) is likely to cause less steric hindrance for 
enzymatic cleavage and hence may cause faster cleavage of drug in the plasma and liver 
homogenate. Conjugation of naproxen to dendrimer increased its transepithelial transport 
across Caco-2 cells [134]. The transport of drug was further improved by lauroyl-
modifying PAMAM G0.0. [134]. The study shows that PAMAM based drug conjugates 
with appropriate linkers have the potential to improve drug solubility, increase 
transepithelial transport and act as carriers for the oral delivery of drugs such as 
naproxen.  
In another study Kolhatkar et al. complexed SN-38, a potent camptothecin 
analogue to PAMAM G4.0-NH2 (Figure 2-8) and assessed the transport of the dendrimer-
drug complex across Caco-2 monolayers (Figure 2-9) [118]. SN38 has poor aqueous 
solubility (<10 µg/mL), poor and variable permeability and severe dose-limiting gastric 
as well as other nonspecific toxicity, thus limiting its oral use. It was hypothesized that 
complexing SN-38 to G4.0-NH2 will result in increased solubility and permeability of the 
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Figure 2-8. Schematic representation of G4S5 complex. With permission 





Figure 2-9A. Gastrointestinal stability and transepithelial transport of PAMAM-SN38 
complex. Stability of polymer-SN-38 complexes G4S5 (open squares, solid line) and 
G4S11 (filled squares, solid line) at pH 7.4, and G4S5 (open circles, dotted line) and 
G4S11 (filled circles, dotted line) at pH 5. G4S5, G4S11: 5 and 11 moles of SN38 
complexed to PAMAM G4.0 respectively. B. Permeability of G4S5, G4S11 and SN-






drug and will help reduce toxicity of SN-38. When complexed with PAMAM G4.0-NH2, 
SN-38 showed up to 10 fold higher permeability and 100 fold higher uptake than free 
SN-38 (Figure 2-9B) [118]. PAMAM-SN38 complexation was attributed to surface 
electrostatic interaction, which is sensitive to pH. Therefore, the complex was not stable 
under acidic conditions. Only 10% of the drug remained complexed with the PAMAM 
after 30 minutes of exposure to pH 5.5 buffer (Figure 2-9A) [118]. These studies indicate 
that while complexation is a simple and viable approach, it has distinct drawbacks of 
instability and premature release.  
To overcome stability problems of the G4.0-SN38 complex and toxicity of the 
cationic G4.0-NH2 carrier, covalent conjugates of the non-toxic PAMAM G3.5-COOH 
and SN-38 with glycine and β-alanine spacers were synthesized, characterized (Figure 2-
10) and evaluated for cytotoxicity, mechanism of action (Figure 2-11), gastrointestinal 
stability (Figure 2-12A-B) and enzymatic release (Figure 2-12C) in the liver 
environment, as well as transepithelial transport in vitro (Figure 2-13) [124, 135]. 
PAMAM G3.5-COOH was chosen for its optimum balance of biocompatibility and 
Caco-2 permeability. The glycine spacer has been used in the clinically evaluated PEG 
and PGA-camptothecin conjugates [23, 136, 137]. Architecture of the polymeric carrier is 
likely to influence release and for the same spacer, a sterically hindered carrier like 
PAMAM will potentially cause drug to be released more slowly than a linear polymer 
like PEG or PGA, thus making the conjugate more stable to hydrolysis. An ester linkage 
is likely to be cleaved in the presence of carboxylesterase in the liver. Small spacers 
differing in one carbon atom were chosen in order to prevent indiscriminate acid and base 
























































































Figure 2-11. Nuclear fragmentation in HCT-116 cells treated with drug/conjugates. 
Untreated cells (column 1); 5 nM SN38 (column 2); 40 nM G3.5-gly-SN38 
(column 3); 120 nM G3.5-βala-SN38 (column 4). Scale bar is 10 μm. Arrows 
indicate nuclear fragments. From bottom: 1st row, differential interference contrast 
image; 2nd row, fluorescence image; 3rd row, overlay of differential interference 
contrast and fluorescence images. Reprinted with permission from Ref [135]. 

















































































































































































































































































































Figure 2-13. Transepithelial transport of G3.5-Gly-SN38 and G3.5-Ala-SN38 
conjugates. Equivalent SN38 flux across differentiated Caco-2 monolayers treated with 
G3.5-SN38 conjugates and SN38. Equivalent SN38 flux was calculated by multiplying 
the measured molar flux of the conjugates with the number of SN38 molecules per 
dendrimer. Mean ± standard deviation (n=4). (***) indicates a significant difference with 




inhibitor and is known to arrest cell cycle in the G2/M phase. Both free drug and 
conjugates caused majority of the cells to arrest in the G2/M phase and caused condensed 
nuclear fragments and mitotic cells when nuclear morphology was observed using 
fluorescence microscopy (Figure 2-11) [135]. This suggests that  the PAMAM-SN38 
conjugates had a similar mechanism of action as the free SN38 and that release of the free 
drug from the PAMAM carrier was necessary for it to exert cytotoxic action. These 
observations are also indicative of apoptosis or necrosis and suggest that free and 
conjugated SN38 has the same mode of action. 
The conjugates were further evaluated for stability in the GIT and enzymatic 
release. The glycine conjugate (G3.5-gly-SN38) was more susceptible to hydrolytic as 
well as enzymatic  release. Hydrolytic release under different conditions was less than 
enzymatic release for the glycine conjugate, minimizing nonspecific release and toxicity 
of the drug in the GIT and maximizing site-specific release in presence of 
carboxylesterases [124]. The glycine conjugate showed a good balance of gastrointestinal 
stability, transepithelial transport and cytotoxicity against colorectal carcinoma cells (HT-
29 cells) and effective release of free drug in the presence of liver carboxylesterases. The 
alanine conjugate (G3.5-βala-SN38) was mostly stable under all conditions (Figure 2-
12A-C) [124]. The extent of drug release correlated to cytotoxicity of the conjugates with 
the glycine conjugate being more cytotoxic than the alanine conjugate [124]. The 
transepithelial transport of SN38 when conjugated via the glycine spacer to G3.5 was 
concentration dependent and higher than the SN38 flux for the alanine conjugate, which 
was unchanged over the concentration range tested (10 and 100 μM) (Figure 2-13) [124]. 
This suggested a different mechanism of transport for the two conjugates-the glycine 
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conjugate by a more passive diffusion-related process (paracellular) and the alanine 
conjugate by a more active, cellular uptake related process (transcellular). 
 The PAMAM dendrimer used for complexation was amine-terminated while that 
used for conjugation was carboxylic acid-terminated. Hence, it is not possible to do a 
head to head comparison of the conjugate to the complex. But an interesting observation 
was that the increase in SN38 flux across Caco-2 cell monolayers was similar for the 
PAMAM-SN38 conjugates and complexes.  
The choice of linker or mechanism of drug association to dendrimer is critical to 
the stability of the dendrimer-drug conjugate/complex in the harsh conditions of the 
gastrointestinal tract and to the efficient release of the drug at the site of action. In the 
context of solid state malignancies, both the GIT and tumor physiology can have a 
common range of enzymes and pH. It is a chemical paradox to design a system perfectly 
stable in one condition and completely hydrolyzed in the other. It is therefore important 
to strike a balance between stability in the GIT and site-specific release. Identifying 
tumor-specific elevated enzymes and designing linkers to be specifically cleaved by them 
can potentially overcome this problem.  
2.5.5. In vivo oral bioavailability of PAMAM – drug complexes 
The work summarized in the above sections includes the in vitro evaluation of the 
transepithelial transport of dendrimer-drug conjugates or complexes. It was seen than 
conjugation and complexation of drugs to dendrimers has the potential to control release 
and improve bioavailability. In vitro models lack the variables of gastric emptying, 
intestinal tract motility and enzymatic environment of the gastrointestinal tract present in 
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in vivo models. However, they are useful to provide mechanistic insight into 
transepithelial transport and absorption and help come up with strategies to enhance the 
same. The choice of technique will depend on the research question and a combination of 
different models will ultimately provide an answer to the use of PAMAM dendrimers as 
oral drug delivery carriers. Two recent studies have evaluated the in vivo bioavailability 
of PAMAM-drug complexes. 
The extent of complexation of silybin, a potent hydrophobic alkaloid by cationic 
and anionic PAMAM dendrimers of varying generations, i.e., G1.5, G2.0, G2.5, and G3.0 
was evaluated at different molar ratios of dendrimer and drug [138]. G1.5 and G2.5 
incorporated 4 and 6 moles of silybin per mole of PAMAM while G2.0 and G3.0 
incorporated 20 and 32 moles of silybin per mole of PAMAM. At basic pH (9-10), 
around pKa of the primary amine terminal groups of the full generation dendrimers, both 
the amine groups of the dendrimer and the phenolic groups of silybin are ionized. This 
facilitates an additional electrostatic interaction between the surface amine groups and the 
oppositely-charged phenolic hydroxyl groups of silybin, explaining the higher association 
of silybin to full generation dendrimers. The in vitro release experiments suggested a 
controlled release of the drug from the complexes in simulated gastric (SGF) and 
intestinal (SIF) fluids. G2.0-silybin and G3.0-silybin complexes released up to 20% 
silybin in SGF at 2 hours and up to 90% silybin release in SIF at 10 hours [138]. The 
complexes were not highly stable in gastric conditions indicating that part of the drug is 
going to be released from the PAMAM in the small intestine, effectively resulting in free 
as well as complexed drug presented for oral absorption. The relative oral bioavailability 
of silybin was enhanced 2-fold by complexing with amine terminated PAMAM G2.0-
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NH2 when administered by oral gavage to male rats [138]. Part of the drug might have 
remained complexed to the dendrimer explaining an extended Tmax (15 minutes) of 
absorption as compared to silybin alone (Tmax = 10 minutes) [138]. The anionic 
PAMAM-silybin complex was not evaluated in vivo in this study. Authors speculated that 
increased oral absorption of silybin when complexed with PAMAM was due to a 
combination of increased solubility, controlled release, tight junction modulation and 
absorptive endocytosis of PAMAM-silybin complex [138]. 
The cellular uptake in Caco-2 cells, transport across rat intestinal segments and 
oral absorption pharmacokinetics of doxorubicin complexed with amine terminated 
PAMAM G3.0-NH2 in rats by oral gavage has also been investigated [120]. Controlled 
release of doxorubicin from doxorubicin–PAMAM (1:2 molar ratio) complex (74.5% 
during 24 hours) was observed in the presence of N-tris(hydroxymethyl)methyl-2-
aminoethanesulfonic acid (TES) buffer (pH 6.0-8.0) [120]. However, in the GIT, the 
PAMAM-doxorubicin complex can be subjected to lower pH in gastric fluid and also to 
enzymatic degradation. Release in simulated GIT conditions was not evaluated in this 
study. Doxorubicin is known to be a P-gp substrate. Its uptake in Caco-2 cells was 
enhanced in the presence of Cyclosporin A (CsA), due to the inhibition of P-gp efflux by 
CsA [120]. However, the doxorubicin uptake was higher when complexed with PAMAM 
compared to free doxorubicin alone or free doxorubicin with P-gp inhibitor. Addition of a 
P-gp inhibitor did not cause significant increase of uptake of the drug suggesting that 
when complexed with PAMAM, doxorubicin bypassed the P-gp efflux pump. Transport 
studies in everted intestinal rat segments of duodenum, ileum and jejunum showed that 
the transport of doxorubicin was higher (4-7 times at 90 min) when complexed with 
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PAMAM. The transport of doxorubicin was highest in the ileum. [120]. When the 
PAMAM-doxorubicin complex was incubated with different segments of the small 
intestine, a slight increase in permeability of mannitol, a paracellular marker, was 
observed. This is indicative of tight junction modulation by the complex and increased 
paracellular transport. The complex was evaluated in vivo by administration of a single 
oral dose in rats. A 300 fold increase in bioavailability of the doxorubicin was achieved 
when complexed with the dendrimer [120]. Increase in plasma exposure of doxorubicin 
when complexed with PAMAM was attributed to the solubilization effect of the 
PAMAM on doxorubicin, a highly hydrophobic drug. The GIT stability profile of the two 
dendrimer-drug complexes of doxorubicin and silybin has not been investigated in detail. 
Thus, there might be partial or complete release of the free drug complexed to the 
dendrimer in the GIT before absorption. The increased amount of drug detected in the 
blood stream could therefore also be due to a combination of the following factors: 1) 
increased solubilization by the dendrimer, 2) controlled release of the drug from the 
dendrimer, 3) intestinal penetration enhancement of the free drug by the dendrimer, and 
4) increased permeability of the PAMAM-drug complex.  
2.5.6. PAMAM dendrimers as intestinal penetration enhancers 
With its large surface area, the small intestine offers the opportunity for increased 
absorption. Cationic PAMAM dendrimers have been recently explored as a class of 
intestinal penetration enhancers that act on increasing the permeability of hydrophilic 




In situ intestinal models have been used to evaluate PAMAM dendrimers as 
penetration enhancers [131]. In an in situ method, the segment of the gut lumen to be 
evaluated is cannulated in the anesthetized animal. All physiological functions of the 
intestine remains intact and it is possible to access both apical and basolateral sides [125]. 
This model preserves mucous layer and sink conditions created by vasculature. However, 
it allows the assessment of absorption without the interference of gastric emptying and 
motility [125].  
The penetration enhancement was achieved using in situ closed loop method in 
SD rats at nontoxic doses and was reversible [131]. Effects of amine-terminated 
PAMAM generations 0-3 were examined on the absorption of 5(6)-carboxyfluorescein, a 
hydrophilic small-molecular weight dye. The absorption enhancing effects of PAMAM 
on the small intestinal segment were concentration and generation dependent. Of the 
dendrimers tested, PAMAM G2.0-NH2 showed maximum absorption enhancement, up to 
11.1 fold, at 0.5 % w/v. At this concentration, PAMAM G2.0-NH2 caused membrane 
damage as evaluated by the LDH assay [131]. However, the damage was found to be 
reversible. The absorption-enhancing effects of G2.0-NH2 were tested in the small 
intestinal segment at 0.5% w/v for hydrophillic macromolecular compounds like 
fluorescein isothiocyanate-dextrans (FDs) of various molecular weights, calcitonin and 
insulin. PAMAM G2.0-NH2 was effective in increasing the absorption of hydrophilic, 
macromolecular FDs up to 4000 dalton through the small intestine [131]. However, 
PAMAM G2.0-NH2 did not significantly increase the permeability of hydrophilic 
macromolecules of a molecular weight above 4,000 dalton, such as insulin and calcitonin 
[131]. Absorption enhancement across the small intestinal segment was found to be a 
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function of molecular weight with the absorption enhancement ratio being highest (about 
11.0) for 5(6)-carboxyfluorescein, a small molecular weight hydrophilic compound [131]. 
It has been speculated that amine-terminated PAMAM dendrimers modulated the tight 
junctions, suggested by decrease in TEER values, leading to an increase in absorption of 
the smaller sized hydrophilic molecules tested. Authors also suggest that the enlargement 
of the tight junction holes may not have been large enough to allow larger sized 
macromolecules like insulin to pass through [131]. Unlike conventional absorption 
enhancers, the absorption enhancing effects for PAMAM G2.0-NH2 observed in the 
small intestine was much greater than that seen in the large intestine in this study. 
Authors speculate that these differences could be due to segmental difference in the 
physiology of the intestine. Variations in the mucosal layer or tight junction arrangement 
can result in different interaction of the PAMAM dendrimer with the epithelial layer, 
resulting in different absorption enhancement action. Further research is needed in order 
to understand the mechanism of penetration enhancement of PAMAM dendrimers in 
order to exploit their absorption enhancement capacity. 
The study summarized above investigated cationic PAMAM dendrimers as 
penetration enhancers in situ. Previous research has shown in Caco-2 cell monolayers and 
isolated intestinal tissue that along with cationic PAMAM dendrimers, anionic, carboxyl-
terminated PAMAM dendrimers can also translocate across the intestinal barrier 
effectively while being less toxic to the epithelium as compared to the cationic 
dendrimers [103, 123]. Anionic PAMAM dendrimers also need to be evaluated for 
absorption enhancing effects. Both cationic and anionic dendrimers have to be evaluated 
for the penetration enhancement in vivo. 
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Co-delivery of poorly-soluble and poorly-absorbable drugs (BCS class IV) with 
PAMAM dendrimers that can act as penetration enhancers (Section 2.5.6) and 
solubilizing agents (Section 2.4) will help solubilize the drug and improve its 
permeability leading to increased oral bioavailability (Section 2.5.5). 
2.6. Oral delivery of chemotherapeutics 
Oral administration of chemotherapeutics has treatment advantages of patient 
preference and convenience and cost-effectiveness [139]. It is also advantageous for 
improving patient quality of life in palliative care. In terms of treatment outcomes, oral 
chemotherapeutics are advantageous for protracted dosage regimens as is the case for 
schedule-dependent cytotoxic drugs [139]. The major limitations for oral chemotherapy 
are significantly low bioavailability, intra and inter-patient variability attributed to 
intestinal metabolic and efflux systems like the CYP3A4 and the P-gp efflux, 
respectively [140]. Most cytotoxic chemotherapeutic drugs have a narrow therapeutic 
index which makes drug exposure variability a substantial concern. For such drugs, slight 
variations in bioavailability can lead to suboptimal exposure and inadequate efficacy or 
greater than optimal exposure and consequently excessive toxicities. 
2.6.1. Camptothecins as model chemotherapeutics for oral delivery 
Camptothecin and its derivatives are potent topoisomerase-I inhibitors [141]. The 
pharmacophore of camptothecins is known to be the closed α-hydroxylactone E ring. The 
lactone ring hydrolyzes under physiological conditions- pH 7.0 or above and in presence 
of serum albumin, that preferentially binds the ring-opened form [142]. Although the ring 
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opened form is pharmacologically inactive, this equilibrium is reversible and the lactone 
form can be obtained under acidic pH (Figure 2-14) [143]. Camptothecins show a 
schedule-dependent activity which means that they are more efficacious with low and 
frequent dosage regimens [140].  
Topotecan, 9-aminocamptothecin and Irinotecan have been evaluated for oral 
dosing preclinically and clinically. Topotecan had moderate bioavailability (30.0 +/- 7.7 
%) in Phase I with equivalent efficacy to IV administration [140]. It showed similar ratio 
of lactone to carboxylate exposure when administered orally as compared to IV along 
with an increased half-life upon oral administration. Irinotecan, evaluated in Phase I 
studies, showed poor and variable bioavailability (8-12 %) [144].  
2.6.2. Hepatic metastasis of colorectal cancer as a model for  
oral delivery of camptothecins 
Colorectal cancer is the third leading cause of cancer in the United States with an 
estimated 103,170 new cases and 51,690 deaths in 2012 [145]. Approximately 50% of the 
patients develop metastatic disease, the most common site being the liver, followed by 
the lung [145]. With improved screening, colorectal cancers are being detected at early 
surgery remains the primary treatment. However, for metastatic disease, very few patients 
qualify for surgical resection. Chemotherapeutics indicated for metastatic colorectal 
cancer include derivatives of floxuridine, 5-fluorouracil, camptothecin and cisplatin. 
Irinotecan, the prodrug of 7-ethyl-10-hydroxy-camptothecin (SN-38), administered 
intravenously, is indicated along with 5-fluorouracil and folic acid (FOLFIRI) for the first 




Figure 2-14. Camptothecin (lactone and carboxylate forms) and its analogues.  
 
Note: Camptothecin: R=R1=R2=R3=H; 10-Hydroxycamptothecin: 
R=R1=R3=H, R2=OH; 10-Methoxycamptothecin: R=R1=R3=H, R2=OCH3; 




of colorectal cancer [145]. IV administration of Irinotecan along with oral prodrug of 5-
fluorouracil (cepecitabine) is a  treatment regimen that has shown promise of increased 
efficacy, decreased toxicity and increased patient compliance [145]. Some of the 
problems with existing systemic chemotherapies are high non-specific toxicities like 
diarrhea and neutropenia along with long infusion times (48 hours). Oral delivery of these 
chemotherapeutics can enable low dose regimens with frequent administration 
(prolonged exposure) required for drugs like camptothecins that show schedule-
dependent activity [144, 146]. Camptothecins, when administered orally, take advantage 
of the first pass effect and accumulate in the liver and liver metastasis. They are primarily 
detoxified via glucoronidation by P450 CYP3A4 in the liver [147]. The liver metastasis 
does not have a mechanism of detoxifying camptothecins via glucuronidation thereby 
generating sufficient drug to be cytotoxic to the tumor [147]. However, irinotecan 
administered orally shows very low (8-12%) oral bioavailability [144, 146]. 
Enhancement in oral bioavailability of camptothecins will improve efficacy of treatment 
and avoid invasive routes of drug administration. 
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COMPARATIVE BIODISTRIBUTION OF PAMAM-OH 
DENDRIMERS AND HPMA COPOLYMERS 
3.1. Introduction 
Biocompatible water-soluble polymers have been widely used for biomedical 
applications such as drug-delivery and in vivo imaging [1]. Conjugation of anticancer 
drugs to polymers has facilitated increased efficacy due to longer blood circulation and 
preferential accumulation in solid tumors as per the enhanced permeability and retention 
(EPR) effect
 
[2]. Polymeric prodrugs have also been actively targeted to receptors of 
malignant cells or endothelial cells of the tumor to increase site-specific localization
 
[3-
5]. Owing to the stealth properties of water-soluble polymers and their ability to passively 
and/or actively target solid tumors, polymer therapeutics demonstrate reduced toxicity 
and higher maximum tolerated doses than small MW anticancer drugs [6]. Polymeric 
carriers may be linear such as poly(N-(2-hydroxypropyl)methacrylamide) (HPMA) or 
branched such as poly (amido amine) or PAMAM dendrimers (Figure 3-1).  
 
1
Note- Reprinted with permission from S. Sadekar, A. Ray, M. Janàt-Amsbury, C. M. 
Peterson, H. Ghandehari, Comparative Biodistribution of PAMAM Dendrimers and 
HPMA Copolymers in Ovarian-Tumor-Bearing Mice, Biomacromolecules, 2011, 12, 88–







Figure 3-1. Schematics of linear random coil HPMA copolymer with side 
chains (left) and branched PAMAM dendrimer (right). 
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 Copolymers of N-(2-hydroxypropyl)methacrylamide (HPMA) with drugs, targeting 
moieties and imaging modalities have been well characterized for the influence of 
comonomer structure and composition on solution properties and in vivo biodistribution 
[3-5]
 
. Attachment of drugs and targeting moieties alters the random coil conformation of 
the HPMA homopolymer into a more folded structure, thereby reducing hydrodynamic 
size, circulation half-live and tumor accumulation 
 
[7]. The charge on the polymer side 
chains also affects half-life and biodistribution with charged HPMA copolymers being 
excreted more rapidly than their neutral counterparts [8].  
Hyperbranched polymers such as PAMAM dendrimers have shown promise as 
drug carriers for targeted delivery to solid tumors, owing to the nature of synthesis, an 
extraordinary level of structural control that is achieved for these constructs
 
[9-12]. The 
extent of branching, and nature and number of surface groups have been correlated with 
toxicity and biodistribution
 
[13-15]. Lower generation PAMAM dendrimers have flexible 
scaffolding, whereas the higher generation systems have a globular, rigid surface [10]. 
The lower generation PAMAM dendrimers are excreted through the kidneys whereas the 
higher generation ones are excreted either by liver alone or by a combination of renal and 
hepatic routes
 
[10]. The nature of surface groups influences dendrimer charge, which in 
turn, is correlated to toxicity both in vitro and in vivo
 
[14, 16, 17]. The cationic, amine 
terminated PAMAMs are more toxic than their anionic or neutral counterparts [14, 16]. 
Majority of the anticancer water-soluble polymer-drug conjugates in clinical trials 
have so far been linear in architecture
 
[18]. The EPR effect, therefore, has been better 
studied for polymer-drug conjugates with a linear backbone as compared to branched 
polymeric carriers. Recent work has focused on the influence of polymer architecture on 
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tumor targeting and drug delivery
 
[19]. A systematic comparison of the effect of polymer 
architecture on biodistribution, tumor localization, in vivo toxicity and elimination will 
aid in a rational, pharmacokinetically-guided design of an anticancer drug delivery 
system.  
The purpose of this study was to conduct a head to head comparison of the in vivo 
fate of PAMAM dendrimers with linear HPMA copolymers in order to understand the 
influence of polymer architecture on biodistribution in tumor-bearing mice. This 
comparison has been done under consistent experimental conditions of polymer 
characterization and animal model used for biodistribution thus providing valid 
comparative data of the biodistribution of the two polymer types. The animal model of 
choice is an orthotopic ovarian tumor model, which is an improvement over widely used 
xenograft tumor models and better simulates ovarian malignancy. Biodistribution studies 
were performed by dosing mice with 
125
Iodine-labeled PAMAM dendrimers and HPMA 
copolymers of comparable molecular weights. All major organ systems, carcass and 
excreta were collected at defined time points. Radiolabeled polymers were detected in 
organ systems by measuring gamma emission of the 
125
Iodine radiolabel.  
Attachment of probes to a polymeric carriers is known to affect size, shape and 
physicochemical properties of the carrier and this would introduce a separate variable in a 
head to head comparison study [8]. The influence of architecture on drug loading, drug 
release, cellular delivery and pharmacological activity in vitro has been investigated 
previously [20]. In this study, we have evaluated the influence of polymer architecture on 
in vivo fate in orthotopic tumor-bearing mouse models. The study has implications in 




PAMAM-OH generations 5.0, 6.0 and 7.0 were purchased from Sigma Aldrich 
(St. Louis, MO, USA). N-Succinimidyl-3-(4-hydroxy-3-[
125
I] iodophenyl) propionate 
(
125
Iodine labeled Bolton Hunter reagent) and radioactive sodium iodide (Na
125
I) were 
purchased from American Radiolabeled Chemicals (St. Louis, MO, USA). 6-8 weeks old 
Nu/Nu mice were purchased from Charles River Laboratories (Wilmington, MA, USA). 
A2780 was procured from American Type Culture Collection (Manassas, Virginia). 
HPMA homopolymer standards were a gift from Dr. Jindrich Kopecek’s laboratory at the 
University of Utah.  
3.3. Methods 
3.3.1. Polymer synthesis and fractionation 
HPMA copolymers were synthesized and fractionated to obtain weight average 
MW of 26 and 52 kDa and 131 kDa in order to have comparable molecular weights with 
PAMAM-OH: G5.0-OH, G6.0-OH and G7.0-OH (Table 3-1). The HPMA copolymers of 
26, 52 and 131 kDa were synthesized with 20, 20 and 5 mole percent glycine-glycine-
ethanolamine respectively in order to provide a linear polymer backbone with pendant 
groups, that facilitate drug loading mimicking previously studied polymers
 
(Figure 3-2 & 
3-3)
 
[4, 21]. Since the glycine-glycine-ethanolamine side chains are hydrophilic in nature, 
we do not expect 5-20 mole percent of these side chains to affect the random coil 
architecture of the HPMA copolymers. The side chains were terminated in hydroxyl 
groups, similar to terminal groups of PAMAM-OH dendrimers under study to minimize 


























































0 0 0 0 
MA-Tyr-
CONH2 
0 0 0 0 2 0.13 1 0.07 
MA-GG-
EtOH 
0 0 20 1.2 0 0 0 0 
MA-GG-
TT 
0 0 0 0 5 0.33 0 0 
MA-GG-
ONP 
20 1.1 0 0 0 0 0 0 
HPMA 78 4.30 78 4.71 93 6.07 99 6.85 
Numbers are theoretical values based on feed mole composition; # Measured values 




Figure 3-2. Synthetic scheme of HPMA copolymers (26 and 52 kDa). 
Copolymerization of the comonomers of HPMA (1), MA-GG-ONp (2) and MA-Tyr-
COCH3 (3) by free radical precipitation copolymerization with azobisisobutyronitrile 
(AIBN) as the initiator to form low MW HPMA copolymer (26 kDa) poly(HPMA-
co-(MA-GG-ONp)-co-(MA-Tyr-COCH3) (4) (Feed composition in Table 3-1). ONP 
aminolysis of (4) with ethanolamine to form low MW poly(HPMA-co-(MA-GG-
EtOH)-co-(MA-Tyr-COCH3) (6). Copolymerization of the comonomers HPMA (1), 
MA-GG-EtOH (5) and MA-Tyr-COCH3 (3) by free radical precipitation 
copolymerization with azobisisobutyronitrile (AIBN) as the initiator to form HPMA 
copolymer (52 kDa) poly(HPMA-co-(MA-GG-EtOH)-co-(MA-Tyr-COCH3) (6) 






Figure 3-3. Synthetic scheme of HPMA copolymers (131 kDa). 
Copolymerization of the comonomers HPMA (1), MA-GG-TT (2) and MA-Tyr-
CONH2 (3) by free radical precipitation copolymerization with azobisisobutyronitrile 
(AIBN) as the initiator to form high MW HPMA copolymer poly(HPMA-co-(MA-
GG-TT)-co-(MA-Tyr-CONH2) (4) (Feed composition in Table 3-1). ONP aminolysis 





 The comonomers N-(2-hydroxypropyl)methacrylamide (HPMA), N-
methacryloyl-glycylglycyl-para-nitrophenyl ester (MA-GG-ONp), and N-methacryloyl-
glycylglycyl-ethanolamine (MA-GG-EtOH), N-methacryloyl-glycylglycyl-thiazolidine-
2-thione (MA-GG- TT), N-methacryloyl tyrosine-methyl ester (MA-Tyr-COCH3) and N-
methacryloyl tyrosinamide (MA-Tyr-CONH2) were synthesized by previously reported 
procedures [22]. To synthesize the lower molecular weight HPMA copolymer of 26 kDa, 
poly(HPMA-co-(MA-GG-ONp)-co-(MA-Tyr-COCH3), the comonomers HPMA (78 
mole %), MA-GG-ONp (20 mole %) and MA-Tyr-COCH3 (2 mole %) were 
copolymerized by free radical precipitation copolymerization with azobisisobutyronitrile 
(AIBN) as the initiator at 50
0
C for 24 hours using acetone with 10% dimethyl sulfoxide 
as the solvent and 12.5 weight % monomer and 0.6 weight % initiator concentration 
(Table 3-1). The copolymer was reacted with ethanolamine at room temperature for 3-4 
hours to yield hydroxyl-terminated side chains (Figure 3-2). To synthesize the higher 
molecular weight HPMA copolymer of 52 kDa, poly(HPMA-co-(MA-GG-EtOH)-co-
(MA-Tyr-COCH3), the comonomers HPMA (78 mole %), MA-GG-EtOH (20 mole %) 
and MA-Tyr-COCH3 (2 mole %) were copolymerized by free radical precipitation 
copolymerization with AIBN as the initiator at 50
0
C for 24 hours using acetone with 10% 
dimethyl sulfoxide as solvent and 12.5 weight % monomer and 0.6 weight % initiator 
concentration (Table 3-1, Figure 3-2). To synthesize the high molecular weight HPMA 
copolymer of 131 kDa, poly(HPMA-co-(MA-GG-TT)-co-(MA-Tyr-CONH2), the 
comonomers HPMA (93 mole %), MA-GG-TT (5 mole %) and MA-Tyr-CONH2 (2 mole 
%) were copolymerized by free radical precipitation copolymerization with 
azobisisobutyronitrile (AIBN) as the initiator at 50
0
C for 24 hours using methanol as the  
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solvent and 18.5 weight % monomer and 0.5 weight % initiator concentration (Table 3-
1). The copolymer was reacted with ethanolamine at room temperature for 3-4 hours to 
yield hydroxyl-terminated side chains (Figure 3-3). The HPMA copolymers and 
PAMAM G7.0-OH  were fractionated by Size Exclusion Chromatography using a Fast 
Protein Liquid Chromatography system with a Hiload 16/60 Superdex
TM
 preparatory 
grade column and an ultraviolet detector (GE Healthcare, Piscataway, NJ). PAMAM 
G5.0-OH and G6.0-OH eluted as monodisperse peaks in a size exclusion chromatograph 
and did not need to be fractionated. The mobile phase for fractionation was 20% (v/v) 
acetonitrile and 80% (v/v) phosphate buffer saline (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.76 mM KH2PO4, pH 7.4) at a flow rate of 0.5 mL/minute. Eluted peaks were 
detected at a wavelength of 280 nm.  
3.3.2. Polymer characterization 
The chromatographic elution profiles of all the HPMA copolymers and PAMAM-
OH dendrimers under study were obtained using a Fast Protein Liquid Chromatography 
(FPLC) system with Superose 6
TM
 10/300 GL column (GE Healthcare, Piscataway, NJ) 
and an ultraviolet detector (GE Healthcare, Piscataway, NJ) in order to evaluate relative 
elution volumes and to check for the absence of small molecular weight impurities 
(Appendix A). The mobile phase for elution was 20% (v/v) acetonitrile and 80% (v/v) 
phosphate buffer saline (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.76 mM 
KH2PO4, pH 7.4) at a flow rate of 1.0 mL/minute. Eluted peaks were detected at a 
wavelength of 280 nm. The molecular weights and molecular weight distributions of the 
fractionated HPMA copolymers were estimated on the same  FPLC setup using HPMA 
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homopolymer standards of known molecular weights. The molecular weight distribution 
profile was estimated using multiangle light scattering setup attached to the FPLC system 
using a Dynamic Light Scattering (DLS) detector (Helleos II) attached to the FPLC 
system and analyzed using Astra
TM
 5.3.4.13 software (Wyatt Technologies, Santa 
Barbara, CA). The HPMA copolymers, HPMA homopolymer standards and PAMAM-
OH dendrimers were further characterized for hydrodynamic radius (Rh) using a 
Dynamic Light Scattering (DLS) detector (Helleos II) attached to the FPLC system and 
analyzed using Astra
TM
 5.3.4.13 software (Wyatt Technologies, Santa Barbara, CA). The 
tyrosine content in the HPMA copolymers of 26 and 52 kDa was analyzed by amino acid 
analysis (University of Utah Core Facility). The zeta potential of polymers dispersed in 
distilled (DI) water at a concentration of 5.0 mg/ml was measured using a Malvern 
Instruments Zetasizer Nano ZS (Westborough, MA).  
3.3.3. Radiolabeling of polymers 
The fractionated HPMA copolymers, containing tyrosine methyl ester in the side 
chains, were reacted with Na
125
I (American Radiolabeled Chemicals, St. Louis, MO) at 
room temperature in phosphate buffer (pH7.4, 0.02M) for 30 minutes with intermittent 
shaking. Ten mg of HPMA copolymer was reacted with 2 millicurie (mCi) of Na
125
I, 
dissolved in 0.5 mL of buffer each making up a reaction volume of 1.0 mL. PAMAM 
dendrimers were reacted with 2200 Ci/mmol of 
125
Iodine-labeled Bolton Hunter reagent 
(American Radiolabeled Chemicals, St. Louis, MO) over ice in Borate Buffer (pH 8.5, 
0.05M) for 30 minutes with intermittent shaking
 
[15]. 10 mg of PAMAM dendrimer was 
reacted with 1 mCi of 
125
Iodine labeled Bolton Hunter reagent, dissolved in 0.5 mL of 
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buffer each reaching a reaction volume of 1.0 mL. The radiolabeled polymers were 
dialyzed using clear cellulose ester FloatALyzer® tubes with a cutoff of 3.5 to 5.0 kDa 
(Spectrum® Laboratories Inc., Houston, TX) against five-4 Liter changes of deionised 
water over a period of 5 days (one water change per day). Upon dialysis, they were 
checked for absence of free iodine using a PD-10 size exclusion chromatography column 
(GE Healthcare, Piscataway, NJ) before use (Appendix A). Following dialysis of the 
reaction volume, the HPMA copolymers showed a specific radioactivity of 1.35 
microcurie/mg and the PAMAM dendrimers exhibited radioactivity of 4.5 microcurie/mg 
of polymer, as measured by a Gamma counter (Cobra Autogamma, Perkin Elmer, 
Wellesley, MA). 
3.3.4. Animal model and tumor inoculation 
Six- to eight-week old female Nude/Nude (Nu/Nu) mice were orthotopically 
inoculated by injecting a cell suspension of 1x10
6
 A2780 cells in 10μL of phosphate 
buffer saline directly beneath the left ovarian bursa for all the study groups except 
PAMAM G7.0-OH [23]. Animals used to assess the biodistribution of G7.0-OH were 
inoculated with 2x10
5
 A2780 cells. The tumor sizes at the time of animal sacrifice and 
organ harvesting were in the same range as those obtained by inoculation of 1x10
6
 cells 
for other groups. The non-metastatic tumors were allowed to grow for 4 weeks. Tumor 
size was monitored by palpating the tumors and by change in animal weight. All animal 
experiments were performed in accordance with the University of Utah IACUC 




Five groups of tumor-bearing mice were dosed intravenously by tail vein injection 
with 50 mg/Kg of radiolabeled G5.0-OH, HPMA copolymer (26 kDa), 40 mg/Kg of 
HPMA copolymer (52 kDa) and 20 mg/Kg of HPMA copolymer (131 kDa), PAMAM 
G6.0-OH, and G7.0-OH in 0.2 mL sterile saline. The solution of radiolabeled polymers 
was mixed with accurately weighed nonradiolabeled polymers in saline to prepare a 
radioactive dose of about 50,000 cpm per animal. The amount of polymer contributed by 
the radiolabeled polymer solution in preparing the dose was considered negligible. The 
mice were sacrificed at defined time points of 5 minute, 30 minute, 2 hour, 6 hour, 24 
hour and 1 week. All major organ systems were collected including blood, heart, lung, 
liver, spleen, kidney, tumor, contralateral ovary, brain and the rest of the carcass that 
included skin, muscle and intestines. Urine and stool were collected by housing animals 
in metabolic cages and were pooled for all the animals for a given study group at a 
particular time point. Blood and homogenized carcass were sampled whereas the rest of 
the organs collected were measured as a whole for radioactive count using a Gamma 
counter (Cobra Autogamma, Perkin Elmer, Wellesley, MA). All animal experiments 
were performed in accordance with the University of Utah IACUC guidelines under 
approved protocols. 
3.3.6. In vivo data analysis 
The radioactive readings obtained for the individual organs were expressed as a 
percentage of injected dose normalized to weight of the organ. Statistical Analysis was 
done using Analysis of Variance (Graphpad Prism®, version 5.01).  
93 
 
3.4. Results and discussion 
3.4.1. Characteristics of the polymers 
The PAMAM-OH dendrimers under study were generations 5.0, 6.0 and 7.0 with 
hydroxyl surface groups. These generations were chosen such that their molecular 
weights (29, 58 and 117 kDa) lie in the physiologically relevant range for kidney 
filtration, extended plasma circulation and tumor retention. The HPMA copolymers were 
synthesized and fractionated in order to have comparable molecular weights with the 
PAMAM-OH dendrimers. The HPMA copolymers were synthesized with 5-20 mole 
percent glycine-glycine-ethanolamine side chains in order to provide the linear polymer 
backbone with pendant groups that typically facilitate the attachment of bioactive and 
imaging agents
 
[4, 21]. The polymeric side chains terminated in hydroxyl groups, similar 
to the terminal groups of PAMAM-OH dendrimers under study in order to minimize the 
influence of surface or pendant functional group characteristics on comparative 
biodistribution. 
Polymer architecture affected molecular conformation and hence hydrodynamic 
size of the PAMAM dendrimers and HPMA copolymers of comparable molecular 
weights. The increment in hydrodynamic size (Rh) of HPMA copolymers with increase in 
molecular weight (MW) was greater than the increment in Rh of PAMAM dendrimers 
with the same increments in MW (Figure 3-4).  
Below a MW of about 40 kDa, PAMAM G5.0-OH (MW = 29 kDa) was larger 
(Rh = 2.3 nm) than HPMA copolymer of comparable MW (MW= 26 kDa, Rh = 1.4 nm) 
(Table 3-2). Above this cutoff of 40 kDa, the opposite trend was observed. PAMAM 
G6.0-OH (MW = 58 kDa, Rh = 3.0 nm) was smaller than HPMA copolymer of 
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Figure 3-4. Correlation of molecular weight with hydrodynamic radius of 
PAMAM-OH dendrimers, HPMA copolymers and HPMA homopolymer 





*Theoretical values based on perfect dendrimer synthesis [11]; Values are Mean +/- 
SD (n=3). 




























































comparable MW (MW = 52 kDa, Rh = 3.3 nm) (Table 3-2). The trend was consistent 
amongst the higher MW polymers with the HPMA copolymer (MW = 131 kDa, Rh = 8.2 
nm) being twice the hydrodynamic size of G7.0-OH (MW = 117 kDa, Rh = 4.0 nm) of 
comparable MW (Table 3-2). This difference in size increment with MW can be 
attributed to the difference in architecture of linear HPMA copolymers that have a 
random coil conformation compared to hyperbranched PAMAM dendrimers which are 
more compact. 
The conformation of hyperbranched polymers such as PAMAM depends on 
generation with the smaller dendrimers having a flexible scaffolding and higher 
generations assuming a more compact, globular shape with a dense exterior and relatively 
hollow interior
 
[10]. The   hydrodynamic sizes of amine-terminated dendrimers measured 
by dilute solution viscometry, light scattering, diffusion nuclear magnetic resonance and 
theoretically calculated by computer simulations that have been widely reported in 
literature are slightly higher than the hydrodynamic sizes measured for hydroxyl-
terminated dendrimers of the same generation (Table 3-1) [24-26]. This can be attributed 
to a more extended structure of the amine-terminated PAMAMs with charged surface 
groups as compared to neutral terminal groups in case of the hydroxyl terminated 
PAMAMs.  
Depending on the chemical nature of the pendant side chains, linear polymers 
may possess a random-coil architecture in case of hydrophilic groups, an extended chain 
conformation for negatively charged moieties or a unimicellar folded structure in the case 
of hydrophobic side groups [3]. The HPMA copolymers under study possess hydrophilic, 
hydroxyl-terminated ethanolamine side chains that are not likely to disrupt the random-
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coil conformation of the polymers. Upon comparing the sizes of the HPMA copolymers 
containing 5-20 mole % glycine-glycine ethanolamine and 2% tyrosine groups with 
HPMA homopolymer standards containing 1 % pendant tyrosine groups, the HPMA 
copolymer of 26 kDa had a hydrodynamic radius of 1.4 nm, comparable to that of the 
HPMA homopolymer standard (22 kDa) with a hydrodynamic radius of 1.5 nm. The 
HPMA copolymer of 52 kDa, however, had a hydrodynamic radius of 3.3 nm, smaller 
than that of the HPMA homopolymer standard (51 kDa) with a hydrodynamic radius of 
4.2 nm. This can be attributed to a higher tyrosine content in the HPMA copolymer of 52 
kDa (0.22 mmol tyrosine/g polymer), as measured by amino acid analysis; than the 
theoretical tyrosine content in the HPMA homopolymer (0.07 mmol/g polymer) (Table 3-
1). An increased number of tyrosine grafts on the HPMA copolymer backbone can lead 
to intra-molecular, hydrophobic interactions leading to a decrease in the hydrodynamic 
radius of the HPMA copolymer (52 kDa). Similarly, literature reported values of 
hydrodynamic radii of HPMA copolymers of similar molecular weights also vary 
depending on nature and percentage of side chains [7]. HPMA copolymer (131 kDa) had 
a slightly higher hydrodynamic radius than HPMA homopolymer standard (132 kDa) 
with a hydrodynamic radius of 7.5 nm. HPMA copolymer of 131 kDa was noted to have 
a slightly negative charge due to a hydrolysis side reaction, resulting in pendent 
carboxylic acid groups (Table 3-2). This side reaction can occur in the final aminolysis 
step in the copolymer synthesis reaction that imparts a majority of hydroxyl-terminated 
surface groups. The slight negative charge could result in a more extended coiled 
structure of the HPMA copolymer. This extended structure could potentially result in a 
greater hydrodynamic size of the copolymer in solution. 
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3.4.2.    In vivo biodistribution 
 The smallest of the PAMAM dendrimers under study, G5.0-OH showed 
predominant and persistent accumulation in the kidney compared to all other organs 
(Figure 3-5). G6.0-OH was taken up both by the kidney and the liver (Figure 3-6). 
However, it did not demonstrate extended circulation in the plasma. G7.0-OH is known 
to have a rigid sphere-like conformation [10]. It had a hydrodynamic radius of 4.0 nm 
and showed the highest plasma circulation time (Figure 3-7). This polymer was 
distributed over all organ systems due to retention in the plasma. Tumor accumulation 
profile of G7.0-OH was characteristic of macromolecules with slow accumulation that 
peaked at 6 hours and retained for 1 week.  
Small changes in hydrodynamic size of macromolecules in the nanometer range 
have been known to drastically affect pharmacokinetics
 
[27, 28]. MRI contrast agents 
based on PAMAM cores have shown a similar trend when increase in generation affected 
biodistribution, extravasation and mode of excretion [27, 28]. PAMAM based gadolinium 
contrast agents have shown that constructs below 6.0 nm were predominantly excreted 
via the kidneys, while larger constructs were taken up by the liver instead [27]. Those 
constructs in the size range of 5 to 8.0 nm were observed to extravasate into the tumor 
tissue from tumor vasculature. However, this data had limitations in quantitative 
interpretation owing to the detection technique (magnetic resonance). The size and 
conformation of the native PAMAM dendrimers of different generations may have also 
caused its interaction with plasma proteins, platelets and other components in the blood to 
differ. Detailed studies on interactions of these native PAMAM dendrimers with blood 
components could help better explain the effect of size and generation regarding its in  
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Figure 3-5. Percentage of injected dose / g of tissue for G5.0-OH in principal 




Figure 3-6. Percentage of injected dose / g of tissue for G6.0-OH; in principal 





Figure 3-7. Percentage of injected dose / g of tissue for G7.0-OH in principal 




vivo fate. HPMA copolymer of 26 kDa with the smallest hydrodynamic radius (1.4 nm) 
amongst the polymers tested, was excreted through the kidney (Figure 3-8) within two 
hours of administration and recovered in the urine (12% of injected dose, Appendix A). It 
showed slight kidney accumulation (20 % injected dose/g) with slow renal clearance for 
up to 1 week (6 % injected dose/g). A neutral HPMA copolymer with 5 mol% GFLG-OH 
and 0.6 mol% tyrosine in the side chains has been reported to have a similar 
biodistribution profile in a tumor-bearing rat model [8]. All major organ systems at one 
week were measured to have less than 1 % of injected dose/g including the kidneys [8]. 
The difference in kidney accumulation between the reported HPMA-GFLG-OH 
copolymer and the HPMA copolymer under study can be attributed to the electronegative 
charge on the HPMA copolymer under study (zeta potential of -15.0mV, Table 3-2). 
Reports in literature have demonstrated that ionized linear polymers accumulate in 
kidneys as a function of electronegative charge [29, 30]. The HPMA copolymer of 52 
kDa and 131 kDa circulated in the plasma slightly longer than HPMA copolymer of 26 
kDa and showed distribution in all organ systems (Figure 3-9 & 3-10). HPMA 52 kDa 
showed slight tumor accumulation that peaked at 6 hours but did not show prolonged 
retention at 24 hours. Its tumor accumulation seemed less than that reported for HPMA 
homopolymer of similar molecular weight studied in a tumor-bearing rat model [8]. This 
can be explained due to the difference in hydrodynamic radius of the HPMA copolymer 
(52 kDa) under study and the HPMA homopolymer standard as discussed in the polymer 
characterization section, thereby highlighting the importance of hydrodynamic size of the 
polymer in deciding the in vivo fate. The HPMA copolymer (52 kDa) under study was 




Figure 3-8. Percentage of injected dose / g of tissue for HPMA copolymer 26 
kDa in principal organs; Values are Mean +/- SEM; n=5; except n=4 for 2 hour 
HPMA copolymer (26 kDa). 
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Figure 3-9. Percentage of injected dose / g of tissue for HPMA copolymer 52 kDa in 
principal organs; Values are Mean +/- SEM; n=5; except n=4 for 5 minute and n=3 
for 1 week. 
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Figure 3-10. Percentage of injected dose / g of tissue for HPMA copolymer 131 
kDa in principal organs; Values are Mean +/- SEM; n=3 for 5 minute, 30 
minute, 2 hour; n=4 for 6 hour and n=5 for 24 hours and 1 week. 
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injected dose in the urine 24 hours after injection (Appendix A) and showed negligible 
liver accumulation. The HPMA copolymer (131 kDa) was long circulating in the plasma 
owing to its large hydrodynamic size. It did not show persistent kidney or liver 
accumulation. However, it did show characteristic tumor permeability and enhanced 
retention greater than the smaller HPMA copolymers (Figure 3-10). The filtration size 
cut-off for the kidney is known to range from a hydrodynamic diameter of 3.7 to 6.0 nm
 
[31]. PAMAM G5.0-OH and HPMA copolymer of 26 kDa (<5.0 nm in hydrodynamic 
diameter) can be readily filtered through the glomeruli. We observed kidney retention for 
G5.0-OH for 1 week up to 150 percent injected dose/gram of tissue (Figure 3-11). HPMA 
copolymer of comparable molecular weight showed a lesser extent of kidney 
accumulation and did not persist in the kidney for a week indicating that polymer 
conformation affected renal reabsorption and retention. Data in literature reports 80 
percent of injected dose of PAMAM dendrimer, amine terminated, generation 4.0 (G4.0-
NH2)/gram of kidney tissue, which reduced to 10 percent of injected dose/gram of kidney 
upon PEGylating the dendrimer
 
[32]. It has been reported that PAMAM G4.0-gadolinium 
complexes accumulate in the proximal   straight tubules in the outer medulla stripe of the 
kidney
 
[33]. Limited mechanistic studies for renal retention of PAMAM dendrimers 
report the localization of these polymers in the lysosomes of proximal tubule cells [33]. 
This uptake is only possible upon filtration of the dendrimers, providing access to 
reabsorption into the proximal tubules. The biodistribution of acetylated PAMAM G5.0 
has been reported and the construct has shown negligible kidney accumulation [34]. 
Acetylation may increase the hydrodynamic size of the PAMAM beyond the glomerular 




Figure 3-11. Percentage of injected dose / g of kidney tissue for PAMAM 
dendrimers and HPMA copolymers. Values are Mean +/- SEM; n=5; except  n=4 
for 5 minute HPMA copolymer (52 kDa), 2 hour HPMA copolymer (26 kDa) and 
G5.0-OH, 6 hour HPMA copolymer (131 kDa); 6 hour and 24 hour G7.0-OH and 
n=3 for 1 week HPMA copolymer (52 kDa), 5 minute, 30 minute, 2 hour HPMA 
copolymer (131 kDa). *** indicates a statistically significant difference as per 
ANOVA and Bonferroni’s multiple comparison test comparing G5.0-OH with all 
other treatment groups, p < 0.001. Kidney exposure calculated by area under the 
curve using trapezoidal rule was statistically significantly different (p<0.001) for 
G5.0-OH compared with other treatment groups as per ANOVA and Bonferonni’s 




PAMAM G6.0-OH (Rh = 3.0 nm, Table 3-2) and G7.0-OH (Rh = 4.0 nm, Table 3-2) 
studied here are not readily filtered due to their  hydrodynamic sizes being above the 
filtration threshold cutoff and hence do not show prolonged renal retention comparable to 
G5.0-OH (Figure 3-11). However, the renal accumulation of G6.0-OH was greater than 
HPMA copolymer of 52 kDa suggesting that polymer architecture affected renal 
retention (Figure 3-11). The renal uptake for PAMAM G7.0-OH is comparable to that of 
pegylated G4.0-NH2 dendrimers reported in the literature [32]. This indicates that it is 
possible to reduce non-specific kidney uptake by increasing dendrimer generation to a 
hydrodynamic size beyond kidney filtration pore size cut-off. The smaller generation 
G5.0-OH that is observed to accumulate in the kidney may be used for kidney imaging to 
detect renal tubular damage
 
[35, 33]. The constructs suggested for this application have 
been dendrimer-based-magnetic resonance imaging (MRI) contrast agents that are amine 
terminated [35, 33]. A hydroxyl-terminated dendrimer such as PAMAM G5.0-OH shows 
the same or higher extent of kidney accumulation and is likely to be less toxic in vivo 
than the amine terminated dendrimer of same generation [13]. Inspite of persistent kidney 
accumulation, PAMAM G5.0-OH did not show elevated kidney toxicity markers at 1 
week (refer to Appendix A). An elevated white blood cell count was observed (refer to 
Appendix A). It has been observed that physicochemically modified HPMA copolymers 
accumulate in the kidney to a higher extent than their non-modified counterparts
 
[8]. The 
introduction of peptide moieties was found to increase kidney accumulation and a direct 
correlation was observed between the amount of carboxyl and hydrazide groups on the 
HPMA copolymer and the extent of kidney localization [36]. HPMA copolymer of 26 
kDa, under study, had a slightly negative zeta potential indicative of the presence of 
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carboxyl groups which could potentially explain its renal accumulation. HPMA 
copolymers functionalized with the targeting peptide RGDfK and DTPA (1,2-diamine-
N,N-N′,N′,N″,N″-pentaacetic acid) chelating moiety in the side chains showed persistent 
kidney accumulation that correlated with the amount of peptide loading [29]. It would be 
interesting to study the effect of surface modification of PAMAM dendrimers with 
peptides on kidney accumulation and establish a systematic correlation of the same in 
non-linear, hyperbranched polymers.  
PAMAM dendrimers (G5.0-OH and G6.0-OH) accumulated to a larger extent in 
the liver than HPMA copolymers of similar molecular weight (26 kDa and 52 kDa) 
(Figure 3-12). PAMAM G6.0-OH, with a hydrodynamic radius of 3.0 nm (Table 3-1) is 
on the threshold of kidney filtration size cutoff. It showed a high extent of accumulation 
observed in the liver (Figure 3-12). PAMAM G7.0-OH with its rigid sphere-like globular 
structure and a hydrodynamic radius of 4.0 nm circulates longer in the plasma than 
PAMAM G6.0-OH (Figure 3-12). Its liver accumulation is less than G6.0-OH at the time 
points under study. However, there is a possibility of an increase in RES organ uptake 
when the polymer may be eliminated from the tumor (beyond the range of the time points 
under study). It has been shown that amine terminated PAMAM Generation 4.0 and 5.0 
interact with plasma proteins such as human serum albumin, bovine serum albumin and 
enzymes such as human erythrocyte acetyl cholinesterase and alter  the protein 
conformation and enzyme activity [37-40]. It has also been shown that in the case of 
other nanoparticulate constructs, smaller particles with higher surface curvature had a 
better retention of the native protein structure and function than larger nanoparticles [41]. 
There is, therefore, a possibility that PAMAM G6.0-OH with a smaller hydrodynamic 
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Figure 3-12. Percentage of injected dose / g of liver tissue for PAMAM 
dendrimers and HPMA copolymers. Values are Mean +/- SEM; n=5; except  n=4 
for 5 minute HPMA copolymer (52 kDa), 2 hour HPMA copolymer (26 kDa) and 
G5.0-OH, 6 hour HPMA copolymer (131 kDa); 6 hour and 24 hour G7.0-OH and 
n=3 for 1 week HPMA copolymer (52 kDa), 5 minute, 30 minute, 2 hour HPMA 
copolymer (131 kDa). *** indicates a statistically significant difference as per 
ANOVA and Bonferroni’s multiple comparison test comparing G6.0-OH with all 
other treatment groups, p< 0.001. Liver exposure calculated by area under the 
curve using trapezoidal rule was statistically significantly different (p<0.001) for 
G6.0-OH compared with other treatment groups as per ANOVA and Bonferonni’s 
multiple comparison test. Using the same statistical tests, liver exposure was 






radius than G7.0-OH and a less dense surface exterior may interact differently with 
opsonizing proteins, causing it to be taken up by the liver. It would be necessary to 
investigate how the interaction of the PAMAM dendrimer with opsonizing proteins 
affects macrophage uptake and consequently in vivo fate.  Accumulation of PAMAM 
G6.0-OH up to 40% dose/gram of liver tissue did not affect liver function as indicative of 
plasma levels of alanine aminotransferase and aspartate aminotransferase (data not 
shown). The liver accumulation of the higher molecular weight polymers of varying 
architecture- HPMA copolymer (131 kDa) and G7.0-OH was not different, suggesting 
that in this molecular weight range, polymer architecture did not affect liver uptake. 
Within a given polymer series, tumor accumulation was correlated to 
hydrodynamic sizes as measured by dynamic light scattering. The largest dendrimer 
under study PAMAM G7.0-OH (Rh = 4.0 nm) showed the highest and most persistent 
tumor accumulation of about 4-6 percent injected dose/gram of tumor tissue up to a week 
(Figure 3-13). As is characteristic of the EPR effect, PAMAM G7.0-OH showed time-
dependent accumulation in the tumor that peaked at 6 hours and persisted for up to 1 
week with a tumor to blood ratio (T/B ratio) of about 12.75 [35, 42]. Inspite of the Rh of 
HPMA 131 kDa being twice that of G7.0-OH of comparable MW, the extent of tumor 
accumulation of HPMA copolymer of 131 kDa was less than that of G7.0-OH (p < 
0.001). Additional studies are needed to understand the effect of the linear and 
hyperbranched polymer architecture on rates and extent of microvascular extravasation to 
explain this difference in accumulation. The extent of tumor accumulation of HPMA 52 
kDa was less than the HPMA homopolymer of comparable MW reported in the literature
 




Figure 3-13. Percentage of injected dose / g of tumor tissue for PAMAM 
dendrimers and HPMA copolymers; Values are Mean +/- SEM; n=5; except  
n=4 for 5 minute HPMA copolymer (52 kDa), 2 hour HPMA copolymer (26 
kDa) and G5.0-OH, 6 hour HPMA copolymer (131 kDa); 6 hour and 24 hour 
G7.0-OH and n=3 for 1 week HPMA copolymer (52 kDa), 5 minute, 30 
minute, 2 hour HPMA copolymer (131 kDa).*/**/*** indicates a statistically 
significant difference with p<0.05, p<0.01 and p < 0.001, respectively, as per 
ANOVA and Bonferroni’s multiple comparison test comparing G7.0-OH and 





chains (0.22 mmol/g of polymer) on the HPMA copolymer leading to a decrease in 
hydrodynamic radius (3.3 nm, Table 3-2) as compared to 4.2 nm for the HPMA 
homopolymer standards, emphasizing the importance of nanoscale size variations in 
deciding in vivo fate. PAMAM G5.0-OH and HPMA copolymer of 26 kDa were cleared 
from circulation by kidney filtration and hence did not show tumor accumulation. The 
tumor accumulation data indicated a hydrodynamic radius cutoff of about 4.0 nm, below 
which prolonged tumor retention was not observed for the orthotopic ovarian carcinoma 
tumors under study. The HPMA copolymer of 52 kDa with a radius of 3.3 nm showed 
enhanced tumor accumulation up to 2 % injected dose/gram of tumor. However, unlike 
the HPMA copolymer of 131 kDa, it did not show enhanced retention. PAMAM G6.0-
OH with a hydrodynamic radius of 3.0 nm did not passively target the tumor (Figure 3-
13).  
The plasma exposure of the polymers is consistent with the hydrodynamic sizes of 
the macromolecules under study (Figure 3-14). The largest carriers in each of the 
polymer series HPMA copolymer (131 kDa, Rh = 8.1 nm) and G7.0-OH (Rh = 4.0 nm) 
showed the highest plasma exposures. The extended circulation times of these polymers 
allowed enhanced tumor accumulation. Comparing the linear and branched polymers of 
similar MW, percentage of injected dose / g of plasma tissue was statistically 
significantly different between HPMA copolymer (131 kDa) and G7.0-OH (117 kDa) of 
comparable molecular weights with the HPMA showing longer plasma circulation than 
PAMAM. This can be attributed to the hydrodynamic size of the HPMA copolymer being 
twice that of PAMAM. HPMA copolymer of 52 kDa circulated in the plasma for a 
slightly longer duration than PAMAM G6.0-OH of comparable MW. This can be 
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Figure 3-14.  Percentage of injected dose / g of plasma tissue for PAMAM 
dendrimers and HPMA copolymers. Values are Mean +/- SEM; n=5; except  
n=4 for 5 minute HPMA copolymer (52 kDa), 2 hour HPMA copolymer (26 
kDa) and G5.0-OH, 6 hour HPMA copolymer (131 kDa); 6 hour and 24 hour 
G7.0-OH and n=3 for 1 week HPMA copolymer (52 kDa), 5 minute, 30 minute, 
2 hour HPMA copolymer (131 kDa).**/*** indicates a statistically significant 
difference, p < 0.01 and p < 0.001, respectively, as per ANOVA and 
Bonferroni’s multiple comparison test comparing G7.0-OH and HPMA 131 kDa 




attributed to a slightly higher hydrodynamic radius of the HPMA   copolymer (Rh = 3.3 
nm) as compared to the compact dendrimer (Rh = 3.0 nm) that reduces kidney filtration. 
PAMAM G6.0-OH was also extensively taken up by the liver, thus reducing its plasma 
circulation time.    
The biodistribution results of the polymeric constructs under study have 
implications in the choice of carriers for drug delivery and imaging. Due to its selective 
and persistent kidney accumulation, PAMAM G5.0-OH should be used with caution to 
deliver drugs such as cisplatinum, methotrexate, stroptozotocin and mitomycin that cause 
kidney toxicity, but these polymers may be effectively used for kidney imaging to detect 
renal tubular damage and assess kidney function [33, 43]. This polymer also has the 
potential to treat kidney diseases due to preferential renal targeting, which is an area of 
growing interest. Although G5.0-OH did not show signs of acute renal toxicity over the 
period of the study (Appendix A), its  prolonged retention could lead to chronic renal 
toxicity. PAMAM dendrimers accumulated in the liver to a higher extent than the HPMA 
copolymers under study and hence should be used with caution to deliver drugs like 
adriamycin, methotrexate, 6-mercaptopurine, carboplatin, L-asparaginase and pentostatin 
that can cause liver damage. High generation PAMAM G7.0-OH showed reduced non-
specific uptake in the liver and kidney comparable to that of PEGylated dendrimers [32]. 
The effect of polymer architecture on drug loading, drug release, cellular delivery 
and pharmacological activity have been evaluated in vitro [20, 44]. In this study, we have 
evaluated the influence of polymer architecture on in vivo fate utilizing orthotopic A2780 
ovarian tumor-bearing nude mouse models. Polymer architecture affected renal and 
hepatic uptake of the constructs under study. The branched PAMAM dendrimers 
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accumulated to a larger extent in the liver than the linear HPMA copolymers. For 
polymers that could be easily filtered through the kidney, PAMAM dendrimers persisted 
for a longer period of time in the kidney tissue as compared to HPMA copolymers. This 
is indicative of a difference in the extravasation of polymers of varying architecture 
through fenestrations of healthy tissue [45]. Inspite of a greater hydrodynamic size and 
longer plasma circulation, the HPMA copolymer (131 kDa) accumulated in the tumor to 
a lesser extent than G7.0-OH of comparable MW. More work is needed to understand the 
effect of linear and hyperbranched polymer architecture on rates and extent of 
microvascular extravasation.  
3.5.   Conclusion 
 Macromolecular architecture affected the increment in hydrodynamic radius of 
the polymer with increase in molecular weight. Along with molecular weight, polymer 
architecture and hydrodynamic volume were critical to the in vivo fate of the 
macromolecules. Specifically, polymer architecture affected renal and hepatic uptake of 
the constructs under study, with the hyperbranched PAMAM dendrimers showing more 
persistent accumulation than their linear HPMA copolymer counterparts. The difference 
in hepatic and renal accumulation between PAMAM dendrimers and HPMA copolymers 
is indicative of a difference in the extravasation of polymers of varying architecture 
through fenestrations of healthy tissue. The tumor accumulation data indicated a 
hydrodynamic radius cutoff of about 4.0 nm, below which prolonged tumor retention was 
not observed for orthotopic ovarian carcinoma tumors under study. However, the 
hyperbranched PAMAM G7.0-OH (117 kDa) showed a higher tumor uptake than the 
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linear HPMA copolymer (131 kDa) of comparable molecular weight suggesting that 
polymer architecture affected tumor uptake. Additional studies are needed to understand 
the effect of the linear and hyperbranched polymer architecture on rates and extent of 
microvascular extravasation. A pharmacokinetic analysis of the data can give insight into 
the same (discussed in Chapter 4). The biodistribution result of the polymeric constructs 
guides the choice of a carrier of certain architecture and hydrodynamic size for 
preferential organ accumulation, which can be exploited for drug delivery and imaging 
applications. 
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COMPARATIVE PHARMACOKINETICS OF PAMAM–
OH DENDRIMERS AND HPMA COPOLYMERS 
4.1.   Introduction 
 The pharmacokinetics of hyperbranched PAMAM dendrimers has been 
correlated to its physicochemical properties-generation or molecular weight, chemical 
composition of core and nature of surface groups as well as type of surface modification 
[1-3]. The linear HPMA copolymers have also been well characterized for the influence 
of co-monomer structure, composition and charge on solution properties, molecular 
conformation as well as in vivo biodistribution and pharmacokinetics [4-6].  
Along with the molecular weight, polymer architecture and hydrodynamic size 
are also known to affect the biodistribution and consequently the pharmacokinetics of the 
polymeric carriers [7-10]. The shape and ability of macromolecules to deform  have  been 
 
1
Note- Reprinted with permission from S. Sadekar, O. Linares, GJ. Noh , D. Hubbard, A. 
Ray, M. Janát-Amsbury, C. M. Peterson, J. Facelli, H. Ghandehari, Comparative 
Pharmacokinetics of PAMAM-OH Dendrimers and HPMA Copolymers in Ovarian-





reported to influence their glomerular filtration and consequently elimination clearance 
and blood exposure [8]. In Chapter 3, a head to head comparison of the in vivo fate of 
hyper-branched hydroxyl-terminated poly(amido amine) or PAMAM-OH dendrimers 
with linear HPMA copolymers of comparable molecular weights in tumor-bearing mice 
was described. It was observed that along with molecular weight, hydrodynamic size and 
polymer architecture were critical in affecting the accumulation of these polymers in the 
tumor and elimination organs such as kidney and liver [10]. The purpose of this study 
was to model the previously obtained experimental data on the biodistribution of HPMA 
copolymers and PAMAM-OH dendrimers by compartmental pharmacokinetic analysis. 
By modeling the biodistribution data, the pharmacokinetic parameters of these polymeric 
carriers of varying hydrodynamic sizes and architecture were quantified in order to 
understand their effect on in vivo kinetics.  
4.2.   Pharmacokinetic analysis 
The radioactive readings obtained in counts per minute from blood, tumor, liver, 
kidney, urine and feces were expressed as milligram of dose (weight of polymer) using 
the correlation of administered dose in mg/kg of mouse and total counts per minute of 
radioactivity measured for each dose. The blood weights of each mouse were expressed 
in milliliters (volume of blood) assuming the density of mouse blood to be 1.05 g/mL. 
Consequently, the plasma concentration of polymers (Cp) was expressed as the weight of 
PAMAM-OH dendrimer / HPMA copolymer per unit volume of blood (mg/ml). The 
organ accumulations for tumor, liver and kidney were expressed in milligram of polymer 
per gram of organ weight (mg/g). The biodistribution data was modeled using a naïve 
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pooled data approach. Blood concentration data was fitted to one and two-compartmental 
models with single bolus input using WinNonlin® 2.1 (Pharsight, a Certara Company, St. 
Louis, Missouri). The Akaike Information Criterion (AIC) values obtained from each of 
the model fits indicated that the two-compartment model fit the blood concentration time 
profile better than the one-compartment model (Appendix A). The blood data was 
therefore modeled by two-compartment analysis using Winnonlin® 2.1 to obtain 
elimination clearance (E.CL) and blood exposure (AUCblood). Renal clearance (CLR) was 
calculated from urine data collected over 1 week (Equations (1) and (2), Section A.8., 
Appendix A). A compartmental model was set up in order to link the blood and the tumor 
compartments (Figure 4-1, 4-2). The model allowed a two-compartmental distribution for 
the blood between the central blood (Cp) and the peripheral fast distribution compartment 
(Cf) (as determined from fitting blood data alone). For the lower molecular weight 
polymers that did not show tumor retention, the tumor compartment (Ct) allowed 
elimination of the polymers back into the blood via the rate constant K5 (model 1, Figure 
4-1). For the higher molecular weight polymers that showed prolonged retention in the 
tumor, the tumor compartment was subdivided into two compartments, linked serially to 
the blood (model 2, Figure 4-2). The first compartment (Ct1) allowed elimination of the 
polymers back into the blood. For model 2, the second tumor compartment (Ct2) did not 
allow elimination in order to account for the tumor retention of the higher MW polymers 
observed in the study and in accordance with the EPR effect. An alternate model (model 
3) was also attempted where elimination was allowed from the second tumor 




Figure 4-1. Compartmental model linking the blood and the tumor compartment. 
Model 1- For lower MW polymers that did not show prolonged retention in the 
tumor. Model allows elimination from a single tumor compartment (t) back into 





Figure 4-2. Compartmental model linking the blood and the tumor compartment. 
Model 2- for higher MW polymers with prolonged retention in the tumor. Model 
allows elimination from the first tumor compartment (t1) via rate constant K5 
back into the plasma compartment but does not allow elimination from the second 
tumor compartment (t2). Model 3- Extension of model 2 where elimination is 
allowed from the second tumor compartment (t2) to the first tumor compartment 




constant K7. The blood elimination (K1) and distribution (K2, K3) rate constants were 
initially fixed as per the two-compartmental distribution of the blood data. The model 
was fitted to experimental blood and tumor data by varying the tumor extravasation (K4, 
K6) and elimination (K5, K7) rate constants using multivariable constrained optimization 
solver in Matlab® to obtain initial estimates of the tumor rate constants. Using initial 
estimates of the tumor rate constants as well as blood elimination and distribution rate 
constants, the model was refitted to experimental blood and tumor data by varying all of 
the rate constants by the multivariable constrained optimization solver in Matlab®. The 
AIC of model 3 for all the high MW polymers except G7.0-OH was slightly higher than 
the AIC of model 2 (that did not allow elimination from the second tumor compartment) 
(Appendix A). Hence, for high MW polymers showing prolonged retention, model 2 was 
chosen to fit blood and tumor data of higher MW polymers G6.0-OH and HPMA 131 
kDa while model 3 was chosen to fit data of G7.0-OH (compartmental model equations, 
optimization code, AIC and χ2 values given in Section A.11., Appendix A).  
Tumor exposures (AUCtumor) were computed from area under the tumor 
concentration time profile curve by the linear trapezoidal method. Blood and tumor 
exposures were dose normalized assuming linear pharmacokinetics over the dose ranges 
studied for the polymers (20-50 mg/Kg).  
4.3.    Results 
4.3.1.    Blood exposure 
The polymers showed a biphasic exponential blood circulation with an apparent 
fast distribution component and a much slower elimination component (Figure 4-3). 
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 The two-compartmental pharmacokinetic parameter estimates showed a significant 
difference across molecular weights for each of the polymer series-PAMAM-OH 
dendrimers and HPMA copolymers (Table 4-1). The dose normalized blood exposure 
(AUCblood/dose) increased with increase in molecular weight or hydrodynamic size for 
the PAMAM-OH dendrimers (Table 4-1, Figure 4-4). The HPMA copolymers had 
similar blood exposures for the 26 and 52 kDa copolymers, while the blood exposure 
increased drastically for the HPMA copolymer (131 kDa) (Table 4-1, Figure 4-4). 
Consistent with the trend for elimination clearance (Section 4.3.2), HPMA copolymer (26 
kDa) (Rh = 1.4 nm) had a higher blood exposure in spite of being smaller in 
hydrodynamic size than G5.0-OH (Rh = 2.3 nm) of comparable MW. The opposite was 
seen for HPMA copolymer (52 kDa) (Rh = 3.3 nm) and G6.0-OH (Rh = 3.0 nm) of 
comparable MW with the hyperbranched dendrimer showing higher blood exposure than 
HPMA copolymer of comparable MW even though the dendrimer was slightly smaller 
than the HPMA copolymer. This observation can also be attributed to the trend in 
elimination clearance where the linear HPMA copolymer on the threshold of kidney 
filtration eliminated faster than the branched dendrimer (elaborated in Section 4.3.2). 
Owing to its hydrodynamic size being twice that of G7.0-OH (Rh = 4.0 nm), HPMA 
copolymer (131 kDa) (Rh = 8.2 nm) had a much higher blood exposure than G7.0-OH of 



































































































































































































































































































































































































































































































































































































































































































































































Figure 4-4. Dose normalized blood exposure (0-24 h) of PAMAM-OH 
dendrimers and HPMA copolymers computed from model fit. Data are 
represented as mean estimate ± standard error of fit. Dose normalized blood 
exposure of G7.0-OH and HPMA 131 kDa is statistically significantly different 
from lower MW polymers with p<0.5 and p<0.001, respectively, as per 
ANOVA and Bonferroni’s multiple comparison tests comparing G7.0-OH and 




4.3.2.  Elimination clearance-correlation with hydrodynamic size 
Elimination clearance decreased with increase in MW within each of the polymer 
series (Table 4-1). The hydrodynamic diameter of G5.0-OH (29 kDa) and HPMA (26 
kDa) were below the threshold diameter for kidney filtration (~ 6.0 nm) [11]. In spite of  
being greater in hydrodynamic size, the blood elimination clearance of G5.0-OH (Rh = 
2.3 nm) was significantly higher than that of HPMA (26 kDa) (Rh = 1.4 nm) of 
comparable MW. In this size range, the highly compact structure of the PAMAM 
dendrimer may facilitate extravasation faster than the linear HPMA copolymer, 
explaining its faster rate of disappearance from the blood compartment. These 
observations demonstrate that polymer architecture affected elimination clearance below 
kidney filtration threshold. G6.0-OH (58 kDa) and HPMA copolymer (52 kDa) were on 
the threshold of kidney filtration cutoff diameter (6.0 nm). Their elimination clearances 
were comparable with the HPMA (Rh = 3.3 nm) being eliminated from the blood slightly 
faster than the G6.0-OH (Rh = 3.0 nm). This difference was not statistically significant. 
However this observation suggests that at the kidney filtration threshold size, the linear 
copolymer was eliminated faster than the hyperbranched dendrimer, even though it was 
slightly greater in hydrodynamic size. G7.0-OH was almost half the hydrodynamic size 
of HPMA (131 kDa) and had a faster clearance than the HPMA copolymer (131 kDa) of 
comparable MW. Over the MW range studied, elimination clearance decreased log 
linearly with increase in hydrodynamic size within each of the polymer series (Figure 4-
3). However, elimination clearance decreased more rapidly for PAMAM-OH dendrimers 
with increase in hydrodynamic volume as compared to HPMA copolymers indicated by 
slopes (Figure 4-5). This can be attributed to the effect of architecture on the change in 
132 
 
Figure 4-5. Correlation of elimination clearance of PAMAM-OH dendrimers 
and HPMA copolymers to hydrodynamic size. Data are represented as mean 




molecular conformation of polymers with increase in MW (elaborated in detail in Section 
4.4) [12, 13]. The observed trend of decrease in elimination clearance is only expected to 
hold over this range of molecular weights since the polymers transition from being small 
enough to be readily filtered through the kidney: G5.0-OH and HPMA copolymer 26 
kDato being on the threshold of kidney filtration (G6.0-OH, HPMA copolymer (52 
kDa)), and further to being long circulating in the blood (G7.0-OH, HPMA copolymer 
(131 kDa)) with a minimal renal clearance. This trend is not expected to hold outside of 
this molecular weight or size range, where the elimination clearance is likely to be 
independent of hydrodynamic size, although such studies warrant further investigation 
[14]. 
4.3.3.  Renal clearance 
Renal clearance decreased with increase in hydrodynamic size for each of the 
polymer series (Table 4-1, Figure 4-6). However, at comparable molecular weights, 
linear HPMA copolymers were eliminated renally to a higher extent (by an order of 
magnitude) than hyperbranched PAMAM-OH dendrimers (Table 4-1, Figure 4-6). In 
spite of the hydrodynamic size of HPMA copolymer (131 kDa) (Rh = 8.2 nm) being 
double that of G7.0-OH (Rh = 4.0 nm), HPMA copolymer (131 kDa) was eliminated 
renally to a greater extent than G7.0-OH. This can potentially be attributed to the unique 
ability of a linear polymer to reptate through a renal filtration pore while the branched 
polymer has to deform in order to pass through [8, 15]. Renal clearance was significantly 
less than the total elimination clearance for all of the polymers under study. This is 
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Figure 4-6. Renal clearances of PAMAM-OH dendrimers and HPMA 
copolymers. Data are represented as mean clearance calculated from data pooled 




indicative of the presence of other clearance mechanisms, potentially through the liver 
and the spleen. 
4.3.4.  Tumor exposure 
Tumor concentration peaked at about 0.5-6 hours for the polymers under study 
with the larger molecular weight polymers showing a greater Tmax than the lower 
molecular weight polymers (Figure 4-7) indicating a longer diffusion time for the larger 
polymers into the tumor. The dose normalized tumor exposure (AUCtumor/dose) increased 
with increase in molecular weight or hydrodynamic size within a given polymer series 
(Table 4-1, Figure 4-8). However, the tumor exposure of the PAMAM-OH dendrimers 
was greater than that of HPMA copolymers of comparable molecular weights. In spite of 
a smaller hydrodynamic radius, faster elimination and lesser blood exposure, G7.0-OH 
(Rh = 4.0 nm) accumulated in the tumor twice as much as HPMA copolymer (131 kDa) 
(Rh = 8.2 nm) of comparable MW. The tumor to blood exposure ratios indicate that the 
polymers in circulation passively accumulated in the tumor and this accumulation was 
greater for the PAMAM dendrimers than the HPMA copolymers under study. The tumor 
to blood exposure ratios suggest that when in circulation, PAMAM-OH dendrimers have 
a higher affinity to accumulate in the tumor than the HPMA copolymers (Figure 4-9).   
4.3.5. Blood and tumor extravasation and elimination rate constants 
In accordance with the trend in elimination clearance, discussed in detail in 




Figure 4-7. Tumor concentration-time profile of PAMAM-OH dendrimers and 
HPMA copolymers. Experimental data are represented in symbols-mean ± SEM. 
Model predicted best fit values are represented as a line. Tumor accumulation of 
G7.0-OH is statistically significantly higher than HPMA 131 kDa at 6 hours and 
24 hours with a p<0.01 and p<0.001, respectively. Tumor accumulation of 
HPMA 131 KDa is higher than accumulation of lower MW polymers (except 




Figure 4-8. Dose normalized tumor exposure (0-168 h) of PAMAM-OH dendrimers 
and HPMA copolymers. Tumor exposure calculated by area under the curve using 
the trapezoidal rule was statistically significantly different for G7.0-OH (p<0.001) 
compared with other treatment groups as per ANOVA and Bonferonni’s multiple 
comparison test. Using the same statistical tests, tumor exposure was different for 
HPMA 131 kDa compared to smaller MW polymers (p<0.05) and G7.0-OH 




Figure 4-9. Ratio of tumor/blood exposure of PAMAM-OH dendrimers and 
HPMA copolymers.  
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of polymers within a given series (Table 4-2). As a consequence of increased blood 
circulation, tumor extravasation rate constant (K2) increased with increase in molecular 
weight/hydrodynamic size within a polymer series (Table 4-2). It was also observed that 
PAMAM dendrimers extravasated into the tumor slightly faster than their equivalent 
molecular weight counterparts in the HPMA polymer  series. It should be noted that all 
the rate constants computed by the global curve fitting method had significant error 
associated to them. In most cases, error was greater than 100%. Some of the χ2 values 
(Appendix A) were high for the curve fits of all models. This suggests either inadequate 
estimation of standard deviation (obtained from experimental data limited in sample size) 
or inadequate choice and assumptions in model.  
Blood and tumor data from smaller MW polymers G5.0-OH and HPMA 26 kDa 
as well as HPMA 52 kDa was fitted to model 1 without the second tumor compartment. 
These polymers showed diffusion in and out of tumor but did not show prolonged tumor 
retention over 1 week.  Hence model 1 was used to globally curve fit blood and tumor 
data (Figure 4-1). For the higher MW polymers-G7.0-OH and HPMA 131 kDa as well as 
G6.0-OH, rate constant K6 facilitated extravasation into the second tumor compartment 
and prolonged tumor retention over the time period of study which is in agreement with 
the EPR effect. Blood and tumor accumulation data of PAMAM G6.0-OH fit model 2 
while that of HPMA 52 kDa, comparable in MW to G6.0-OH, fit model 1 indicating that 
the G6.0-OH showed a more prolonged tumor retention than HPMA copolymer of 
comparable MW (χ2 values in Appendix A).  G7.0-OH also had a higher extravasation 
rate constant into the second tumor compartment (K6) than HPMA 131 kDa of 




















































































































































































































































































































































































































































































































































































































































































































































tumor retention than HPMA copolymers in the orthotopic xenograft ovarian tumors under 
study. This propensity of the PAMAM dendrimers to passively target the tumor was also 
reflected in tumor to blood exposure ratios of the polymer discussed in Section 4.3.4 
(Figure 4-9). Both models 2 and 3 facilitated prolonged tumor retention with the second 
tumor compartment (Figure 4-2). However, model 3 allowed elimination from the  
second tumor compartment (via rate constant K7) while model 2 did not. Amongst the 
higher MW polymers showing prolonged tumor retention, data from G6.0-OH and 
HPMA 131 kDa showed a better fit for model 2 while that from G7.0-OH showed a 
better fit for model 3 (χ2 values in Appendix A). For all of these polymers, the presence of 
the elimination rate constant from second tumor compartment (K7) marginally decreased 
fit error (χ2 values in Appendix A). However, this decreased error came at the cost of 
increased model parameterization. The Akaike Information Criterion (AIC), which is a 
balance of both fit error as well as degrees of freedom was lower for model 2 in the case 
of G6.0-OH and HPMA 131 kDa (AIC values in Appemdix A). In case of G7.0-OH, AIC 
was lower for model 3. Within the scope of the given experimental dataset (12 
experimental data points), the models that were set up are tending to be over-
parameterized (6 parameters for model 2 and 7 for model 3). Hence, choice of model, 
based on a lower value of AIC, is limited by degrees of freedom. If these experiments are 
designed to include more time points, it is likely that model 3 would fit all of the higher 




Polymeric carriers used in drug delivery have a favorable pharmacokinetic profile 
over small molecular weight drugs owing to their reduced renal clearance and resulting 
long circulation half-life in the blood [16]. Unlike small molecular weight drugs which 
are known to have instantaneous distribution into blood-perfused organs, macromolecular 
distribution to both target organs such as tumor, and clearance organs such as kidney and 
liver is limited by their size [16]. Target organs like the tumor are known to have 
increased uptake and retention of macromolecules due to the enhanced permeability and 
retention effect [17]. The extent of accumulation of macromolecules in these organs and 
their blood pharmacokinetics depend on their physicochemical attributes such as 
chemical composition, molecular weight, hydrodynamic size, charge, extent of blood 
protein binding and molecular architecture [18]. Architecture of a polymeric carrier is 
determined by its molecular conformation, chain flexibility, deforming capability and 
extent of branching [8]. The polymeric carriers that were evaluated had distinct 
architectures: PAMAM-OH dendrimers are hyperbranched polymers with a globular 
shape while the HPMA copolymers are linear with side chains, known to assume a 
random coil conformation in solution [12, 13]. PAMAM dendrimers become more rigid 
at higher generations [19, 12]. With every increase in generation, extent of branching 
increases and so does surface congestion. This affects the molecular conformation and 
deforming capability of the dendrimer. The smaller generation PAMAMs (G0.0-3.0) are 
flexible, floppy and disc-like. Generations 4.0 through 6.0 have a hollow core and 
permeable outer shells that render them as nano-containers. Generations 7.0 onwards, the 
dendrimers start to possess a very rigid surface scaffolding with a globular shape [19]. 
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The PAMAM-OH dendrimers under study, i.e., G5.0 through G7.0 lie in a range where 
they transition from a more flexible conformation for G5.0-OH to a more rigid, globular 
shape for G7.0-OH. The HPMA copolymers on the other hand are not known to undergo 
a significant conformational change for the range of molecular weights that were studied 
(26-131 kDa). This trend in molecular conformational change of polymers of different 
architecture affected their pharmacokinetics. The polymers under study interacted 
minimally with blood proteins due to their neutral charge (Section A.9., Appendix A). 
Hence, blood protein binding is not expected to influence observed trends in 
biodistribution and pharmacokinetics. 
Elimination clearance decreased more rapidly for PAMAM dendrimers with 
increase in molecular weight or hydrodynamic size than for HPMA copolymers for the 
same increase in molecular weight (Figure 4-5). These results are in agreement with other 
studies which show that the shape and ability of the polymer to deform play important 
roles in the glomerular filtration rate and hence elimination clearance [8, 9, 20, 21]. 
Previous reports suggest that increased hydrodynamic size, decreased flexibility and 
increased extent of branching of polymer chains limits passage of a polymer through a 
pore of comparable size and reduces elimination through the kidneys [8]. In vitro 
diffusion studies of polymers through porous structures have shown that transport of 
linear polymers in tissue containing complex extracellular matrix is different from that of 
branched polymers [15, 22-25]. The exponent for power law stating the molecular weight 
dependence on diffusion coefficient through a membrane with defined pore sizes is 
different for a linear (exponent = -1 to -2.5) versus branched (exponent = -0.33) polymer. 
These observations are explained by de Gennes’s polymer reptation theory where a linear 
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polymer can move through a network of fibrous obstacles presented by the extracellular 
matrix while the branched polymer cannot [26]. The branched polymer has to deform in 
order to diffuse through. In vivo, the glomerular basement membrane, which is a complex 
fibrous network is known to be the primary barrier to filtration of neutral macromolecules 
[27]. Hence, it has been considered fairly realistic to apply the theory of molecular 
sieving in polymeric gels to the glomerular filtration of macromolecules [27]. For the 
lower molecular weight polymers, in spite of a higher hydrodynamic radius, G5.0-OH 
(Rh = 2.3 nm) eliminated faster than HPMA copolymer (26 kDa) (Rh = 1.4 nm), possibly 
due to a compact and flexible structure that allowed faster extravasation. The 
conformational change of PAMAM dendrimers with increase in hydrodynamic size can 
affect their deforming capability and drastically reduce transport through the capillary 
endothelium of clearance organs thereby reducing their clearance. G6.0-OH (Rh = 3.0 
nm) eliminated slower than HPMA copolymer (52 kDa) (Rh = 3.3 nm) of comparable 
MW, possibly due to increased rigidity and consequently slower extravasation. HPMA 
copolymers, owing to a linear architecture can potentially reptate through pores of 
capillary endothelium, even if their effective hydrodynamic radii are greater than pore 
size of fenestration. Hence, even though the elimination clearance for G7.0-OH (Rh = 4.0 
nm) was greater than HPMA copolymer (131 kDa) (Rh = 8.2 nm) of comparable MW, the 
rate at which the elimination clearance changed over a fixed MW range was different for 
the two polymers of varying architecture. The elimination clearance changed less rapidly 
with increase in molecular weight and hydrodynamic size of HPMA copolymers as 
compared to PAMAM dendrimers. In addition to differences in interstitial transport rates 
of PAMAM-OH dendrimers and HPMA copolymers, their intrinsic differences in 
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physicochemical properties could potentially alter their rate and extent of endocytosis and 
transcytosis through cells, directly affecting their blood clearances. Extensive kidney 
accmumlation  of G5.0-OH and liver accumulation of G6.0-OH also suggests differences 
in cellular uptake of these polymers based on accumulation size and architecture [10].  
Renal clearance showed a trend similar to the elimination clearance where along 
with hydrodynamic size, the polymer architecture affected this parameter (Figure 4-5). 
The effective pore size for glomerular filtration through the kidney is 3.7-6.0 nm in 
hydrodynamic diameter [11]. PAMAM G5.0-OH and HPMA copolymer (26 kDa) fall 
below the size cutoff of glomerular filtration and should readily eliminate through the 
kidneys. However, renal clearance of G5.0-OH was less than HPMA copolymers of 
comparable molecular weight since G5.0-OH showed persistent accumulation in the 
kidney (up to 80% injected dose) (Chapter 3) [10]. Limited mechanistic studies for renal 
retention of PAMAM dendrimers report the localization of these polymers in the 
lysosomes of proximal tubule cells
 
upon glomerular filtration [28]. G6.0-OH (Rh = 3.0 
nm) and HPMA copolymer (52 kDa) (Rh = 3.3 nm) are comparable in hydrodynamic size 
and fall on the threshold of the size cutoff range for kidney filtration. HPMA copolymer 
(52kDa) was renally cleared to a higher extent than G6.0-OH. HPMA copolymer (131 
kDa) (Rh = 8.2 nm) is twice the hydrodynamic size of G7.0-OH (Rh = 4.0 nm), and yet 
was renally cleared to a greater extent than its PAMAM counterpart of comparable MW. 
This can be explained by the architectural difference in the two constructs. The primary 
impediment to renal clearance of these polymers is likely to be the tortuous path through 
the fibrous mesh of the glomerular basement membrane [27]. While the linear HPMA 
copolymers can potentially reptate through a pore smaller in size than their hydrodynamic  
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radii in a random coil conformation, PAMAM dendrimers have to deform in order to 
permeate across the pores (Figure 4-10). With increase in molecular weight or generation, 
the deforming capacity of PAMAM-OH dendrimers is known to decrease, making it 
harder for higher generation PAMAM-OH dendrimers to sieve through the glomerulus as 
compared to HPMA copolymers of comparable molecular weights.  
Renal clearance was however significantly less than the total elimination 
clearance suggesting clearance through the liver and spleen. It could also suggest  
distribution of the polymers into other compartments outside the central compartment 
(blood). Specifically renal clearance was significantly less for PAMAM dendrimers than 
HPMA copolymers. PAMAM-OH dendrimers showed high liver accumulation (15-50% 
injected dose/g of liver tissue), which could potentially be indicative of biliary clearance 
[10]. 
Polymer concentration in a given tumor type is a function of blood clearance rate 
and vascular exposure along with kinetics of transendothelial transport within the tumor 
or effective interstitial diffusion coefficient [29, 18]. These factors are governed by a 
number of physicochemical characteristics of the polymer including size, surface 
characteristics, shape, and rigidity [18]. Of these properties affecting interstitial tumor 
transport, the molecular conformation or polymer architecture has been the least studied. 
In general, polymers with a flexible conformation have demonstrated more ideal tumor 
transport properties leading to higher tumor accumulation [30-32]. Findings reported in 
this analysis, however are contradicting this literature-reported trend with the globular, 
rigid PAMAM dendrimers showing higher tumor to blood exposure ratio and 
extravsation rate constants (K2, K6) than the random coil, flexible HPMA copolymers of 
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Figure 4-10. Proposed explanation for the difference in elimination clearance of 
PAMAM-OH dendrimers and HPMA copolymers. Adapted from Ref [8]. 
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comparable MW (Figure 4-9).  This could be indicative of a phenomenon in the complex 
fibrous extracellular matrix of angiogenic neovasculature where rigid nanoscale 
constructs may show higher permeability than coiled polymers that can entangle in the 
matrix. Besides the conformation, the difference in hydrodynamic size of polymers of 
varying architecture and comparable molecular weights could also contribute to 
differences in tumor extravsation rate constant (K6) and total exposure (AUCtumor/dose). 
For instance, HPMA copolymer (131 kDa) (Rh = 8.2 nm) is twice the hydrodynamic size 
of G7.0-OH (Rh = 4.0 nm) of comparable molecular weight. It is known that the primary 
impediment for the transvascular extravasation of particles across the blood-tumor-barrier 
is at the level of the glycocalyx that coats the surface of pores formed in the trans-
endothelial cell fenestrations and inter-endothelial cell gaps [18, 22]. The luminal 
glycocalyx layer acts as a nanofilter for transvascular flow creating an effective 
physiological upper limit of pore size for the blood-tumor-barrier [18, 22]. This pore size 
cutoff can vary for different tumor types and is not precisely known for the orthotopic 
xenograft A2780 ovarian carcinoma tumors under study. However, based on the pore size 
range for other tumor types, it could range between the hydrodynamic sizes of HPMA 
copolymer (131 kDa) and G7.0-OH [33]. This could potentially explain the difference in 
tumor accumulation of these higher molecular weight polymers. These findings suggest 
that further investigation and optimization of polymer size and conformation is necessary 
for optimal tumor transport and accumulation. 
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4.5.  Conclusion 
Along with MW and hydrodynamic size, polymer architecture was critical in 
affecting the blood pharmacokinetics of the PAMAM-OH dendrimers and HPMA 
copolymers. Over the MW range studied, elimination clearance decreased more rapidly 
with increase in Rh for PAMAM-OH dendrimers as compared to HPMA copolymers. 
Linear HPMA copolymers were eliminated renally to a higher extent than hyperbranched 
PAMAM-OH dendrimers. These results were indicative of a difference in extravasation 
of polymers of varying architecture through fenestrations of the kidney tissue. In 
addition, PAMAM-OH dendrimers had a higher tumor to blood exposure ratio than 
HPMA copolymers indicating that when in circulation, PAMAM-OH were taken up in 
the tumor to a greater extent than HPMA copolymers.  
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CHAPTER 5 
PAMAM DENDRIMERS AS ORAL ABSORPTION  
ENHANCERS FOR ORAL DELIVERY OF  
CAMPTOTHECIN 
5.1.    Introduction 
5.1.1. Oral delivery of camptothecin 
Oral administration of chemotherapeutics has treatment advantages of patient 
preference, convenience of administration, cost-effectiveness and improving quality of 
life in palliative care [1, 2]. In terms of treatment outcomes, oral chemotherapeutics are 
advantageous for protracted dosage regimens as is the case for schedule-dependent 
cytotoxic drugs [1, 3]. Camptothecin and its derivatives are potent topoisomerase-I 
inhibitors that show a schedule-dependent activity which means that they are more 
efficacious with low and frequent oral dosage regimens [4]. However, the oral delivery of 
camptothecins is limited by poor and variable bioavailability attributed to low solubility, 
low permeability and P-gp efflux of the drug [5].  
Camptothecin and its derivatives have been solubilized in various micellar, 
liposomal, microsphere, microemulsion and cyclodextrin-based formulations [6-10]. A 
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number of water-soluble analogues and prodrugs have also been synthesized [6, 11-18]. 
However, the majority of these formulations have not been evaluated for oral delivery.  
5.1.2. Poly(amido amine) or PAMAM dendrimers as oral drug carriers 
Poly(amido amine) (PAMAM) dendrimers are a class of hyperbranched polymers 
[19]. They are synthesized with alternating repeating units of ethylene diamine and 
methyl acrylate and can be terminated to have primary amines, carboxylic acids or 
hydroxyl-terminated groups [20, 19]. As a result of the repeated branching, PAMAM 
dendrimers have a dense surface exterior and a relatively hollow interior, where they are 
known to solubilize hydrophobic moieties by encapsulation or surface interactions [21-
32].  
PAMAM dendrimers have also been extensively evaluated in vitro for potential 
oral drug delivery applications as intestinal penetration enhancers as well as carriers for 
transepithelial transport of small molecules [33]. Both cationic, amine-terminated as well 
as anionic, carboxylic acid-terminated PAMAM dendrimers are known to modulate tight 
junctions and increase paracellular transport of small molecules [34-36]. They are also 
known to be translocated across the intestinal epithelial barrier by endocytic mechanisms 
[37-40]. Additionally, cationic PAMAM dendrimers are known to interact with lipid 
bilayers on cell membranes increasing their cellular uptake [41]. Their solubilizing 
potential combined with their transepithelial transport make PAMAM dendrimers 
attractive for oral delivery of biopharmaceutics classification system (BCS) class IV 
drugs such as camptothecin [15-17]. There have been very limited studies in vivo to 
evaluate PAMAM dendrimers for oral drug delivery [42, 43]. In this study, camptothecin 
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was formulated and co-delivered with cationic, amine-terminated PAMAM dendrimer 
generation 4 (G4.0) and anionic, carboxylate-terminated generation 3.5 (G3.5) in CD-1 
mice.  
5.2. Materials and methods 
5.2.1. Materials 
Poly(amido amine) dendrimers generation 4 (G4.0-NH2) and generation 3.5 
(G3.5-COONa) were purchased from Dendritech (Midland, MI). Camptothecin was 
procured from A.K.Scientific (Union City, CA). Tritium (
3
H)-labeled camptothecin and 
14
C-labeled Mannitol were purchased from American Radiolabeled Chemicals (St. Louis, 
MO). Reagents for beta detection were purchased from Perkin Elmer (Waltham, MA).  
5.2.2. Methods 
5.2.2.1.   Physicochemical characterization of PAMAM dendrimers 
The chromatographic elution profiles of the PAMAM dendrimers under study, 
G4.0-NH2 and G3.5-COONa, were obtained using a Fast Protein Liquid Chromatography 
(FPLC) system with an analytical Superose 6
TM
 10/300 GL column (GE Healthcare) and 
an ultraviolet detector (GE Healthcare) in order to evaluate relative elution volumes and 
to check for the absence of small molecular weight impurities (Appendix B). The mobile 
phase for elution was 20% (v/v) acetonitrile and 80% (v/v) phosphate buffer saline (137 
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.4) at a flow rate of 
1.0 mL/minute. Eluted peaks were detected at a wavelength of 280 nm. PAMAM 
dendrimers were further characterized for hydrodynamic radius (Rh) using a Dynamic 
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Light Scattering (DLS) detector (Helleos II) attached to the FPLC system and analyzed 
using Astra
TM
 5.3.4.13 software (Wyatt Technologies Corp).  
5.2.2.2.   Camptothecin formulations with poly(amido amine) dendrimers 
The camptothecin alone (0.5 mg/mL, 14.4 x 10
-4
 M) was formulated in a solution 
of DMSO: 0.05M borate buffer-pH 8.5: poly(ethylene glycol) 400 in the ratio 1:9.5:9.5. 
For the formulations of camptothecin co-delivered with PAMAM, a dispersion of 
camptothecin (0.5mg/mL, 14.4 x 10
-4
 M) was prepared using the solvent system DMSO: 
deionized water: poly(ethylene glycol) 400 in the ratio 1:9.5:9.5. Methanolic solutions of 
PAMAM dendrimers were evaporated up to the constant weight. The drug dispersion was 
stirred with PAMAM dendrimers at room temperature for 12 hours by mixing with 
varying concentrations and generations of PAMAM dendrimers (Table 5-1)  
The pH of all the formulations including the camptothecin was adjusted to be 
between 8.5-9.0, to facilitate head to head comparison of the oral absorption of 
camptothecin across different treatment groups. The ratios of drug to dendrimer were 
chosen based on maximum tolerated oral doses of the two as well as the reported 
solubilization potential of PAMAM dendrimers specifically for camptothecin [44, 30]. In 
order to ascertain the solubility of the formulations, they were filtered through a 100 kDa 
centrifugal membrane filter (Nanosep 100K Omega, Pall Corporation, Ann Arbor, MI) 
that was pretreated with 5 weight % solution of Triton-X to minimize adsorption to the 
membrane. The filtrate obtained after spinning the centrifuge tubes at 14,000g for 20 
minutes was spectrophotometrically analyzed for camptothecin content at an absorbance 
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5.2.2.3.   Mannitol oral absorption  
Mannitol alone (0.5 mg/mL) was dissolved in a solution of DI water. Methanolic 
solutions of PAMAM dendrimers were evaporated up to the constant weight. For the 
mixtures of mannitol co-delivered with PAMAM, the mannitol solution was mixed with 
the highest doses of PAMAMs of various generations under study as follows: 
1. G4.0-NH2 (30 mg/mL or 21.1 x 10
-4
 M)-300 mg/kg 
2. G3.5-COONa (100 mg/mL or 77.4 x 10-4 M)-1000 mg/kg 
The pH values of all the solutions were adjusted to be between 8.5-9.0, to 
facilitate head-to-head comparison of the paracellular transport of mannitol across 
different treatment groups. 
5.2.2.4.   Characterization of camptothecin – PAMAM formulations 
To evaluate the percentage of camptothecin associated with the PAMAM 
dendrimers in the formulations, they were diluted 5x with DI water and filtered through a 
3.5 kDa centrifugal membrane (Amicon® Ultra 0.5 mL, EMD Millipore, Billerica, MA) 
that was pretreated with 5 weight % solution of Triton-X to minimize adsorption to the 
membrane. The filtrate obtained after spinning the tubes at 14,000g for 20 minutes was 
spectrophotometrically analyzed for camptothecin content at an absorbance maximum of 
370 nm (Spectramax M2, Molecular Devices, LLC.) (U.V absorbance standard curve in 
Appendix B). 
In order to assess the percentage of camptothecin in the lactone and carboxylate 
forms, camptothecin alone and PAMAM camptothecin formulations were eluted on a 
reverse phase C18 (5 µm, 250 mm x 5 mm) high performance liquid chromatography 
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column (XTerra, Waters®; Agilent HPLC system). The mobile phase used was 
acetonitrile: aqueous triethylamine acetate buffer (prepared using 0.1% v/v triethylamine, 
adjusted with glacial acetic acid to pH 5.5), in the ratio of 27:73 delivered at a flow rate 
of 1.0 ml/min with an injection volume of 20 µl (method adapted from [30]). 
Camptothecin in the lactone form was detected at an absorbance wavelength of 370 nm 
and a retention time of 11.47 ± 0.12 minute. Camptothecin in the carboxylate sodium salt 
form was detected at an absorbance wavelength of 370 nm and a retention time of 4.16 ± 
0.03 min. The camptothecin calibration curve for the lactone form was y =75.19x-5.50 (r
2
 
= 0.99), when the peak area was plotted vs concentration of camptothecin in µg/mL 
(Appendix B). The camptothecin calibration curve for the carboxylate sodium salt form 
was y =58237x+100.88 (r
2
 = 0.99) when the peak area was plotted vs concentration of 
camptothecin in mg/mL (Appendix B). The solution for the camptothecin lactone form 
standard curve was prepared in DMSO acidified with 0.1N HCl while the solution for the 
camptothecin carboxylate sodium salt form standard curve was prepared in 0.1N NaOH. 
The solvent system of the HPLC run (pH 5.5) did not cause inter-conversion of the 
lactone and carboxylate forms during the duration of the run. 
In order to check the precipitation kinetics of the drug when formulated with 
PAMAM, camptothecin alone and PAMAM-camptothecin formulations were incubated 
with simulated gastric (0.2% w/v NaCl, 0.7% w/v HCl) and intestinal (6.8% w/v 
KH2PO4, 0.9% w/v NaOH) fluids at 37
0
C. 500 µL of solutions were sampled at the end 
of 2 hours for simulated gastric fluid (SGF), and 3 hours for simulated intestinal fluid 
(SIF), and filtered through a 100 kDa centrifugal membrane filter (Nanosep 100K 
Omega, Pall Corporation, Ann Arbor, MI) that was pretreated with 5 weight % solution 
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of Triton-X to minimize adsorption to the membrane. The filtrate obtained after spinning 
the centrifugal tubes at 14,000g for 20 minutes was buffered back by incubation with 1:1 
0.1N HCl at 37
0
C for 2 hours. The filtrate was spectrophotometrically analyzed for 
camptothecin content at an absorbance maximum of 370 nm (Spectramax M2, Molecular 
Devices, LLC., Sunnyvale, CA). Formulations were evaluated in the simulated instestinal 
fluid for only 3 hours because the absorption enhancement action of PAMAM dendrimers 
is known to be in the upper gastrointestinal tract [42, 43]. 
5.2.2.5.   In vivo oral absorption 
Six-to eight-week female CD-1 mice were dosed by oral gavage with 0.2 mL of 
camptothecin alone (5 mg/kg) and camptothecin (5 mg/kg) mixed with PAMAM G4.0-
NH2 (100 and 300 mg/kg) and G3.5-COONa (300 and 1000 mg/kg) (Dose preparation 
detailed in Section 5.2.2.2). In vivo dose selection of PAMAM dendrimers was based on 
maximum tolerated oral doses evaluated previously [44]. In addition, 6-to 8-week female 
CD-1 mice were dosed by oral gavage with 0.2 mL of mannitol alone (5 mg/kg) and 
mannitol (5 mg/kg) mixed with the highest doses of PAMAMs under study- G4.0-NH2 
(300 mg/kg) and G3.5-COONa (1000 mg/kg). (Dose preparation detailed in Section 
5.2.2.3). Camptothecin and mannitol were tritium and 
14
C-labeled respectively to 
facilitate detection. For the camptothecin formulations, animals were sacrificed at 0.5, 1, 
2, 4 and 8 hours. Blood and liver samples were analyzed by 
3
H-Camptothecin beta 
detection (procedure detailed below). For the mannitol solutions, animals were sacrificed 
at 2 hours, the Tmax of mannitol absorption and blood samples were analyzed by 
14
C-
mannitol beta detection.  
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For tissue digestion, blood (50 µL) and liver (50 mg) samples were digested using 
0.5 mL of Solvable
TM 
(PerkinElmer, Inc.) and Soluene
TM
-350 (PerkinElmer, Inc.) 
respectively with incubation and shaking at 60
0
C for 1 hour. 
For tissue bleaching, 50 µL of 0.1M EDTA solution was added to the digested 
samples to minimize foaming during the bleaching process. 150 µL of a 30% solution of 
hydrogen peroxide was added to the digested tissue samples in 3 aliquots of 50 µL each, 
over 30 minutes, with intermittent shaking. Samples were allowed a reaction time of 30 
minutes at room temperature and subsequently incubated at 60
0
C for 30 minutes. This 
facilitated the quenching of excess free radicals generated during the bleaching process. 
For beta detection, the bleached blood and liver samples were mixed with 4.5 mL 





respectively. The samples were light and temperature adapted for 24 hours and counted 
using a liquid scintillation system (Beckman LS 6000IC, Beckman Coulter, Inc.). 
Beta detection of tissue samples is sensitive to the ratio of digestion, bleaching 
and detection agents. This ratio was optimized to obtain the lowest luminescence 
interference and the most optimal processing parameters and efficiencies (Table 5-2). 
5.2.2.6.    Histologic assessment of small intestinal segments 
Six- to eight-week female CD-1 mice were dosed by oral gavage with 0.2 mL of 
saline, G4.0-NH2 (100 and 300 mg/kg) and G3.5-COONa (300 and 1000 mg/kg) to 
evaluate changes in intestinal histology by dendrimers. In addition, 6- to 8-week female 
CD-1 mice were dosed by oral gavage with 0.2 mL of CPT alone (5 mg/kg) and CPT (5 
mg/kg) mixed with PAMAM G4.0-NH2 (100 and 300 mg/kg) and G3.5- 
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Table 5-2. Processing parameters of Tritium and 
14
Carbon counting from blood 







Lumex (%) 4.19 ± 3.19 0.17 ± 0.02 
Extraction Efficiency 
(%) 
75.48 ± 6.09 88.26 ± 0.01 
Blank Blood 46.28 ± 11.35 37.17 ± 0.76 
Liver 
Lumex (%) 1.14 ± 0.63 - 
Extraction Efficiency 
(%) 
77.39 ± 4.81 - 




 COONa (300 and 1000 mg/kg) (Dose preparation detailed in section 5.2.2.2). In vivo  
dose selection of PAMAM dendrimers was based on maximum tolerated oral doses 
evaluated previously [44]. Animals were sacrificed at 4 hours. Tissue samples were taken 
from different sections of the small intestine and stained by H and E staining to evaluate 
morphological changes in the small intestinal segments using a dark-field microscope 
(Olympus® BH-2, Olympus Corp., Center Valley, PA) and a digital camera for imaging 
(DXM1200C, Nikon Instruments Inc., Melville, NY). Small intestinal segments were 
also evaluated by Transmission Electron Microscopy (Hitachi I-7100 operated at 75 kV 
using a Leica EMUC6 ultramicrotome, South San Francisco, CA) to assess microvilli 
integrity. 
5.3. Results and discussion 
5.3.1. Characteristics of the formulation of PAMAM  
dendrimers with camptothecin 
With increase in PAMAM generation or extent of branching, these dendrimers are 
known to undergo a conformational change [20, 45]. Owing to a high functional group 
density on the surface, PAMAM generations 3.5 and 4.0 are known to have a relatively 
hollow interior and a dense exterior possessing nano-container-like properties by which 
they efficiently encapsulate and complex small hydrophobic molecules [46]. PAMAM 
generations 3.5-COONa and 4.0-NH2 are reported to have a molecular weight of 
12,927.69 and 14,214.17 kDa respectively, assuming perfect dendrimer synthesis [19]. 
The hydrodynamic radius range of G3.5 was 1.3 ± 0.1 nm and that of G4.0 was 1.7 ± 0.1 
nm as measured by dynamic light scattering. The surface functionality of PAMAM G4.0 
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is a primary amine group (n= 64) with a reported pKa of 8-9 while that of PAMAM G3.5 
is a carboxylic acid group (n=64) with a pKa of 3-4 [20]. The interior of the PAMAM 
G4.0 and G3.5 has 62 tertiary nitrogen atoms (pKa of 3-6) [20]. These functional groups 
on the surface and the interior of the PAMAM dendrimers are known to interact with 
guest molecules via electrostatic interactions, hydrogen bonding and hydrophobic 
interactions [22, 21]. This interaction depends on a number of factors, some of which are 
PAMAM generation and core, ratio of dendrimer to drug, physicochemical properties of 
drugs and pH [22, 21]. Camptothecin formulated with PAMAM G4.0 showed up to 80% 
association with the dendrimer (Table 5-3). The concentration of G4.0 did not influence 
this association. On the other hand, camptothecin formulated with PAMAM G3.5 showed 
only a 20-30% association with the dendrimer (Table 5-3). In case of G4.0, at a 100 
mg/kg dose, there was one molecule of PAMAM for every two molecules of 
camptothecin while at 300 mg/kg, there were two molecules of PAMAM for every 
molecule of camptothecin (Table 5-1). Every molecule of PAMAM also has 64 primary 
amine surface functionalities, 62 internal tertiary nitrogens and other internal hydrogen 
bonding sites contributed by the amide bonds. Camptothecin has a lactone E-ring that 
hydrolyzes around pH 7.0 to yield the carboxylate form of the drug [47]. When 
camptothecin was solubilized with PAMAM G4.0 at pH 8-9, the primary amine group 
(protonated about 50%) hydrolyzed the lactone of the camptothecin to yield the 
carboxylate form (as observed by HPLC, Figure 5-1). The carboxylate group of 
camptothecin potentially formed an ionic bond with the protonated primary amine groups 




Formulation Percentage associated with PAMAM 
CPT + G4.0-NH2 
(100 mg/kg) 
80.27 ± 0.66 
CPT + G4.0-NH2 
(300 mg/kg) 
81.80 ± 0.24 
CPT + G3.5-COONa 
(300 mg/kg) 
29.57 ± 3.31 
CPT + G3.5-COONa 
(1000 mg/kg) 
23.23 ± 0.46 
 
 
Table 5-3. Association of camptothecin with PAMAM dendrimers 
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Figure 5-1. Percentage of camptothecin in the lactone form in its formulation 
alone and with PAMAM G4.0 (100 and 300 mg/kg), and G3.5(300 and 1000 
mg/kg). Statistically significant difference between camptothecin alone and 
camptothecin formulation with G4.0, G3.5, * p<0.05, ***p<0.001 by one-way 
ANOVA and Bonferroni’s multiple comparison tests comparing PAMAM-CPT 
formulations with CPT alone. Camptothecin formulated with PAMAM to form a 
soluble formulation had a higher % of drug in the lactone (unionized form) 
compared to camptothecin solution alone suggesting potential encapsulation of 




In addition to surface electrostatic interaction, camptothecin could also have been 
partially encapsulated into the dendrimer interior. The association of camptothecin to the 
interior of PAMAM G4.0 can be attributed to hydrophobic interactions between the drug 
and the relatively hydrophobic interior of the dendrimer (tertiary nitrogens will not be 
protonated at pH 8-9) compared to the external aqueous environment. It could also be due 
to hydrogen bonding between the drug and the dendrimer interior. The dense dendrimer 
interior could result in local pH environments to facilitate hydrogen bonding that 
stabilizes the lactone form of the drug, accounting for the small percentage of 
camptothecin in the lactone form when formulated with the PAMAM dendrimers (Figure 
5-1). Detailed 2D-NOESY NMR spectroscopy studies on the interaction of cationic 
PAMAM dendrimers and anionic guest molecules have demonstrated that there exists an 
inclusion complex of the anionic hydrophobic drug with the cationic PAMAM dendrimer 
in addition to the surface electrostatic interactions [28, 48, 49]. Camptothecin formulated 
with PAMAM G3.5 showed significantly less association with the dendrimer (Table 5-3). 
This can be attributed to electrostatic repulsion between the negatively-charged PAMAM 
surface and the carboxylate group on the drug. Unlike PAMAM G4.0, there was no 
potential for surface interaction with PAMAM G3.5. The partial association observed can 
be attributed to encapsulation of the drug in the PAMAM interior (similar for both 
PAMAM G4.0 and G3.5). Concentration of the dendrimer influenced this association. A 
smaller ratio of G3.5 to camptothecin (1.61) showed a slightly higher drug association 
(29.57 ± 3.31) than a larger ratio (5.38) which showed a drug association of 23.23 ± 0.46 
(Tables 5-1 and 5-3). This can be attributed to a higher extent of electrostatic repulsion in 
the formulation with a higher dose of G3.5 that potentially reduced encapsulation. As a 
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consequence of lesser encapsulation, the percentage of lactone form of camptothecin in 
the higher dose of G3.5 (1000 mg/kg) was also slightly less than the percentage of 
lactone in the formulation with a smaller dose of G3.5 (300 mg/kg) (Figure 5-1). Such a 
difference in the association of drug to the cationic and anionic dendrimers has been 
reported for the solubilization of the hydrophobic drug sylibin (containing ionizable 
phenol groups) and indomethacin (containing carboxylic acid groups) [43, 50]. Both 
these drugs associated to a higher extent to the cationic dendrimers due to a surface 
electrostatic interaction that was not likely in case of the anionic dendrimer. This trend 
was not observed for nifedipine which does not have an ionizable group that can 
electrostatically interact with cationic surfaces [27]. Camptothecin delivered alone 
precipitated in the gastric fluid at 2 hours to a  higher extent than when co-delivered with 
PAMAM suggesting that both cationic and anionic PAMAM dendrimers controlled 
release and precipitation kinetics of camptothecin at pH 1.2 (Figure 5-2). It is known that 
the solubilization potential of cationic dendrimers for anionic molecules decreases with 
decrease in pH due to elimination of electrostatic interaction. [25, 43, 48, 51]. At pH 1.2, 
the tertiary nitrogen atoms in the interior of the PAMAM dendrimers G4.0 and G3.5 and 
the primary nitrogen atoms on the surface of G4.0 will be completely protonated but the 
carboxylate group will be unionized, thus not available for ionic interaction. However, 
there is a possibility of intermolecular hydrogen bonding between: 1) the hydrogen atom 
of the carboxylic acid of camptothecin and the carbonyl group from the amide bond of 
the PAMAM, and 2) the hydrogen atom of the secondary nitrogen from the amide bond 
and the oxygen atom from the carbonyl group of camptothecin. This stabilizes the drug as 




Figure 5-2. Percentage of total camptothecin solubilized in simulated gastric 
and intestinal fluids at 2 and 3 hours, respectively. n=3. Statistically 
significant difference between camptothecin alone and camptothecin 
formulation with G4.0, G3.5, *** p<0.001 by one-way ANOVA and 
Bonferroni’s multiple comparison tests comparing PAMAM-CPT 




carboxylic acid-containing hydrophobes like benzoic acid [32]. Inclusion complexes of 
drug with PAMAM dendrimer can also potentially control release of the drug thus 
altering precipitation kinetics over 2 hours [51, 43]. In case of the camptothecin solution 
alone, majority of the drug (80%) precipitated out of solution. However, only 40 % of the 
drug precipitated out of solution over 2 hours when camptothecin was formulated with 
PAMAM G4.0 and G3.5.  
In the simulated intestinal fluid, there was no difference in the precipitation of the 
drug when formulated with the PAMAM, with about 40% of the drug precipitating out of 
solution in 3 hours. At pH 6.8, the carboxylic acid group of the drug is ionized thus 
preventing intermolecular hydrogen bonding in the dendrimer interior. The primary 
amine groups of the cationic dendrimer will also not be protonated eliminating surface 
electrostatic interactions. However, the tertiary nitrogens (pKa 3-6) could be partially 
protonated, facilitating electrostatic interaction between  the ionized drug and the 
dendrimer interior. This internal association (similar for both cationic and anionic 
dendrimers) was not reflected in the precipitation kinetics in the SIF due to the water-
solubility of the drug in the ionized form at pH 6.8. Inclusion complexes of the 
dendrimer-drug can, however, control drug release and improve oral bioavailability as 
seen for oral absorption studies with cationic PAMAM solubilized drugs sylibin and 
doxorubicin [42, 43].  
171 
 
5.3.2. In vivo oral absorption of camptothecin co-delivered  
with PAMAM dendrimers 
Both cationic, amine-terminated PAMAM G4.0-NH2 and anionic, carboxylic-acid 
terminated PAMAM G3.5-COONa dendrimers caused an approximate 2- to 3-fold oral 
absorption enhancement of camptothecin in vivo at 2 hours (Tmax of camptothecin oral 
absorption). For both G4.0-NH2 (100-300 mg/kg) and G3.5-COOH (300-1000 mg/kg), 
there was no statistically significant dose-dependence on absorption enhancement at 2 
hours in the dosing range studied (Figure 5-3). Camptothecin levels in the blood when 
delivered alone or with G4.0 (300 mg/kg) and G3.5 (1000 mg/kg) increased in the first 2 
hours and plateaued up to 8 hours (Figure 5-4). The drug exposure of camptothecin 
(AUC = 3.9 ± 0.1 μg-h/mL) increased 2.2 and 2.5–fold respectively when codelivered 
with PAMAM G4.0 (AUC = 8.6 ± 0.6 μg-h/mL) and G3.5 (AUC = 9.4 ± 0.8 μg-h/mL). 
The camptothecin lactone E-ring is known to hydrolyze to the carboxylate form in the 
plasma and bind to human serum albumin, thus prolonging its circulation half-life to 36 
hours [52].  
All of the formulations tested had the same drug content but varied in the surface 
charge and concentration of PAMAM dendrimer and hence in the extent of drug 
association. The increase in absorption of camptothecin was similar for the cationic (80% 
camptothecin associated with PAMAM) and anionic dendrimer (20-30% camptothecin 
associated with PAMAM). Total amount of bioavailable drug in this formulation would 
be a result of multiple factors. These are drug association to PAMAM, drug solubilization 
in the simulated gastric and intestinal environments by PAMAM, fraction of drug 
retained in the unionized form by PAMAM, drug release rate from PAMAM, species 
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Figure 5-3. Blood concentration of orally administered 
3
H-Camptothecin at 2 
hours alone and co-delivered with PAMAM G4.0 at 100 mg/kg, 300 mg/kg 
and G3.5 at 300 mg/kg and 1000 mg/kg, n= 3 animals per time point, 
PAMAM dendrimers G4.0 and G3.5 statistically significantly increased the 
blood concentration of 
3
H-Camptothecin, **p<0.01, ***p<0.001 by one-way 
ANOVA and Bonferroni’s multiple comparison tests comparing PAMAM-





Figure 5-4. Blood concentration-time profile of orally administered 
3
H-
Camptothecin alone and co-delivered with PAMAM G4.0 (300 mg/kg) and 
G3.5 (1000 mg/kg), n= 3 animals per time point, PAMAM dendrimers 
statistically significantly increased the blood exposure (AUC computed by the 
trapezoidal rule) of 
3
H-Camptothecin, p<0.001 by one-way ANOVA and 
Bonferroni’s multiple comparison tests comparing PAMAM-CPT formulations 




being absorbed (free drug or drug associated dendrimer) and tight junction modulation by 
the polymer. Drug solubilization in SGF and SIF as well as fraction of drug retained in 
unionized lactone form by PAMAM was similar for both cationic and anionic PAMAM 
dendrimers at varying concentrations tested (Figure 5-1, 5-2). Limited reports have 
shown that association of drugs with PAMAM dendrimers controls drug solubilization 
and release, thereby increasing the oral bioavailability [42, 43]. It is expected therefore 
that the higher the extent of association, the higher would be the bioavailability of the 
drug. However, the surface electrostatic interaction between cationic PAMAM and 
carboxylate group of drug was diminished at lower pH (below pKa of terminal primary 
amine groups of G4.0), thus suggesting that drug inclusion in PAMAM interior 
controlled solubilization in SGF, SIF and oral bioavailability. It was also observed that 
the cationic PAMAM dendrimers bind to mucous layer restricting their interaction with 
the epithelial barrier in vivo. Anionic PAMAM dendrimers did not show this 
phenomenon. This difference in mucosal interaction and access to epithelial barrier can 
affect drug release and absorption in vivo. Tight junction modulation, which is a factor 
that affects drug absorption was not seen for either the cationic or the anionic PAMAM 
dendrimers at doses tested (discussed in Section 5.3.3). 
Along with enhancement in blood levels, both cationic, amine-terminated 
PAMAM G4.0-NH2 (300 mg/kg) and anionic, carboxylic-acid terminated PAMAM 
G3.5-COOH (1000 mg/kg) caused an approximate 2-fold increase in liver accumulation 
of camptothecin in vivo at 2 hours (Figure 5-5). Campthtecin derivative (Irinotecan) is 
approved for hepatic metastasis of colorectal cancer [53]. Oral delivery of camptothecin 




Figure 5-5. Liver concentration of orally administered 
3
H-Camptothecin at 2 
hours alone and co-delivered with PAMAM G4.0 (300 mg/kg) and G3.5 (1000 
mg/kg), n= 3 animals per time point, PAMAM dendrimers statistically 
significantly increased the liver concentration of 
3
H-Camptothecin, *p<0.05 by 
one-way ANOVA and Bonferroni’s multiple comparison tests comparing 




exposure to plasma and consequently reducing non-specific systemic toxicities. It has 
been reported that liver/blood exposure of camptothecin is higher when camptothecin is 
delivered orally [54]. However, the oral delivery of camptothecin is limited by variable 
and low absorption [54]. An increase in oral absorption of camptothecin will allow a 
therapeutic dose to reach the liver, while decreasing blood exposure of the drug as 
compared to a similar dose given intravenously. 
5.3.3. In vivo oral absorption of paracellular marker-mannitol 
PAMAM dendrimers did not cause an increase in blood levels of the paracellular 
marker 
14
C-mannitol at 2 hours. (Tmax of Mannitol) (Figure 5-6). This observation 
suggests that at doses of 300mg/kg for amine-terminated PAMAM G4.0-NH2 and 1000 
mg/kg for carboxylic acid-terminated PAMAM G3.5-COONa, tight junction modulation 
was not observed and that the increase in absorption of camptothecin was not due to 
opening of tight junctions. 
Previous in vitro transepithelial transport studies of PAMAM dendrimers across 
Caco-2 monolayers have reported tight junction modulation by amine and carboxylic 
acid-terminated PAMAM dendrimers as investigated by TEER (transepithelial electrical 
resistance) measurements and the permeability of 
14
C-mannitol [39, 35, 34]. Tight 
junction modulation was observed to be a function of PAMAM surface chemistry, 
concentration and incubation time [35]. Both PAMAM G4.0-NH2 (partially surface 
modified by FITC) and G3.5-COOH were shown to cause a sharp decline in TEER and a 
5- to 10-fold increase in mannitol flux at concentrations of 1.0 mM, when incubated for 2 




Figure 5-6. Blood concentration of orally administered 
14
C-Mannitol at 2 
hours alone and co-delivered with PAMAM G4.0 (300 mg/kg), G3.5 (1000 





formulations tested in the current in vivo study were 2.1 mM for G4.0-NH2 
(corresponding to 300 mg/kg in animals) and 7.7 mM (corresponding to 1000 mg/kg in 
animals) for G3.5-COOH. These doses are slightly higher than the doses tested in vitro 
across Caco-2 However, the PAMAM dendrimers dosed in this study were subjected to  
variables in the in vivo GIT system like dilution in the gastric and intestinal fluid, 
gastrointestinal transit and mucosal barrier. This potentially reduced the effective 
concentration and incubation time of PAMAM dendrimers at the intestinal surface at 
which tight junction modulation was not achieved. 
5.3.4. Histologic assessment of small intestinal segments 
At the PAMAM G4.0-NH2 and G3.5-COOH doses tested, no clinically significant 
histologic changes were observed. No morphological changes were noted at the villi 
(Figure 5-7 and Appendix B) or the microvilli levels (Figure 5-8 and Appendix B). Slight 
irregularities of microfilaments were observed for the group treated with saline (Figure 5-
8 and Appendix B). Previous studies in vitro have shown that anionic PAMAM G3.5 (1.0 
mM) did not affect microvilli structure in Caco-2 cell monolayers over a 2 hour 
incubation period while at the same concentration, cationic PAMAM G4.0 showed 
disruption and loss of microvilli [38]. The influence of surface groups on histologic 
morphology was not observed in this study. PAMAM G4.0 doses at concentrations of 0.7 
mM (100 mg/kg) and 2.1 mM (300 mg/kg) and PAMAM G3.5 doses at 2.3 mM (300 
mg/kg) and 7.7 mM (1000 mg/kg) were subjected to gastrointestinal transit time and 
dilution variables which reduced their effective concentration at the epithelial layer in 
vivo as compared to that on Caco-2 cell monolayers in vitro. The camptothecin dosed 
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Figure 5-7. H and E staining of the small intestinal segments of CD-1 mice 
orally administered with saline, G4.0 (100 mg/kg), G4.0 (300 mg/kg), G3.5 





Figure 5-8. TEM images of the small intestinal segments of CD-1 mice orally 
administered with saline, G4.0 (100 mg/kg), G4.0 (300 mg/kg), G3.5 (300 




alone or with the PAMAM dendrimers under study also did not cause any apparent 
morphological changes to the villi of the small intestinal segments being evalulated 
(Figure 5-9 and Appendix B). However, slight irregularities in the plasma membranes 
and microfilaments of microvilli were observed for the camptothecin dosed alone (Figure 
5-10 and Appendix B). Disruption of microvilli has been previously noted in cells treated 
with camptothecin [55, 56]. When the camptothecin was dosed with the PAMAM 
dendrimers-G4.0 and G3.5, the microvilli did not show swelling and the microfilaments 
inside the microvilli were well organized (Figure 5-10 and Appendix B). This suggests a 
protective effect of the PAMAM dendrimers to the potential histologic changes caused by 
camptothecin, probably due to encapsulation of the drug within the interior cavities of the 
dendrimers. H and E staining of small intestinal segments in animals dosed with 
camptothecin + G4.0 or G3.5 as well as saline showed dilated lymphatics indicative of an 
absorptive process (Figure 5-7, Figure 5-9 and Appendix B). 
5.4. Conclusion 
When formulated with cationic, amine-terminated PAMAM generation 4.0 and 
anionic, carboxylate-terminated G3.5, camptothecin associated to a higher extent with 
G4.0 than G3.5 due to an electrostatic interaction on the surface of G4.0. Inspite of a 
difference in drug association, both G4.0 and G3.5 caused a 2- to 3-fold increase in oral 
absorption of camptothecin when co-delivered with the drug at 2 hours (the Tmax of 
camptothecin absorption). This was attributed to better solubilization of the drug in 
simulated gastric fluid which can affect drug association with PAMAM, precipitation 




Figure 5-9. H and E staining of the small intestinal segments of CD-1 mice orally 
administered with CPT (5 mg/kg), CPT + G4.0 (100 mg/kg), CPT + G4.0 (300 





Figure 5-10. TEM images of the small intestinal segments of CD-1 mice orally 
administered with CPT (5 mg/kg), CPT + G4.0 (100 mg/kg), CPT + G4.0 (300 




bioavailability. Increased oral absorption of camptothecin was also attributed to a higher 
fraction of the drug in the unionized form (lactone) when formulated with PAMAM 
dendrimers. There was no significant difference in drug solubilization in SGF and SIF by 
either cationic or anionic PAMAM dendrimers. This was attributed to the absence of 
surface electrostatic interaction with G4.0 at lower pH. PAMAM G4.0 and G3.5 did not 
cause tight junction modulation at the doses tested suggesting that increase in oral 
absorption of camptothecin was not due to tight junction modulation. At doses tested, 
PAMAM dendrimers did not cause any histologic changes to the epithelial layer of the 
gastrointestinal tract at 4 hours post dosing. This study demonstrates that both cationic 
and anionic PAMAM dendrimers were equally effective in enhancing the oral absorption 
of camptothecin. Results suggest that drug inclusion in PAMAM interior controlled drug 
solubilization in SGF and SIF, and increased oral bioavailability. 
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CHAPTER 6 
CONCLUSIONS AND FUTURE DRIECTIONS 
                                                    6.1.   Conclusions 
In this dissertation, PAMAM dendrimers were evaluated as polymeric carriers for 
delivery of anticancer agents. The hypothesis in the first part of the dissertation was that 
the difference in polymer architecture and molecular conformation of PAMAM 
dendrimers from traditionally used linear polymers can influence its hydrodynamic size 
and deforming capacity, which in turn influences biodistribution and pharmacokinetics of 
these polymers (Chapters 3 and 4). Polymer architecture affected the increase of 
hydrodynamic size with molecular weight [1]. PAMAM dendrimers are generally known 
to be more globular and compact structures than linear polymers that assume a random 
coil or an extended conformation in solution [2-5]. An interesting observation in the size 
characterization of these polymers was that there was a MW cutoff (40 kDa) below which 
the HPMA copolymers was smaller than the PAMAM dendrimer of comparable MW [1, 
6]. With increase in MW, the size of PAMAM dendrimers grew at a much slower rate 
than HPMA copolymers by virtue of the compact nature of their divergent growth from 
the core [1, 6]. 
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The biodistribution study showed that along with MW, hydrodynamic size and 
polymer architecture influenced blood circulation, nonspecific uptake in the kidney and 
liver as well as site-specific uptake in the tumor [1]. In general, the PAMAM dendrimers 
had a higher tumor to blood ratio. This suggests that given the same opportunity to be 
taken up into the tumor when circulating in the blood, hyperbranched PAMAM 
dendrimers had a higher affinity to the tumor tissue than HPMA copolymers [6]. 
PAMAM dendrimers, therefore, had better passive targeting potential than HPMA 
copolymers in the orthotopic ovarian carcinoma tumors under study. However, PAMAM 
dendrimers also had a higher and more persistent accumulation in the liver and kidney 
tissue than HPMA copolymers. This could potentially cause long-term, non-specific 
toxicities in these elimination organs affecting primary physiological functions, although 
we did not observe any acute toxicity at doses tested. The pharmacokinetic analysis of 
blood data revealed that the clearance decreased more drastically for PAMAM 
dendrimers over the molecular weight range studied as compared to HPMA copolymers 
over the same molecular weight range [6]. It should be noted that although the MW of the 
polymers being studied was comparable, the hydrodynamic size range was not. The 
largest HPMA copolymer (131 kDa) was twice the size of the largest PAMAM 
dendrimer (G7.0-OH). Clearance is known to decrease exponentially with hydrodynamic 
size for polymers over a range of MWs or hydrodynamic size, where they can be partially 
filtered through the kidney. However, below or above this range, the clearance is likely to 
be independent of molecular weight, in which case the glomerulus is not a rate-limiting 
barrier for the smaller polymers and other mechanisms of elimination such as the RES 
uptake or biliary excretion kick in for the larger polymers. This study only included a 
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range of sizes where clearance was seen to be a function of MW. In this size range, the 
linear polymers were excreted renally to a greater extent than the PAMAM dendrimers. 
The renal and elimination clearance trends suggested that the deforming capacity of 
PAMAM dendrimers decreases more drastically with increase in generation, size or MW 
than that of HPMA copolymers, affecting their extravasation rates across glomerular 
basement membrane. Head-to-head comparative study of HPMA copolymers and 
PAMAM dendrimers can guide the rational design and development of carriers based on 
these systems for delivery of bioactive and imaging agents. 
In Chapter 5, PAMAM dendrimers were evaluated for oral delivery of 
camptothecin, a schedule-dependent chemotherapeutic. The drug was co-delivered with 
different ratios of cationic, amine-terminated PAMAM G4.0-NH2 and anionic, carboxylic 
acid-terminated PAMAM G3.5-COOH. The drug associated to a greater extent to the 
PAMAM G4.0-NH2 than PAMAM G3.5-COOH due to the potential for surface 
electrostatic interaction between the carboxylate group on drug and the amine group on 
G4.0 (unstable under gastric conditions) [7]. Inspite of this difference in association, both 
G4.0 and G3.5 increased oral absorption of camptothecin to the same extent (2-fold at 2 
hours post dosing) [7]. This was attributed to partial encapsulation of the drug in the 
PAMAM interior via hydrogen bonding or hydrophobic interactions, solubilizing it under 
gastric conditions [7]. It was also attributed to a small percentage of drug in the unionized 
form when encapsulated in the PAMAM, which is a more favorable form for absorption 
[7]. Mannitol absorption remained unchanged at 2 hours after dosing and no histological 
toxicity was observed at 4 hours after dosing in presence of both cationic and anionic 
PAMAM dendrimers, indicating that they did not modulate tight junctions and were 
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biocompatible in vivo at these doses [7]. This was contradictory to previously observed 
results in vitro at comparable doses [8-10]. These findings suggest that in vivo variables 
such as presence of the mucous layer, and gastrointestinal transit time diluted the 
effective concentration of the dendrimer at the epithelial layer. This study demonstrates 
the potential of PAMAM G4.0 and G3.5 to enhance the oral absorption of camptothecin, 
possibly by altering precipitation kinetics of the encapsulated drug in the GI.   
6.2.    Future directions 
In Chapters 3 and 4, two polymer series, PAMAM dendrimers and HPMA 
copolymers over a certain size range, were evaluated and shown that clearance decreased 
exponentially with hydrodynamic size. However, this trend is not expected to hold for 
polymers with hydrodynamic sizes outside of this range, where clearance is likely to be 
independent of MW or size of polymers. A systematic evaluation of each of the polymer 
series across a broader range of MWs or hydrodynamic sizes is likely to result in a 
sigmoidal curve when clearance is plotted as a function of hydrodynamic size [11]. 
Different sigmoidal curves can be generated for polymers of varying architecture which 
can help simulate elimination clearance of a polymer with known molecular weight and 
conformation in solution.  
Molecular conformation of a polymer is known to depend on the physicochemical 
properties and extent of cargo loaded on the polymer [12]. A slight increase in tyrosine 
loading caused the hydrodynamic size of HPMA copolymer to decrease as compared to 
that of HPMA homopolymer of comparable MW (Chapter 3). It is expected that the 
hydrodynamic size, molecular conformation and consequently the in vivo fate of the 
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PAMAM dendrimers and HPMA copolymers will change with loading of drugs and 
targeting moieties. The architecture of the polymeric carrier is likely to influence this 
change as well. The presentation of the targeting moiety and the resulting active targeting 
potential of a polymer can be affected by polymer architecture. A systematic study 
evaluating the effect of drug loading and targeting moieties on hydrodynamic size, 
molecular conformation, biodistribution and pharmacokinetics of polymers of varying 
architecture will aid in the rational choice of a polymeric carrier. 
Polymer architecture was also seen to influence tumor uptake in the 
biodistribution studies (Chapter 4). This can be attributed to: 1) differences in the 
extravasation of the polymer in the tumor interstitium, and 2) difference in cellular uptake 
of polymers of varying architecture. The extravasation rates of polymers of varying 
architecture in the tumor can be studied by intravital microscopy. Such study can give 
insight into the influence of polymer architecture on depth of polymer penetration in the 
tumor, which is known to be one of the limitations in tumor-targeted delivery.  
It should be noted that the conclusions drawn from Chapters 3 and 4 were based 
on an orthotopic xenograft ovarian carcinoma tumor model. The type of tumor model is 
known to influence EPR due to differences in interstitial pressure as well as 
vascularization [13, 14]. A comparison of polymers of varying architecture in different 
tumor models would help understand the influence of tumor interstitial, cellular and 
angiogenic environment on polymer uptake.  
Camptothecin or its derivatives have been conjugated to PAMAM G4.0 and G3.5 
via a glycine spacer [15, 16]. It is critical to achieve linker stability sufficient to prevent 
gastrointestinal toxicity and a release rate efficient and specific enough for effective 
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therapy. Identifying site-specific elevated enzymes and designing linkers to be 
specifically cleaved by them is necessary to overcome this problem. These constructs 
have shown promise in vitro as oral delivery constructs by demonstrating a good balance 
of stability in the GIT, site-specific release in presence of liver carboxylesterases and 
enhanced transepithelial transport compared to drug alone [15, 16]. There has been no in 
vivo demonstration of the absorption of an intact dendrimer-drug conjugate. It would be 
beneficial to compare camptothecin exposure in vivo to GIT, blood and liver (site-
specific organ of interest) when complexed and conjugated with PAMAM dendrimers. 
Such a study will provide insight into the advantages of either complexation or 
conjugation to improving the oral delivery of camptothecin. It is possible that a 
combination of solubilization, penetration enhancement and transepithelial translocation 
will be beneficial for oral drug delivery using PAMAM dendrimers.  
Several surface modifications for PAMAMs such as acetyl groups, fatty acids and 
amino acids have shown increased permeability across Caco-2 cell monolayers or 
isolated intestinal tissue [17, 18]. Studying the effect of these surface modifications on 
the drug encapsulating potential and absorption enhancing effect of PAMAM on 
hydrophobic and hydrophilic drugs in vivo could lead to the establishment of a structure-
activity relationship between surface modification and absorption-enhancement effect.  
In vitro models employed to assess transepithelial transport have been useful to 
rank the translocation of PAMAM dendrimers of different generations and surface 
functionalities. However, they lack the variables of mucous membrane barrier, 
gastrointestinal transit time and/or enzymatic milieu pertinent to the gastrointestinal tract 
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[19]. Systematic modeling and correlation of in vitro transport to in vivo absorption can 
facilitate high throughput screening of PAMAM-based conjugates and complexes.  
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APPENDIX A  
BIODISTRIBUTION AND PHARMACOKINETIC MODELING  
PARAMETERS OF PAMAM-OH DENDRIMERS  
AND HPMA COPOLYMERS 
 
A.1. Dose recoveries of PAMAM-OH dendrimers and HPMA  
copolymers in the biodistribution study 





Percentage recovered dose 
G5.0-OH (29 kDa)* 71.58 +/- 17.04  
 
G6.0-OH (58 kDa) 97.22 +/- 12.99  
 
G7.0-OH (117 kDa) 85.99 +/- 12.83  
 
HPMA copolymer (26 kDa)* 20.38 +/- 7.28 
 
HPMA copolymer (52 kDa) 70.44 +/- 32.82 
 
HPMA copolymer (131 kDa) 
 
57.65 +/- 9.73 
 
*Carcass unaccounted; lower dose recovery of HPMA copolymer (26 kDa) may be 




A.2. Dose recovery of PAMAM dendrimers and HPMA copolymers  
in urine and stool in the biodistribution study 
Table A-2. Percentage of administered dose in urine and stool per animal for PAMAM 




















0.5 Urine 0.888 - - 6.246 - - 
 Stool - - 0.008 0.016 - - 
2 Urine 1.69 - 0.862 11.916 - 12.34 
 Stool 0.648 0.112 0.138 0.832 0.338 0.14 
6 Urine 2.764 1.47 0.978 9.298 3.664 12.81 
 Stool 2.052 0.09 0.302 - 1.32 0.41 
24 Urine 2.312 1.198 1.332 13.288 16.292 23.62 
 Stool 1.444 0.352 2.99 1.952 1.774 1.76 
 
Values are pooled for each group, n=5, except n=4 for 2 hour HPMA copolymer (26 
kDa) and G5.0-OH; 6 hour and 24 hour G7.0-OH; n=3 for 5 minute, 30 minute, 2 hour; 
n=4 for 6 hour for HPMA 131 kDa. 
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A.3. Size exclusion chromatographs of 
125
Iodine-labeled PAMAM-OH  
dendrimers and HPMA copolymers  
 
 
Figure A-1. Size exclusion chromatograms of 
125
Iodine-labeled PAMAM dendrimers 
(PD-10, GE Healthcare). Absence of radioactivity between 6.0 to 8.0 mL indicates that 
there is no free 
125
Iodine in the radiolabeled polymer samples. 
 
Figure A-2. Size exclusion chromatograms of 
125
Iodine-labeled HPMA copolymers (PD-
10, GE Healthcare). Absence of radioactivity between 6.0 to 8.0 mL indicates that there 
is no free 
125




A.4. In vivo toxicity of PAMAM-OH dendrimers and HPMA copolymers 
 
Figure A-3. Blood urea nitrogen levels in plasma of A2780 orthotopic ovarian tumor 
bearing mice at 1 week. Values are mean +/- SEM, n=5. 
 
Note- The PAMAM dendrimers and HPMA copolymers were assessed for in vivo 
toxicity at  doses corresponding to those used for the in vivo biodistribution study. The 
doses were prepared in 0.2 mL sterile saline. Five A2780 orthotopic ovarian tumor 
bearing nude mice were used per study group along with a control group (administered 
with saline) for the experiment. Acute toxicity was evaluated over 1 week by monitoring 
whole blood counts and organ function. Organ function was assessed by measuring 
enzyme levels for liver and kidney function monitored using a HESKA Blood analysis 
instrument (HESKA, Loveland, Colorado) with Fuji Dri-Chem slides (Fujifilm Global, 






Figure A-4. White blood cell count in plasma of A2780 orthotopic ovarian tumor bearing 
mice at 1 week. Values are mean +/- SEM, n=5; *** indicates a statistically significant 
difference from control p<0.001. 
 
Note-The differential blood count (RBC, WBC, Platelets) and haemoglobin levels were 






A.5. Size exclusion chromatograms of PAMAM-OH dendrimers  
and HPMA copolymers  
 
Figure A-5. Size exclusion chromatograms of PAMAM G5.0-OH, G6.0-OH, G7.0-OH 
and HPMA copolymers 26 and 52 kDa (Superose 6
TM
, GE Healthcare). Reprinted with 
permission from S. Sadekar, A. Ray, M. Janàt-Amsbury, C. M. Peterson, H. Ghandehari, 
Comparative Biodistribution of PAMAM Dendrimers and HPMA Copolymers in 
Ovarian-Tumor-Bearing Mice, Biomacromolecules, 2011, 12, 88–96. Copyright 2011 
American Chemical Society. 
 
 
Figure A-6. Size exclusion chromatogram of HPMA copolymer (131 kDa) (Superose 
6
TM
, GE Healthcare). 
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A.6. Kidney accumulation of PAMAM G5.0-OH 
 
Figure A-7. Percentage of injected dose/g of kidney tissue. Black bars represent the 
biodistribution of PAMAM G5.0-OH from the experiment reported in Chapter 3. Grey 
bars represent the biodistribution of PAMAM G5.0-OH from a repeat biodistribution 
experiment of the dendrimer at 30 m and 1 week. In both experiments, PAMAM G5.0-
OH showed a high and extended kidney accumulation of 90-130 % injected dose/g 
confirming the tendancy of this polymer to be uptaken and retained over one week in the 




A.7.  Blood compartmental modeling 
Table A-3. Akaike Information Criterion (AIC) for blood compartmental model analysis 









G5.0-OH -4.16 -78.41 
G6.0-OH -17.42 -77.87 
G7.0-OH -24.63 -43.61 
HPMA copolymer (26 kDa) -5.23 -74.08 
HPMA copolymer (52 kDa) -8.42 -62.57 
HPMA copolymer (131 kDa) -29.06 -47.66 
AIC was computed using Winnonlin
®
 Version 2.1 for compartmental analysis 
Note-The AIC values (Table A-3) indicated that a two-compartmental model with bolus 
input was a better fit for the polymer biodistribution data as compared to a one 




A.8.  Renal clearance 
Renal clearance was calculated from urine data collected over time using the 
following equations: 
      
    
              
  (1)  






    (2)  
ClR: Renal clearance 
AUC blood, 0-ti: Area under the blood concentration-time curve of the polymer 
U, ti: Extent of accumulation of polymer in urine at time ti 
A.9.  Polymer interaction with bovine serum albumin 
Stock solutions of BSA (10 μmol/L) and polymers (160 μmol/L) were prepared in 
phosphate buffer saline (PBS: 150 mmol/l NaCl, 1.9 mmol/l NaH2PO4, 8.1 mmol/l 
Na2HPO4, pH 7.4). Polymers were serially diluted to study the interaction of PAMAM-
OH dendrimers and HPMA copolymers with BSA at a concentration range of 2.5-80 
μmol/L for the polymers and 5μmol/L for BSA [4-6]. After a 30-minute incubation at 
room temperature, sample solutions were measured for fluorescence quenching in a 96 
well black polymer BTM P-D-L plate (Nalge Nunc International, Rochester, NY) with 
opaque walls for wells. The spectrofluorometer used was SpectraMax® M2 (Molecular 
Devices Corporation, Sunnyvale, CA). The excitation wavelength employed was 280 nm 
and the emission spectra were recorded from 300 to 500 nm. Quenching data was 
collected for BSA and polymers alone and for BSA upon addition of each polymer at 
varying concentrations. The fluorescence intensity at the absorption maximum (λmax = 
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380 nm) was noted in presence and absence of quenching agent (BSA) and plotted as per 
the Stern-Volmer equation: 
         
  
 
       [ ] 
  
F0 = Fluorescence intensity of BSA in absence of quencher (polymer) 
F = Fluorescence intensity of BSA in presence of quencher (polymer) 
Ksv = Quenching coefficient  
[Q] = Concentration of quencher (polymer) 
Serum albumin is a major component of the soluble proteins present in plasma 
[7]. Bovine serum albumin has two tryptophan residues (Trp-134 and Trp-212) that 
possess intrinsic fluorescence. This fluorescence is sensitive to the presence of a 
quenching agent in the vicinity of the BSA molecule. The extent of fluorescence 
quenching is known to be indicative of the binding affinity of the quenching agent to 
BSA. Therefore, the quenching coefficient (Ksv) is indicative of the interaction of the 
polymer with bovine serum albumin (BSA) [8]. The higher the Ksv value, the greater is 
the interaction of the polymer with BSA. All of the polymers had very low Ksv values 
close to zero, suggesting that these polymers interacted minimally with bovine serum 








Table A-4. Quenching coefficients (Ksv) for the interaction of PAMAM-OH 
dendrimers and HPMA copolymers with bovine serum albumin. 
 
Polymer Ksv 
G5.0-OH (29 kDa) -0.0001 +/- 0.0005 
G6.0-OH (58 kDa) 0.0042 
G7.0-OH (117 kDa) 0.0107 
HPMA copolymer(26 kDa) -0.0016 +/- 0.0019 
HPMA copolymer (52 kDa) 0.0059 
HPMA copolymer (131 kDa) 0.0064 
 
Note: The quenching of BSA fluorescence observed is static or ground state 
quenching. Such quenching is better analyzed using a binding isotherm. The 
graph of F0/F was linear as a function of quencher concentration for all the 
polymers under study, suggesting that the BSA was not saturated with the 
quencher or polymer over the concentration range studied. Bound and unbound 
fractions of polymer with BSA were also not measured in the experiment. 
Hence, it was not possible to analyze the data using binding isotherms. 
Alternatively, the Stern-Volmer method, originally derived for dynamic or 
excited state quenching was used. Also, note that quenching coefficient values 
cannot be negative. Negative values of Ksv for polymers G5.0-OH and HPMA 
26 kDa have a standard deviation with a higher limit in the positive range. The 
Ksv values of these polymers are likely to fall within the higher range of error 





A.10.  Blood concentration time profile and terminal blood half-life 
 
Table A-5. Blood concentration-time profile and terminal blood half-life 





G5.0-OH (29 kDa) Cp = 0.682 e
-8.86
t + 0.004 e
-0.12
t 6.36 
G6.0-OH (52 kDa) Cp = 0.271 e
-34.75
t + 0.014 e
-0.15
t 4.49 
G7.0-OH (117 kDa) Cp = 0.158 e
-50.53
t + 0.128 e
-0. 2
t 3.4 
HPMA copolymer (26 kDa) Cp = 0.674 e
-6.95
t + 0.011 e
-0.16
t 4.23 
HPMA copolymer (52 kDa) Cp = 0.513 e
-25.75
t + 0.058 e
-0.52
t 1.34 
HPMA copolymer (131 kDa) Cp = 0.127 e
-11.3




Note: Terminal half-life is a function of both blood clearance and peripheral 
distribution. Hence a long terminal blood half-life can be attributed to larger 
volume of distribution or smaller blood clearance or both. Therefore, terminal 
half-life is not the most robust parameter to assess the ability of the body to 
eliminate the polymer. On the other hand, blood clearance expresses the ability of 
the body to eliminate the polymer. Hence, blood clearance has been used to 





A.11.  Blood-tumor link model 
Equations describing the Blood-Tumor Link model (Figure 4-1): 
Concentration profile of the central blood compartment (Cp) was modeled using the 
following equation: 
   ( )
  
  -     ( )-     ( )-     ( )       ( )        ( ) 
Concentration profile of tumor compartment-1 (Ct1) was modeled using the following 
equation: 
    ( )
  
       ( )        ( )        ( ) 
Concentration profile of tumor compartment-2 (Ct1) was modeled using the following 
equation: 
    ( )
  
        ( ) 
Concentration profile of peripheral fast distribution compartment (Cf) was modeled using 
the following equation: 
   ( )
  
       ( )       ( ) 








1. It was assumed that the distribution of polymer in each of the compartments was 
instantaneous and homogenous.  
2. The intercompartmental rate constants were assumed to be first order. 
 
 
Optimization code for Global curve fitting of experimental blood and tumor 
The generalized methodology of solving a set of simultaneous first order linear 
differential equations with unknown coefficients involves utilizing linear optimization 
techniques in finding the least square fit to the observed experimental data. Initially, K1, 
K2 and K3 were fixed while optimizing K4, K5 and K6 to obtain the desired best fit. The 
obtained values of K4, K5 and K6 were then used as initial estimates and both blood and 
tumor data were refitted by varying all rate constants. Due to the complexity of the 
problem, an unconstrained search for global minimum is often challenging and time 
intensive. Therefore, to circumvent this issue, we have used the Optimization toolbox in 
Matlab® software that offers routines for searching constrained minimum values of 
multivariable scalar functions with intelligible initial estimates. The algorithm starts with  
a user supplied initial guess on rate constants and solves the set of differential equations 
with known initial conditions (namely, blood and tumor compartment 1 and 2 
concentrations at time t=0). It then determines the absolute squared error normalized to 
the experimental value for each data point in every concentration set (Cp, Ct1 and Ct2). 
 
 
   






































where Yp, Yt1 and Yt2 are the blood and tumor compartment 1 and 2 concentrations at each 
time points tk, calculated by solving the set of differential equations based on present 
values of rate constants and eventually summed over all measured time points. This error 
is minimized using a constrained linear optimization tool in Matlab® that iterates through 
all possible combinations of rate constants under pre-specified lower and upper bounds 
on the same to determine the best fit (Error values in Table A-6.).
 
Table A-6. Akaike Information Criteria (AIC) and Reduced Chi square (χ2) values of 
































 AIC  
(Model 1) 
145.16 40.15 - 17.07 23.64 - 
Reduced χ2 
(Model 1) 
41.60 5.02 - 1.77 2.27 - 
AIC  
(Model 2) 
- 29.64 27.40 - - 28.36 
Reduced χ2 
(Model 2) 
- 2.94 2.57 - - 2.73 
AIC  
(Model 3) 
- 30.13 22.03 - - 29.25 
Reduced χ2 
(Model 3) 
- 2.69 1.39 - - 2.54 
 
Model 1- Schematic represented in Figure 4-1A, Chapter 4. Elimination from a single 
tumor compartment into blood via K5 for lower MW polymers not showing prolonged 
tumor retention.  
Model 2- Schematic represented in Figure 4-1B, Chapter 4. Model allows elimination 
from the first tumor compartment (t1) via rate constant K5 back into the plasma 
compartment but does not allow elimination from the second tumor compartment (t2) to 
account for the prolonged retention seen in tumors over the time period of the 
experiment.  
Model 3: Elimination is allowed from the second tumor compartment (t2) to the first 
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PHYSOCOCHEMICAL CHARACTERISTICS AND  
HISTOLOGICAL ASSESSMENT OF SMALL  
INTESTINAL TOXICITY OF PAMAM CPT  
FORMULATIONS 
B.1. Size exclusion chromatogram of elution profiles of  
PAMAM G4.0-NH2 and G3.5-COOH 
 
Figure B-1. Size exclusion chromatograms of PAMAM G4.0-NH2 and G3.5-COOH 
(Superose 6
TM



























B.2. Spectroscopic detection of camptothecin-lactone form 
 




y = 12.359x + 0.1086 
























B.3.  High performance liquid chromatography detection of  
camptothecin-lactone form 
 
Figure B-3. Peak area of camptothecin-lactone form eluted on a C18 reverse phase HPLC 
column (XTerra, Waters®; Agilent HPLC system) over a range of concentrations at 
λ=370 nm. 
 
B.4.  High performance liquid chromatography detection of  
camptothecin-carboxylate form 
 
Figure B-4. Peak area of camptothecin-carboxylate form eluted on a C18 reverse phase 
HPLC column (XTerra, Waters®; Agilent HPLC system) over a range of concentrations 
at λ=370 nm. 
y = 75.185x - 5.4972 
















y = 58237x + 100.88 



















B.5. Histologic assessment of small intestinal segments of animals 




Figure B-5. H and E staining of the small intestinal segments of CD-1 mice orally 







Figure B-6. H and E staining of the small intestinal segments of CD-1 mice orally 









Figure B-7. H and E staining of the small intestinal segments of CD-1 mice orally 








Figure B-8. H and E staining of the small intestinal segments of CD-1 mice orally 









Figure B-9. H and E staining of the small intestinal segments of CD-1 mice orally 








Figure B-10. TEM images of the small intestinal segments of CD-1 mice orally 








Figure B-11. TEM images of the small intestinal segments of CD-1 mice orally 








Figure B-12. TEM images of the small intestinal segments of CD-1 mice orally 








Figure B-13. TEM images of the small intestinal segments of CD-1 mice orally 








Figure B-14. TEM images of the small intestinal segments of CD-1 mice orally 









Figure B-15. H and E staining of the small intestinal segments of CD-1 mice orally 








Figure B-16. H and E staining of the small intestinal segments of CD-1 mice orally 








Figure B-17. H and E staining of the small intestinal segments of CD-1 mice orally 









Figure B-18. H and E staining of the small intestinal segments of CD-1 mice orally 








Figure B-19. H and E staining of the small intestinal segments of CD-1 mice orally 








Figure B-20. TEM images of the small intestinal segments of CD-1 mice orally 








Figure B-21. TEM images of the small intestinal segments of CD-1 mice orally 








Figure B-22. TEM images of the small intestinal segments of CD-1 mice orally 








Figure B-23. TEM images of the small intestinal segments of CD-1 mice orally 








Figure B-24. TEM images of the small intestinal segments of CD-1 mice orally 
administered with CPT + G3.5 (1000 mg/Kg). Scale Bar = 1 µm. 
 
 
 
 
